A supramolecular derivatised study of BIS(Adamantan-1- Aminium) carbonate by Ngilirabanga, Jean Baptiste
  
 
A SUPRAMOLECULAR DERIVATISED 
STUDY OF BIS(ADAMANTAN-1-
AMINIUM) CARBONATE 
 
 
 
 
 
 
 
 
 
 
 
By 
 
Jean Baptiste NGILIRABANGA 
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of 
Magister Scientiae (Pharmaceutical Science) in the School of Pharmacy, 
University of the Western Cape 
 
 
 
 
 
 
Supervisor: Dr. Halima SAMSODIEN 
Co-supervisor: Dr. Jacques JOUBERT 
 
 
 
November 2014  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
  
 
 
i 
 
Abstract  
In this study, new solid supramolecular derivatised forms of bis(adamantine-1-aminium) 
carbonate (ADTCO3) were prepared. ADTCO3 is a derivative of amantadine used for 
Parkinson’s disease and has antiviral properties against influenza-A, dengue fever and 
pharmacological activity towards Parkinson’s disease. The new forms prepared were 
polymorphic and co-crystal forms of ADTCO3. Polymorphism is a phenomenon where the 
ability of a substance to exist in two or more crystalline forms occurs when crystallised 
under different conditions and co-crystallization is the process of formation of 
multicomponent crystals of a drug substance.  
New solid forms often display different mechanical, physicochemical and thermal 
properties that can remarkably influence the bioavailability, hygroscopicity and stability of 
active pharmaceutical ingredients (APIs). For the formation of polymorphs of ADTCO3, 
techniques such as dry grinding, solvent-drop grinding, co-precipitation, sublimation and 
vapour diffusion were applied. For the development of co-crystals and/or complex 
formation, ADTCO3 was treated in combination with ten selected co-formers viz; benzoic 
acid, 4-hydroxybenzoic acid, cinnamic acid, 4-hydroxycinnamic acid, succinic acid, 
tartaric acid, salicylic acid, L-glutamic acid, citric acid monohydrate and L-glutaric acid 
using similar techniques as applied in the polymorphism study. The first four co-formers 
were selected for their potential biological activity and the latter six were selected for their 
generally regarded as safe (GRAS) status. All products were isolated and characterized 
using different analytical techniques to assess the thermal behaviour of the products by hot 
stage microscopy (HSM), differential scanning calorimetry (DSC) and thermogravimetric 
analysis (TGA). FTIR spectroscopy and proton-nuclear magnetic resonance (
1
HNMR) 
were used to identify and determine the purity of the parent compounds and the modified 
forms. X-ray powder diffraction was used to determine the formation of a new phase and 
single crystal X-ray diffraction was applied at the initial stages to identify ADTCO3 by its 
unit cell parameters. Furthermore, the Cambridge Structural Database (CSD) and other 
resources were used to generate information on the molecular structures of all elucidated 
parent compounds, their polymorphs and reported co-crystals.  
Four different polymorphic forms of ADTCO3 were identified (viz. ADTCO3 Forms I to 
IV) and sixteen co-crystals (viz. ADTCO3BA1 to ADTCO3BA5, ADTCO3HBA, 
ADTCO3CIN, ADTCO3HCIN, ADTCO3SUC, ADTCO3LTTA, ADTCO3SA, 
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ADTCO3CA, ADTCO3GLA, ADTCO3GA) were synthesised. Of the sixteen co-crystals 5 
were identified as ADTCO3BA “salt” co-crystal polymorphic forms and 2 as 
ADTCO3SUC co-crystal polymorphic forms.  Two solvated “salt” co-crystal forms were 
also identified, namely; ADTCO3GLA and ADTCO3LTTA. ADTCO3GLA had a mass 
loss of 10.3% (n = 2.4) and ADTCO3LTTA had a mass loss of 5.25% (n = 0.86). Finally, 
the rest of the co-crystals ADTCO3HBA, ADTCO3CIN, ADTCO3HCIN, ADTCO3SA, 
ADTCO3CA and ADTCO3GA all crystallised as “salt” co-crystals. 
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1 
 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
This chapter describes the concept of supramolecular chemistry and events leading up to 
salt formation, polymorphism, solvates, hydrates and co-crystallisation from 
recrystallization studies. Motivation, rationale as well as objectives for this study are also 
presented in this chapter. 
OVERVIEW OF SUPRAMOLECULARY CHEMISTRY 
Supramolecular chemistry is an area of chemistry that mainly focuses on the non-covalent 
interactions of molecules.
1,2 
It is the study of weak and reversible molecular interactions 
such as hydrogen bonding, metal coordination, pi-pi interaction and Van der Waals forces. 
This range of intermolecular interactions originated from only a few attractive and 
repulsive forces and also includes electrostatic interactions such as ion-ion, ion-dipole, 
dipole-dipole interactions and coordinative (metal-ligand) bonding. The use of these 
interactions for the directed self-assembly of a given structure requires knowledge of their 
strength and of their dependence on distances and directionality. Therefore, even if a single 
intermolecular interaction is generally much weaker than a covalent bond, the cooperative 
action of many of such interactions may lead to supramolecular species that are 
thermodynamically and kinetically stable under a variety of conditions.
2 
It was reported 
that the explicitly designed study of weak molecular interactions is of extreme importance 
to the understanding of many biological processes and structure-activity relationships of 
compounds.
3 
Typical examples are the protein structure of cells, where the 
 
double helical 
structure of deoxyribonucleic acid (DNA) is made of two distinct strands of nucleotides 
having the complementary base connected by hydrogen bonds (figure 1.1). 
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Figure 1.1: Representation of two strands of DNA hydrogen bonded. 
5,6,7,8
 
This genetic material is necessary for cell replication and the polymeric strands must be 
unwound in order to be decoded and translated into instructions for cellular components, 
thus a reversible supramolecular process is necessary to read the DNA.
4
 
The H-bonding and supramolecular recognition are necessary for many biological 
functions including receptor binding, immunological responses, protein folding, protein 
function and coordination bonds responsible for the ability of haemoglobin to transport 
oxygen.
9
 
In principle there are two types of approaches to modify physicochemical properties of 
active pharmaceutical ingredients (API) at the molecular level at an early stage; one is the 
covalent approach such as organic lead optimization and the other is non-covalent 
approaches or supramolecular chemistry approaches such as polymorph formation
3
 and 
salt formation
10
 which this study will highlight. 
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In comparison with covalent approaches, the most distinct advantage to apply these 
supramolecular non-covalent approaches is that the molecular structure of the APIs is 
retained so that essential structural features which are responsible for biological activities 
are retained accordingly.
3
 
During this application, hydrogen bonds are the basis of molecular recognition phenomena 
in pharmaceutical systems and are responsible for the generation of families of molecular 
networks with the same molecular components (single component crystals and their 
polymorphs) or with different molecular components (multiple component crystals) in the 
crystalline
11
 and amorphous state. 
Details about such networks will be provided later, whereas hydrogen bonds, the most 
involved in these non-covalent interactions, are discussed. 
HYDROGEN BONDING 
Hydrogen bonding as one of the above mentioned intermolecular interactions dates back to 
the early 1900’s. Pauling first defined hydrogen bonding as a largely ionic interaction 
between two electronegative atoms with hydrogen being attached to both as a bond 
(equation 1.1). However, this definition would include only N-H···O, O-H···O and F-
H···F and excluded C-H···O and O-H···O bonds. However, these bonds were later 
identified as well, universally approved and received extensive attention due to their 
abundance in biomolecules.
12,13,14
 Different literature reviews debated on how a more 
conclusive definition of hydrogen bonding should be.
15,16,17
 
A + BH → A − H ··· B                        Equation 1.1 
H-bonding occurs between a proton donor group (A-H) and a proton acceptor group (B), 
with (A) being an electronegative atom such as O, N, S, P, Se and X taking the place of F, 
Br, I, Cl or C and the acceptor group (B) being a lone electron pair of an electronegative 
atom, or a π-electron orbital of a multiple bond or unsaturated system.18 Generally, a 
hydrogen bond can be characterized as a proton shared by the two lone electron pairs. The 
strength of hydrogen bonding is directly proportional to the dipole moment of the donor 
and the electron pair on the acceptor. 
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The strength of hydrogen bonds is typically around 20 kJ mol
-1
 but can even be as strong 
as 163 kJ mol
-1
 as has been reported for the F···H-F interaction between fluorine, the most 
electronegative element of the halogen group and hydrogen. This hydrogen bond is the 
strongest one known.
18
 
A detailed understanding of the supramolecular chemistry of the functional groups present 
in a given molecule is compulsory for designing organic non-covalent complexes because 
of its capability to facilitate the selection procedure of suitable crystal formers.
19 
Table.1.1 
shows examples of different categories of hydrogen bonding.
16 
 
Table 1.1: Different categories of bonding. 
Type of hydrogen bond Examples 
Ionic   N+ − H ⋯ O−, N+ − H ⋯ Cl− 
Very strong  P − OH ⋯ O = P ,F − H ⋯ F− 
Strong  O − H ⋯ O = O, N − H ⋯ O = O, O − H ⋯ O − H 
Weak C − H ⋯ O, C − H ⋯ N, C − H ⋯ F − C  
The strength of hydrogen bonds varies considerably. The weakest possesses (1-2 kJ mol
-1
) 
and the strongest which is also as strong as the covalent bond; possess (40.3756 kJ mol
-1
). 
Typical values include; F
-
-H
…
F
-
 (163 kJ mol
-1
), O-H
…
N (29.288 kJ mol
-1
), O-H
…
O (20.92 
kJ mol
-1
) and N-H
…
N (12.552 kJ mol
-1
). Strength is temperature, pressure, bond angle and 
environment dependent.
20
 
POLYMORPHISM  
Some chemical elements are known to have allotropes and the phenomenon known as 
allotropism, the existence of a chemical element in different forms. The most common 
example is carbon which is found in its two allotropic forms; graphite and diamond having 
very different properties. This is a distinctive case of how physical structure determines 
properties. When applied to compounds, the phenomenon of allotropism is scientifically 
referred to as polymorphism. 
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Polymorphism comes from the Greek words, Polus meaning “many” and morph meaning 
“shape.” Thus, it is defined as the ability of a substance to exist as two or more crystalline 
phases presenting different arrangements or conformations of the molecules in the crystal 
lattice.
21-26
 
Figure 1.2 shows the different arrangements of neutral molecules in the crystal lattice. 
Because of these differences in molecular packing, energies holding molecules together in 
the crystal lattice differ significantly, therefore leading to differences in structures that 
subsequently confer the distinct physical, chemical and mechanical properties of the drugs. 
 
Figure 1.2: Polymorphs (A) and (B) arranged differently in the crystal lattice. 
Polymorphism is a phenomenon that preformulation investigators use to deliver necessary 
physicochemical, physicomechanical and biopharmaceutical data of drug substances, 
excipients and packaging materials. This may influence the formulation design of an active 
pharmaceutical ingredient (API) as well as the drug products pharmacokinetic or 
biopharmaceutical resultant properties.
27
 
It essentially means that in different polymorphs, the same molecule exists in different 
ways. If this difference is because of packing, the phenomenon is termed as packing 
polymorphism and if it is due to a difference in conformation, it is called conformational 
polymorphism. As a result of polymorphism, molecules have different arrangements in the 
unit cell of its crystal and thus display different physical properties. These include different 
packing properties, thermodynamic properties such as solubility, free energy, melting 
point, spectroscopic properties, kinetic properties such as dissolution rate, stability, 
mechanical properties such as hardness, compatibility with excipients, tableting and tensile 
strength.
26
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Polymorphism is thus very important in areas of chemical research (e.g. in pharmaceutical, 
pigment, agrochemical, explosive and fine chemical industries) where a full 
characterization of a material has a pivotal role in determining its ultimate use.
26
 Most 
drugs are formulated and marketed in crystalline form. Many of the drug molecules are 
highly functionalized and can self-organize in several ways in the solid state with nearly 
the same lattice energies, these are naturally called polymorphs.
28
 
Research on polymorphism and material properties of active drug compounds and 
excipients which are ingredients included in a pharmaceutical preparation for the purpose 
of improving its physical qualities, is an integral part of drug development.
28 
The 
knowledge of solid-state properties in an early stage of drug development helps to avoid 
manufacturing problems, to fine-tune the performance of drugs and particularly provides 
space for innovations. Drugs that were previously known to exist only in a single form are 
now known to have various polymorphic forms.
28 
This has enabled pharmaceutical companies to investigate crystal polymorphism in order 
to optimize the physical properties of a pharmaceutical solid before the drug development 
starts.
28
 Scientists in formulation or drug development need to select the appropriate 
polymorph for the development. For example, Paracetamol also known as acetaminophen, 
which is the most widely used antipyretic and analgesic in the world
28
 is known to exist in 
two polymorphic forms. The first form and the marketed one is the monoclinic Form I 
(P21/n) whereas Form II is orthorhombic (Pbca).
29
 Accordingly, Famotidine, an excellent 
histamine H2 receptor antagonist is shown to exist in two different polymorphic forms; the 
less stable (metastable) polymorph is named B and polymorph A is the stable form. Also, 
Piroxicam, a non-steroidal anti-inflammatory drug, widely prescribed all over the world, 
exists in three forms. Forms I, II and III.
29
 
The antiretroviral, Ritonavir
®
 or Norvir
®
 is a novel protease inhibitor for the Human 
Immunodeficiency Virus (HIV), the causative agent of Acquired Immune Deficiency 
Syndrome (AIDS), was also found to be another important example. The drug marketed as 
Norvir
®
 was launched in 1996 and distributed for about 18 months without trouble, then, 
its manufacturing company, Abbott observed an unexpected occurrence. The final product 
did not show dissolution and the drug was precipitating. Investigations revealed that this 
was because of a new thermodynamically more stable and less soluble polymorph, Form-
II.
29
 
 
 
 
 
Chapter 1 
 
 
7 
 
Surprisingly, the company attempted to formulate Form-I thereafter; it turned out very 
difficult (perhaps the exact conditions could not be reproduced) and put the company 
almost into a market crisis. The drug is now often quoted as an example in pharmaceutical 
industries to show the importance of polymorphism in this field.
29
 Norfloxacin is also a 
good example of polymorphism understanding in the pharmaceutical field. It is a synthetic 
broad spectrum antibacterial fluoroquinolone widely used in the treatment of prostate and 
urinary tract infections. This drug was found to exist in two anhydrous polymorphs (A and 
B), an amorphous form and several hydrated forms. Of the two anhydrous polymorphs, 
Form B is the most stable at room temperature. But the commercial sample of norfloxacin 
used is the Form A, which is metastable at room temperature.
29
 
All these examples clearly show that it is highly important to make the required 
polymorphic form, as the other form may not show the desired effects. Usually the form 
that is most stable is preferred in market formulation as the metastable form may transform 
to other stable forms. But it is a universally accepted rule that the metastable form has a 
higher solubility than the stable form and this form converts into the stable form as a result 
of spontaneous change but the reverse never happens. Thus, whenever possible, metastable 
forms having high solubility that can survive for years without changing to the stable form 
are selected for formulation. This means that forms that have considerable activation 
barrier in moving from the metastable state to the stable state would be selected.
29
 A 
careful evaluation of both thermodynamic parameters and kinetic parameters is of 
significant importance in the crystallization process of such compounds.
29
 
Polymorphs present the same properties in the liquid and gaseous states but they are 
different in the ways they are arranged or packed in the solid states. Hence, due to these 
packing arrangements in the crystal lattice, physical properties of polymorphs such as 
solubility, melting point, density, hardness, crystal shape, optical and electrical properties, 
vapour pressure, hygroscopicity, dissolution rate and bioavailability may differ 
significantly.
30-32
 These properties may have a direct effect on the ability to process the 
drug, its stability and the bioavailability of the drug substance as well as the final product.  
Since most organic polymorphs do not possess a particular name, their nomenclature is 
systematic and arranged in their order of discovery which normally starts from the most 
stable at the ambient conditions of environment (i.e. room temperature and pressure).
29
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It was reported however, that the breakthrough of the metastable form is eventually the 
first choice to introduce into the pharmaceutical development since it has a higher 
solubility compared to the stable one
29
 and thus bioavailability. Furthermore, the 
transformation of an unstable form into the stable one is also possible due to its higher 
Gibbs free energy.
33
 
The investigation of compounds exhibiting the polymorphism phenomenon requires  much 
time, and the number of polymorphs discovered by different researchers working on the 
same compound differ due to the time and efforts spent, environmental conditions as well 
as technics used when studying such a compound.
30, 31
 
SOLVATES 
Apart from polymorphs, solvates are another type of pharmaceutical solid form to look at 
due to its presence in pharmaceutical formulations on the market. Solvates are complexes 
in which the crystallizing solvent is incorporated in its crystal system (lattice). One can 
distinguish two classes of solvates depending on the way in which the solvent is fixed or 
fitted in the crystal system.
34-36
 
STOICHIOMETRIC SOLVATES 
Also called polymorphic solvates; this is a class containing a stoichiometric amount of 
solvent in their crystal lattice, whereby with desolvation results in a disordered non-
crystalline form or a different crystalline solid form.
34-36
 The packing arrangement of 
molecules in the crystal lattice may contribute to the ability of a crystal to incorporate 
molecules of solvents for the stability of the crystal and for structure purposes. In this class 
of solvate, the solvent being tightly bound to the molecules of the compound, becomes an 
integral part of the crystal structure and holds the structure of the crystal intact. Therefore, 
desolvation of this crystal would be more difficult. However, if by any means necessary 
the crystal loses the solvent, it could collapse and lead to the formation of a new crystal 
form. Compared to non-stoichiometric solvates, this class of solvates presents a higher 
stability.
36,37
 
NON-STOICHIOMETRIC SOLVATES 
In this class of solvates, solvent molecules are included in the crystal lattice to fill the 
intermolecular voids. Solvent is not in the crystal bonding within the crystal lattice.  
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Thus, this type of solvate is known for its capacity of freely losing the molecules of solvent 
over desolvation. This creates confusion since after the desolvation process; the crystal 
analysis of the resulting desolvated form shows no changes of the chemical structure. 
Compared to the polymorphic solvates, characterisation of the pseudo-polymorphic 
solvates is complicated by the lack of order.
36
 
Pressure, temperature and humidity change may lead to solvent exchange, loss or uptake. 
Owing to the risk of desolvation, toxicity with regards to organic solvents that are not 
regarded as safe (i.e. solvents that are not in the class III, and the ICH guidelines for limits 
on residual solvents) solvates, are not usually selected for development.
34-36
 
However, when the desolvation characteristic of a solvate from both the kinetic and 
thermodynamic point of view takes place before, developing a resulting crystalline or 
amorphous form may be decided and processing, handling and storage of this may then be 
impacted.  
Due to this amorphicity occurrance upon desolvation, changes in physical properties are 
expected and chemical stability particularly may be a concern owing to the improved 
reactivity of the amorphous solid forms relative to its crystalline counterparts.
38
 Examples 
(such as 1.4 fold for indomethacin, 2 fold for cephalexin, 2.5 fold for tetracycline, and 
more or less 10 fold reported for a macrolide antibiotic, as well as novobiocin acid) were 
reported.
95-96
 
Solvates can also exhibit the polymorphism phenomenon known as solvatomorphism. The 
case of Olanzapine compound
39
 (Figure 1.3) with the structure anhydrate and hydrate 
structure of Olanzapine and nitrofurantoin
40
 were reported (Figure 1.4). 
  
Figure 1.3: Structure of olanzapine.
41 
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Figure 1.4: The packing arrangement of Olanzapine dihydrate with water molecules 
in blue (a) and Olanzapine anhydrate (b) molecules down “a” axis.41 
HYDRATES 
It is well known that solvates are formed by the incorporation of solvent molecules in the 
crystal structure of the active compound generally during the crystallisation process. 
However, when the included solvent is water, then in this case the crystallised solid would 
be referred to as a crystal hydrate. Due to the ubiquitous nature of water in the 
environment and its inclusion in solvent mixtures during the crystallisation process, the 
incorporation of water molecules into crystal structures is sometimes inevitable.
42
 
Hydration of an anhydrous crystal exposed to water can be explained by the following 
reaction: 
A(c) + x.H2O    A.x.H2O(c)           Equation 1.2 
Where A(c) is the anhydrous crystal and x; the amount of water molecules participating in 
the formation of a hydrate (A.x.H2O(c)).
42
 
And this is only possible if water activity is sufficient enough to allow the hydration 
process. Like solvates, hydrates consist of two-component systems (figure 1.5) and they 
are disclosed through factors such as pressure, temperature and water activity. Properties 
of water such as its small size and the ability to act as proton donor (in hydrogen bond 
formation) and acceptor favour its incorporation of water molecules into many areas 
within a crystal lattice, either as a filler of a vacancy or empty space in the lattice or as a 
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crystal stabilising force whose removal would substantially cause the crystal structure to 
collapse.
42
 
 
Figure 1.5: Solvates (A) and hydrates (B) arranged in the crystal lattice.
43,44,45,46 
Water molecules can also act as a link between molecules in the crystal structure. Thus, the 
ability of water in hydrogen bonding is to support the crystal structure of the hydrates. In 
the crystal, water molecules can bind to nearby water molecules or to functional groups of 
the compound. The change in volume of the unit cell is proportional to the volume of 
water molecules added or removed from the hydrate system. It is well understandable that 
any change of water activity during the life-time of the active drug can be of great concern.  
And this is the reason why a third of all pharmaceutical solids are crystal hydrates. A good 
understanding of how an active compound and excipients behave when exposed to water is 
very important.
43,44,46
 
CLASSIFICATION OF HYDRATES 
Two aspects, crystal structure and crystal energy must be considered when classifying 
hydrates. The former which is mainly used in the pharmaceutical industry, classifies 
hydrates into three different classes
46
: 
CLASS I 
In this class also known to the name of isolated site (lattice) hydrates, water molecules do 
not come into contact with each other and dehydration of this class of hydrates occurs very 
slowly even when heated to the actual dehydration temperature.
46
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CLASS II 
Channel hydrates, also referred to as lattice channels, are hydrates in which water 
molecules are part of the crystal structure and they can be in contact with each other in the 
crystal lattice. The adjacency of these water molecules leads to the formation of channels 
that spread throughout the lattice of the crystal. When exposed to heating, the dehydration 
process (which does not impact the crystal structure) starts early. At a definite temperature 
the hydrated system will have a sufficient amount of free energy for the molecules of water 
on the surface to be removed first. According to Morris, after this removal, the channel is 
exposed and a thermodynamic gradient exists in the direction of the water being removed. 
This may finally lead to the formation of an amorphous form.
46,47
 
This class can be further subdivided into expanded (also referred to as non-stoichiometric) 
hydrates, planar hydrates (lattice planes) and dehydrated hydrates.
45,46
 
CLASS III 
This class contains ion-associated hydrates. Its characterisation is based upon the co-
ordination of water and metal ions. The strong interaction between water molecule and 
metal ion affects the structure of the crystal. Therefore, due to these interactions, 
dehydration commences at a very high temperature.
46,47
 
AMORPHOUS 
Amorphous is another type of solid form characterised by a short range molecular packing 
in the structure. Research on the amorphous form has been of a great concern in the 
pharmaceutical industry due to the necessity to overcome the poor physical and chemical 
properties of crystalline solid forms.
48
 
Amorphous is also referred to as liquid-like solid forms since they present a similar 
structure to that of liquids while exhibiting solid properties.
48,49
 Variable intermolecular 
distances between molecules in the structure of amorphous solids are longer than those 
found in the crystalline solid form (figure 1.6). Thus, molecules have more energy and are 
free of motion in disorganised conformations throughout the amorphous solid form.
43,50,51
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Figure 1.6: Structure representation of an amorphous form. 
Therefore, an amorphous solid;  
 Presents different physical and chemical properties from those of crystalline solid 
forms of the same drug. 
 They are isotropic since properties of solids depend on direction of dimension of 
molecular packing. 
 They are characterised by their low stability compared to that of the crystalline 
form. 
 They are unstable thermodynamically compared to their crystalline counterpart, 
due to the low chemical and structural stability.
50
 
However, if chemically and physically stable, the molecular mobility of an amorphous 
form is profitable since it leads not only to the improvement of the dissolution rate of the 
API and subsequently enhanced bioavailability after oral administration, 
45,50,52,53,54
 but 
also to enhanced solubility as shown by novobiocin (figure 1.7). 
 
Figure 1.7: The molecular structure of novobiocin. 
 
 
        
 
 
 
 
 
Chapter 1 
 
 
14 
 
POLYMORPH PREPARATION 
The existence of polymorphs is a critical problem for pharmaceutical companies. 
Therefore preparation as well as investigation, the rudimentary step in preformulation 
should be conducted to avoid later problems. Pharmaceutical companies are required to 
prove that prospective polymorphism of marketed drugs has been investigated in order to 
avoid undesired polymorphs filtering through to the consumer. 
The knowledge about methods that are likely to produce different polymorphs of the same 
compound is also of utmost importance. Various methods are suggested in producing 
polymorphs, solvates, hydrates and amorphous forms.
31
 These methods include 
sublimation, crystallisation from a single or binary solvent system, vapour diffusion, 
thermal treatment on differential scanning calorimetry (DSC), crystallisation from the 
melt, rapid pH changes, thermal desolvation of crystalline solvates, growth in the presence 
of additives and grinding (either dry or solvent assisted grinding). Among these methods 
crystallisation from solution using different solvents is usually the first step in the search 
for polymorphic forms of a compound and has been very successful in many cases.
31
 
POLYMORPH IDENTIFICATION 
TYPES OF POLYMORPHS 
There are two types of polymorphs (figures 1.8 & 1.9) depending upon the stability of 
polymorphs with respect to their range of temperatures and pressures called monotropes 
and enantiotropes. 
In the case where one of the polymorphs is stable (has lower Gibbs free energy content and 
thus poorly soluble) over a certain temperature range and pressure, whereas the other 
polymorph is stable over a different range of temperature and pressure, then the two 
polymorphs are said to be enantiotropes (figure 1.8). 
Polymorphs are said to be monotropes when only one polymorph is stable at all 
temperatures below the melting point, while all the other polymorphs are unstable. Both 
types of polymorphs can be easily understood by looking at the graphs of figures 1.8 &1.9 
describing the variation of Gibbs free energy (G) against Enthalpy (H).
21
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The graphs (figures 1.8 & 1.9) not only help in the assessment of thermodynamic 
relationships between different polymorphs of the same active ingredient but also allows 
for the calculation of transition temperatures. Considering two polymorphs A and B, in 
figures 1.8, polymorph A is stable below the transition temperature (Tt) and therefore has a 
lower free energy (GA) than polymorph B. But as the temperature increases and becomes 
more or higher than the Tt, the free energy (GB) of polymorph B becomes less than that of 
A (GA); thus polymorph B becomes more stable than polymorph A. This gives rise to an 
enantiotropic system of solid phases. 
For an enantiotropic system, a reversible transition can be observed at a definite transition 
temperature at which the free energy curves cross, before the melting point is reached, 
hence the reversibility. Whereas in figure 1.9, polymorph A has its free energy less than 
the other polymorphs throughout the range below the melting point. 
For a monotropic system, the free energy curves do not cross each other, and therefore no 
reversible transition can be observed below the melting point; the polymorph with higher 
free energy curve and solubility, is the unstable polymorph.  
It is possible to distinguish between monotropes and enantiotropes from their heats of 
fusion. An endothermic polymorphic transition indicates enantiotropes whereas an 
exothermic one indicates monotropes. Other than differential scanning calorimetric (DSC) 
analysis, there are a number of efficient ways to characterize polymorphs,
28,55-59
 such as 
vibrational spectroscopy,
60
 thermogravimetric analysis (TGA), X-ray powder diffraction 
(PXRD) methods and the most preferred, single X-ray diffraction (SXRD). However, the 
combination of all these methods gives the most outstanding results. 
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Figure 1.8: Energy-temperature diagram for the identification of the enantiotropy 
dimorph.
151 
 
Figure 1.9: Energy-temperature diagram for identification of the monotropy 
dimorph.
151 
In these figures (figure 1.8 and 1.9), T refers to the absolute temperature. While A and B 
respectively denote form-A and form-B, subscripts L, m and t refer to as liquid state, 
melting or fusion and transition temperature. ∆Ht and ∆Hm denote the polymorphic 
transition and fusion. The graphs (figure 1.8 &1.9) explain and were constructed based on 
the  G = H − TS  relationship where G as previously mentioned is the Gibbs free energy, 
H the enthalpy and S being the entropy. 
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Apart from this graph, different rules were set to thermodynamically distinguish 
monotropy and enantiotropy polymorphs. The Burger and Ramberger rules 
61 
are based on 
statistical mechanical arguments of an ideal model of molecular crystals and are as 
follows: 
Heat of transition rule: states that if an endothermic phase change is observed at a 
particular temperature, the stability relationship is enantiotropic, otherwise it is 
monotropic. 
Heat of fusion rule: states that when the higher melting polymorph has the higher heat of 
fusion, the stability relationship is monotropic, and if not so, it is enantiotropic. 
Entropy of fusion rule: according to this rule if the higher melting polymorph has the 
higher entropy of fusion, the stability relationship is monotropic, otherwise it is 
enantiotropic. 
Heat capacity rule: If the higher melting polymorph has the higher heat capacity at a 
given temperature then the stability relationship is enantiotropic, otherwise it is 
monotropic. 
Density rule: The more stable polymorph/form at the absolute zero of temperature should 
have the higher density. 
Infrared rule: this rule is applied to polymorphs having strong hydrogen bonds. The one 
that possesses the larger frequency for the highest frequency infrared absorption band will 
eventually have the larger entropy.
61
 
Pure thermodynamic arguments may also be used to assume, the difference in Gibbs free 
energy of the polymorphs, and their temperature gradients at the melting point of the lower 
melting polymorph as well as the extrapolation of the temperature gradients to their 
intersection, yielding the transition temperature Ttr. These lead to the stability relationship 
and transition temperature at the same time; an advantage to the former/previous rules. 
Form 2 (Tf,2) → Form 1 (Tf,2)  are: 
 
ΔH0 = ΔHf,2 - ΔHf,1 + (Cp,L – Cp,1) (Tf,1 – Tf,2)             equation 1.3 
ΔS0 = ΔHf,2/Tf,2 - ΔHf,1/Tf,1 + (Cp,L – Cp,1) ln (Tf,1/Tf,2) and            equation 1.4 
ΔG0 = ΔHf,1(Tf,2/Tf,1-1) + (Cp,L – Cp,1) [Tf,1 – Tf,2 – Tf,2 ln (Tf,1/Tf,2)]           equation 1.5 
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Where the subscript 0 is referred to as the function at the melting temperature of the lower 
melting form and (Cp,L – Cp,1) is the difference in heat capacities of supercooled liquid 
and Form 1 between the temperatures Tf,2 and Tf,1. ΔG (T) having the linear dependence;  
The ΔG(T) = ΔG0 - ΔS0 (T-Tf,2)  with ΔG(Ttr) = 0  
gives yield to  Ttr = ΔH0 /ΔS0                  equation 1.6 
In exception of (Cp,L – Cp,1) that was obtained from the equation k = (Cp,L – Cp,1)/ΔHf,1, where   
k based on an empirical study of miscellaneous polymorphic systems, is approximately 
equal to 0.003/K, all parameters in the above equations are directly attained from 
differential scanning calorimetry data.
62
 
KINETICS OF POYMORPHS 
Apart from thermodynamic data that mainly deals with direction and conditions of solid to 
solid transformation as assessed by thermodynamic rules according to Burger and 
Ramberger, kinetic consideration is also important in polymorphic distinction of solid state 
drugs. This is how crystallisation of the same drug in various polymorphs occurs. If, for 
example a metastable form is found, consequently the kinetic pathway, determines which 
form is to be formed by transformation of that metastable form and how long this will 
take.
96
 
Thermodynamic transformation of a metastable into a stable form which is normally 
forbidden by Gibbs energy of activation, is only possible if forces holding together the 
metastable phase are overcome and allow molecules in the crystal to rearrange into a stable 
crystalline phase.
96
 
PHYSICOCHEMICAL CHARACTERISATION OF POLYMORPHS 
The characterization of polymorphs is of utmost importance when studying polymorphism 
and there are several analytical methods ranging from simple melting point determination 
to complete structural determination of the different form.  
The morphology of crystals is observed by microscopic methods, phase transition by 
thermal methods, interpretation of molecular motion and chemical environment by the use 
of vibrational spectroscopy and solid-state NMR.
27,62-66
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A successful single crystal X-ray diffraction analysis can provide unambiguous atomic 
positions and complete structural information, but obtaining a single crystal suitable for 
such a study often becomes the bottleneck. In such cases, powder X-ray diffraction studies 
using microcrystalline samples become a major tool. In fact, it has become routine to take 
powder diffractograms to ascertain the solid state nature and purity of every batch of 
synthetic drugs.
28,56-59
 
Another quick and efficient method is to study the crystal morphology by optical 
microscopy. As unit cell repetition leads to crystal formation, this feature is reflected in the 
outer appearance of crystals that can be observed by simple hand lens or a microscope. A 
detailed study can be performed using polarizing optical microscopy, electron microscopy 
and thermal microscopy. 
The third important method, which is widely used in pharmaceutical industries for 
characterization of polymorphism, solvation, purity, degradation and drug compatibility, is 
thermal analysis, which includes thermogravimetry, differential thermal analysis (DTA) 
and differential scanning calorimetry (DSC).
12,26-29
 
The study of molecular motions by use of vibrational spectroscopy is also sometimes 
employed in the characterization of polymorphs. This method includes infrared absorption 
spectroscopy and Raman spectroscopy. Today solid state NMR is also used for 
characterization when studying the chemical environment of the nuclei which is different 
in polymorphs because of magnetic non-equivalence. Resonance peaks for the 
magnetically non-equivalent nuclei will differ in different polymorphs and this can yield 
very useful information.
28,57,58,59,67
 
IMPACT OF POLYMORPHISM ON DRUG PRODUCT 
Knowing that most drug substances can exhibit the phenomenon of polymorphism, a 
special analytical concern should be made. This is because the phenomenon can affect 
each and every stage of the drug development stages, starting from the preclinical to the 
post marketing phase of the drug product, the reason why special care must be taken from 
the beginning. Particularly, a very careful attention on polymorphs and their effect on the 
drug product bioavailability and chemical decay during stability should be paid in the late 
investigation stages that follow the entire development.  
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The same thing must be done to the post marketing stage to assess whether polymorphism 
can have an impact upon the quality of the final and finished product during storage, 
transport and distribution.
63
 
POLYMORPH SELECTION 
The selection process of a polymorph for formulation is a critical and very important step. 
Therefore it requires the collaboration of different key personnel, such as process chemists, 
engineers, formulators and material scientists. Each physicochemical property for all solid 
phases must be carefully evaluated and compared to be able to decide which one is best for 
selection. Important physical properties such as chemical and physical stability, 
bioavailability, dissolution rate, solubility and hygroscopicity are diligently evaluated. 
Manufacturability and processability must not be ignored since these may have an 
implication on processing. Particle size of crystals is crystallisation process dependant. 
However, milling may also lead to the conversion of crystalline to amorphous phase.  
The most thermodynamically stable polymorph is of preference for product development 
since risks of conversion during manufacturing, packaging and storage is low. The 
exception is made when the lowest-energy form (amorphous or metastable polymorph) 
(solid dispersion) is desired and allowed for development. In this instance, justifiable and 
efficient reasons must be given and guarantee on safety of the patient must be provided.
68
 
However, the developability of a metastable form is more challenging compared to the 
most stable polymorph since the understanding of the impact of many additional factors 
such as humidity, process-induced stresses, processing variables on the phase transition 
and storage temperature is required.
69
 
SALT FORMATION 
INTRODUCTION 
A half of all drug molecules used in pharmaceuticals are administered as salts. The high 
percentage indicates the widespread use and justifies the abundance of crystalline salts 
available on the market.
70-72
 Salts constitute an alternative for drug delivery when the 
physicochemical properties of the parent compound are not suitable for a perfect 
formulation.  
 
 
 
 
Chapter 1 
 
 
21 
 
Salt formation is one of the most ancient traditional methods used to improve not only the 
physicochemical but also formulation, biopharmaceutical and therapeutic properties of the 
active pharmaceutical drug and this is achieved through the understanding of selected 
method.
10,73
 
Salt formation is a very old technique and dates back to the 1950’s when Nelson 
discovered and demonstrated that dissolution rates of salt forms of many weak acidic 
compounds were much higher than those of their respective free acid forms under 
gastrointestinal conditions.
74-82
 Since then and with the progress in medicinal chemistry, 
introduction of combinatorial chemistry and high-throughput screening in identification of 
new chemical entities, interest in salt formation has grown and become the most common 
technique applied in drug product development to increasing solubility and dissolution 
rate.
74-82
 
This is possible by enhancing the ionization which in turn enhances the molecule polarity, 
thus, the increased solubility of the drug molecule in aqueous solution. Furthermore, salts 
of weak acids and bases are often the solid-state equivalent of pH adjustment. A salt is 
normally produced from an anionic interaction between weak acidic or basic drug 
molecules and complementary basic or acidic counterion. Dissolving a salt in an aqueous 
solution dissociates the acidic and basic counterion. In other words, salt formation is 
defined as an acid-base reaction between an API and an acid or basic substance
83
 
(Equation 1.6).  
Therefore, a salt is formed as a result of a proton (H+) transfer from an acidic (A) to a 
basic (B) medium where the pKa of the acid or base is a key factor from which the former 
can be predicted.  
      A − H + B → (A− )(B+ − H)                                            Equation 1.7 
A difference of about 2.7 pKa units between the conjugate acid and base is necessary for 
the formation of a salt.  
           Equation 1.8 
A typical example is of succinic acid (pKa 4.2) forming a salt with L-lysine base (pKa 
9.5). This explains well the reason why a salt is chosen from its free acid or base. 
pKa being the negative base -10 logarithm of the acid dissociation constant. 
[pKa base − pKa acid ≥ 2.7] 
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Brønsted-Lowry defined an acid as a substance that can donate a proton and a base as a 
substance that can accept a proton. The following equilibrium (equation 1.8) explains the 
dissociation of a monotropic acid HA in the aqueous medium. 
     AHHA aK                    Equation 1.9 
Where, Ka is referred to as the equilibrium constant, and it is described by the following 
equation; 
     𝐾𝑎 =
[𝐻+][𝐴−]
[𝐻𝐴]
      Equation 1.10 
The dissociation of the basic compound can be expressed by the following reaction 
     BHHB
aK
        Equation 1.11 
And 
𝐾𝑎 =
[𝐻+][𝐵]
[𝐻𝐵+]
      Equation 1.12 
Where, Ka is the dissociation constant of [𝐻𝐵+]. 
Therefore, isolating a drug as a particular salt form alters the nature of its crystal lattice 
(figure 1.10), leading to widely different physicochemical properties. Compared to the 
untreated compound of the same drug, the change mentioned above, modifies the 
dissolution rate which in turn modifies solubility of the untreated drug (free acid or free 
base of the same parent compound). 
 
Figure 1.10: Salt molecules arranged in the crystal lattice.
43, 44, 45, 46
 
 
 
 
 
Chapter 1 
 
 
23 
 
When salts are subsequently allowed to dissolve and dissociate in water, the acidic or basic 
counterion from which they were derived causes a shift in the pH of the solution to provide 
an analogous endpoint to that obtained by pH adjustment. Diclofenac is a good example of 
the advantage of salt formation. The non-ionised form of diclofenac {2-[(2,6- 
dichlorophenyl)amino]benzeneacetic acid} is poorly soluble in water (<0.02 mg/mL) 
(figure 1.11) while; the sodium or potassium salt forms of diclofenac are >400 times more 
soluble in water.
84
 
 
Figure 1.11: The structure of diclofenac vs sodium diclofenac hydrate. 
 
PROPERTIES OF SALTS 
Different salts of the same active drug rarely differ pharmacologically, only differences 
appear in their physical properties. In addition, Wagner elaborated on this statement and 
said that although the nature of biological responses provided by different salts of the same 
parent compound may not differ significantly, the intensity of response may clearly vary.
85
 
As mentioned above, salt formation affects physicochemical properties of the parent 
compound such as dissolution rate, solubility, stability, and hygroscopicity. 
Pharmaceutical industry formulators are systematically engaged in studying each new drug 
entity extensively in order to determine the most effective form for formulation.  
DISSOLUTION 
The dissolution of an API is a very important property in pharmaceutical formulation since 
this reflects the bioavailability of the compound especially with the poorly soluble drugs.
86
 
Pharmaceutical salts exhibit a higher dissolution rate than that of the corresponding 
conjugate acid or base at equal pH and equilibrium solubility.  
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Description of this property is given by a diffusion model in the following equation 
(Equation 1.12) developed by Nernst and Brunner.
86
 
𝑑𝑊
𝑑𝑡
=
𝐷𝑆
ℎ
(𝐶𝑠 − 𝐶)       Equation 1.13 
Where W is the mass of solute dissolved at time t, dW/dt is the rate of mass transfer per 
unit time, D is the solute molecule dissolution coefficient, S is the surface area of 
dissolving solid, h is the diffusion layer thickness, C is the concentration of the drug in the 
bulk solution at time t, and Cs is the saturation solubility of the solute in the diffusion 
layer. 
86
 
The difference between saturation solubility and concentration of the drug in the bulk 
solution being the driving force for dissolution, if the drug is not absorbed rapidly after 
dissolution, then its concentration C in the bulk solution approaches Cs and the dissolution 
is retarded. In this case the absorption rate (or membrane transport) is limited accordingly. 
The dissolution rate is proportional to saturation solubility (Cs) of the drug in the bulk 
solution.
87
 
However, when the absorption occurs rapidly (if absorption mass transfer is higher than 
DS/h (Equation 1.12) C becomes negligible compared to Cs, and dissolution is said to 
occur under sink conditions (dissolution of the expected amount of drug). In this instance, 
absorption is dissolution limited (case of most poorly soluble drugs).
87
 
Salts frequently enhance dissolution by efficiently acting as their own buffers to change 
the pH of diffusion layer, therefore providing the parent compound with the increased 
solubility Cs over its intrinsic solubility at the pH of the dissolution medium. 
SALT SOLUBILITY 
Solubility of a drug depends essentially upon physical and chemical properties of the 
solute. (e.g., a lower melting point for a compound within a series reveals a reduced energy 
of the lattice, thus a higher solubility). Salts exhibit a higher solubility compared to their 
corresponding acid and base forms of the same compound. However, a careful study needs 
to be performed.
88,89
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SALT SELECTION 
The choice of optimized form is a difficult task due to the fact that each salt imparts its 
unique behaviours to the parent compound of the same drug. In other words various salts 
of the same compound behave very differently due to physical, chemical and 
thermodynamic properties they impart to the parent compound.  Therefore, a very good 
understanding of the physicochemical characteristics is required. However, most of the 
time this choice is based on the cost of raw materials, ease of crystallisation and 
percentage yield. Consideration of other properties such as stability, hygroscopicity, 
flowability of the resulting drug as well as toxicity is of outmost importance.
93,94
 
CO-CRYSTALLISATION 
INTRODUCTION TO CO-CRYSTALLISATION 
While crystallization/recrystallization is regarded as a key purification and separation 
technique used in the pharmaceutical and fine chemical industries, co-crystallization is a 
method of combining two or more former molecules using intermolecular interactions 
between the molecules without creating or breaking covalent bonds.
27 
This is often referred 
to as supramolecular synthesis. Therefore, to explore the co-crystallization potential 
around an API increases the intellectual property protection over a particular drug product; 
thus, reducing the risk of costly litigation and market erosion
11
 
PHARMACEUTICAL CO-CRYSTALS 
Pharmaceutical co-crystals can be defined as crystalline molecular complexes of two or 
more neutral molecular constituents bound together in the crystal lattice through non-
covalent interactions, primarily hydrogen bonding.
95 
The formation of co-crystals represents a potential route (and an alternative strategy to salt 
formation, polymorph formation that sometimes lead to solvate and hydrate formation by 
incorporation of solvent in the crystal system) to achieve pharmaceutical materials with 
improved properties of interest, including dissolution rate and stability under conditions of 
high relative humidity,
96 
properties that once administrated may lead to the product is poor 
performance if not well investigated.  
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Pharmaceutical co-crystal technology is used to identify and develop new proprietary 
forms of widely prescribed drugs and offer a chance to increase the number of forms of an 
API.  
The formation of a pharmaceutical co-crystal involves incorporation of an API with a 
pharmaceutically acceptable molecule in the crystal lattice and the resulting 
multicomponent crystalline phase maintains the intrinsic activity of the parent API.
97 
Hence, pharmaceutical co-crystals are referred to as non-ionic supramolecular complexes 
made by incorporation of two neutral molecules in the crystal lattice, one being an API and 
the other  a co-former
38 
and due to their structure can be used to address physical property 
issues such as solubility, stability and bioavailability in pharmaceutical development 
without changing the chemical composition of the API.
98
  
The co-crystal former employed in co-crystallization studies may be an excipient or 
another drug
99 
and a clear understanding of the supramolecular chemistry of the functional 
groups present in a given molecule is mandatory for designing a co-crystal because it 
facilitates selection of relevant co-crystal formers. A number of pharmaceutical co-crystals 
have been reported to date with co-crystal formers selected from the list of GRAS 
(generally recognized as safe) compounds which includes various food additives, 
preservatives and pharmaceutical excipients.
2 
Figure 1.12 below shows how active 
pharmaceutical ingredients and a stoichiometric amount of a pharmaceutically acceptable 
co-crystal former are arranged in the crystal.  
 
Figure 1.12: The co-crystal molecules arranged in the crystal lattice. 
Because crystalline materials either (single or multiple components) obtain their principle 
physical properties from their molecular arrangements within the solid, any change that 
alters the placement and interactions between these molecules, can have a direct impact on 
the properties of the particular solid.
35 
Therefore, any disturbance either physical or 
chemical may lead to the formation of a new different product. 
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PHARMACEUTICAL CO-CRYSTAL FORMATION AND DESIGN 
Crystal engineering is defined as “the understanding of intermolecular interactions in the 
context of crystal packing and in the utilization of such understanding in the design of new 
solids with desired physical and chemical properties” 101,102 It offers a rational approach to 
the design of new composition and crystal structures. Though, the great understanding of 
how achievable crystalline forms are made. Intermolecular interactions play a significant 
role because they intervene during the crystal packing process and self-assembly, with 
hydrogen bonded networks being the primary and the most commonly studied since a 
certain degree of reliability and predictability exists regarding the interaction of donors and 
acceptors. 
Different researchers have addressed the hierarchy of the supramolecular synthons that can 
occur for a range of common functional groups in order to design new co-crystals and 
certain functional groups such as carboxylic acids, amides and alcohols are particularly 
compliant to the formation of supramolecular heterosynthons (i.e. non-covalent bonds 
between different but complementary functional groups).  
It is becoming evident that these interactions are quite essential to implement a design 
strategy for co-crystals in which a target molecule forms co-crystals with a set or sequence 
of co-crystal formers that are carefully selected for their ability to form supramolecular 
heterosynthons with the target molecule. The statistics that are provided by Cambridge 
Structural Database suggest that as illustrated in figure 1.13, the carboxylic–pyridine 
supramolecular heterosynthon (figure 1.13b) is much more likely to occur than the acid–
acid supramolecular homosynthon (figure 1.13a) and supramolecular heterosynthon (figure 
1.13d) is favoured over homosynthons (figure 1.13a) and (figure 1.13c). Being 
energetically more favoured, heterosynthon formation is the most consistent and robust 
route for co-crystals designing. This is the type of database mining that makes co-crystals 
designable because if the acid and pyridine moieties are in different molecules then it 
follows that a co-crystal is the likely outcome.
 27,102-107
 
As a result of competing molecular associations through hydrogen bonds between similar 
molecules or homosynthons and different molecules or heterosynthons as to figure 1.13, 
pharmaceutical co-crystallization is therefore a reliable method to modify physical and 
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technical properties of drugs such as solubility, dissolution rate, stability, hygroscopicity 
and compressibility without alternating their pharmacological behaviour 
107,108
 
  
Figure 1.13: Representation of homosynthons and heterosynthons. 
Co-crystals in their pure states are solids at room temperature generally and by convention, 
these normally exclude salts. Co-crystals can have different properties to the crystals of 
individual components. They also have different crystal structures to the pure components 
and contain different intermolecular packing patterns. Therefore, co-crystals often exhibit 
widely different physical properties to the pure components. 
Furthermore co-crystals are an alternative to salts when these do not have the appropriate 
solid state properties or cannot be formed due to the absence of ionization sites in the 
API.
110
 Thus, co-crystals of the same active pharmaceutical ingredient will thus have 
strikingly different pharmaceutical properties (viz. melting point, solubility, dissolution, 
bioavailability, moisture uptake, chemical stability, etc.) depending on the nature of the 
second component or co-former. Here are examples of synthesized co-crystals in which 
some had higher melting points and others had lower as compared to their pure 
components. For example, succinic acid (m. p. 135.3 ˚C), urea (m. p. 188.9 ˚C), co-crystal 
of succinic acid and urea (m. p. 149.9 ˚C).111 
The physical and chemical property improvements through pharmaceutical co-crystals 
draw closer the fields of crystal engineering and pharmaceutical sciences.
108,112 
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CO-CRYSTALS CHARACTERISATION 
The characterisation of every new compound is compulsory and must be performed in the 
early stage of drug development.  
This is necessary to avoid problems later and consequences that may rise during pre-clinic 
or post-clinic phases as well as lifetime effects of the drug product. A co-crystal as a new 
multicomponent compound must undergo such identification. 
Different analytical techniques are used when attempting to characterise a co-crystal, 
especially when establishing a co-crystal from a salt, a very difficult process due to the fact 
that the two crystalline materials are alike physically.  
Single crystal X-ray diffraction being the preferred characterization technique is used in 
determining whether a co-crystal has been produced. However, suitable X-ray quality 
crystals cannot always be generated. Therefore other techniques may be necessary.  
A variety of solid state spectroscopic techniques are also employed as an attempt to 
characterize potentially new co-crystalline materials.
89
 These include Raman, H
1
NMR and 
Solid state NMR spectroscopy which play a significant role especially when determining 
the proton transfer from acid to base (location of hydrogen atom determination), the 
process which may be enigmatic.
104,113
 Infrared spectroscopy is powerful tool in detecting 
co-crystal formation, especially when a carboxylic acid is used as a co-crystal former 
and/or when a neutral O-H⋯N hydrogen bond was established between an acid and a base. 
This is indicated by shifts in peaks as well as formation of new peaks in the pattern of the 
resulting co-crystal.  
Distinct differences within the FTIR spectra can be observed between a neutral carboxylic 
acid moiety and a carboxylate anion. A neutral carboxylate (-COOH) displays a strong 
C=O stretching band around 1700 cm
−1
 and a weaker C−O stretch around 1200 cm−1, 
while a carboxylate anion (-COO−), due to resonance, displays a single C−O stretch in the 
fingerprint region of 1000−1400 cm−1. Additionally, if a neutral intermolecular O-H⋯N 
hydrogen bond has formed between the components, then two broad stretches around 2450 
and 1950 cm
−1
 will be observed.
21 
Observations about the state of the carboxylic moiety 
(neutral or ionic) can also be verified through measuring the C−O and C=O bond distances 
from the single-crystal X-ray data.  
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A typical C=O bond distance is around 1.2 Å, while the C−O bond distance is around 1.3 
Å; however, if deprotonation has occurred then the resonance stabilized C−O bond 
distances will be very similar.
104,113
 
PROPERTIES OF PHARMACEUTICAL CO-CRYSTALS 
Physicochemical properties of co-crystals must be carefully investigated like other solid 
forms for the determination of reproducibility and hence the developability into the 
marketable dosage forms. 
MELTING POINT 
The determination of the melting point of a compound as a means of characterization or 
purity identification is an orthodox practice. Melting point plays a significant role in 
pharmaceutical sciences. The existence of a relationship between the melting point and 
aqueous solubility and vapour pressure guarantee a significant role played by the former in 
pharmaceutical sciences.
114
 Accordingly, in fact, the melting point has been directly 
correlated to the Log (logarithm) of solubility, although assumptions pertaining to the 
entropy of fusion had to be drawn.
115
 
In addition, being able to determine the melting point of a particular API before it is 
synthesized would be very beneficial in order to adjust its aqueous solubility toward a 
particular function. However, it is unfortunate that correlations relating the chemical 
structure directly to melting point data remain fugitive.
116
 
Given the various factors contributing to the melting point of a crystalline solid including 
the molecular arrangement within the crystal lattice, molecular symmetry, intermolecular 
interactions and conformational degrees of freedom for a molecule, one clearly sees the 
difficulties when attempting to draw stringent comparisons from molecular structure to 
crystalline lattice energy to melting point.
117
 The situation only becomes more complex 
when observing multicomponent (e.g. the case of co-crystal) systems, for each component 
has its own characteristic properties and those can influence the environment (and 
intermolecular interactions) around its neighbours. 
In this section we will examine the thermal behaviour of co-crystals in which one 
component is an API, although findings and trends should be translatable to all co-
crystalline materials. 
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Comparison of the melting points of 10 co-crystals to the API AMG517 and their 
respective co-formers was conducted.
92 
Each of the co-crystals displayed a melting point 
that fell between the melting point of AMG517 and their co-former. A plot was generated 
using the melting points of the co-crystals and co-formers and displayed a direct 
proportionality between the two.  
A correlation coefficient was determined (r = 0.7849) which means that 78% of the 
variability of melting point of the co-crystal can be attributed to the variability of the co-
formers melting point. These data show that within the set of AMG517 co-crystals the 
melting point can typically be modified in accordance with the selected or chosen co-
former. If a higher melting co-crystal is desired for example, then a higher melting co-
former should be selected and vice versa.
117
 However higher melting point may lead to the 
poor solubility. Therefore, it is also necessary to assess stability properties. 
 
Figure 1.14: Illustration of co-crystal and co-former m.p. correlation. 
 
STABILITY 
Stability comes among essential studied parameters during the development of a new 
chemical entity. Different types of stability are considered depending on the structure and 
characteristics of the molecule. Chemical and physical stability data are commonly 
obtained at accelerated stability conditions to determine the drug developability and shelf 
life.
91
  
Because water uptake is included from a handling and packaging point of view, the 
amount of water present can also lead to form changes and degradation. Therefore, the 
effect of the water uptake should be carefully investigated early in the process.
92
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Thermal stress studies are also incorporated, and extra work may be warranted for hydrates 
or thermally labile materials.  
In the case of co-crystals and salts, solution stability may be a factor due to dissociation of 
the material resulting in precipitation of the less soluble parent compound or a less soluble 
form (such as a hydrate in aqueous media).
92
 
RELATIVE HUMIDITY STRESS 
The changes in relative humidity (RH) range are a key consideration when developing a 
co-crystal as observed in other solid state forms of a compound.
91,92
 
When studying co-crystals, it is necessary to measure the moisture uptake in order to 
establish principles regarding the environmental contact with the compound being 
investigated and thus come up with orientations and direction to more comprehensive 
studies.  
In this process, data from X-ray powder diffraction (PXRD) of the solid are collected at 
the end of the moisture balance experiment and provides information on the final form, but 
not necessarily on any form conversions that may have occurred during the experiment. 
Significant moisture uptake during the course of the experiment may guarantee a longer 
exposure at a specific relative humidity by the use of a relative humidity chamber and 
subsequent analysis of the sample after equilibration. 
For co-crystals, the limited water sorption/ desorption data was found. Different examples 
such as a 1:1 indomethacin/ saccharin co-crystal showed water uptake that is about < 0.05 
% water.
118 
The obtained data suggested that there was no solid-state transformation that 
occurred, although no PXRD data were reported after the moisture balance experiment. 
Therefore, there is not a major concern for co-crystals. Attention should be taken when co-
crystals are exposed to the RHS for a long period since this can create serious effects. 
THERMAL STRESS 
High temperature stress is also a common condition used to determine chemical and 
physical stability of a compound, based on accelerated stability conditions.
90
 This is 
applicable on co-crystals as well. For example, Paracetamol co-crystals were analysed by 
DSC.
119
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Paracetamol/4, 4-bipyridine co-crystal sample did not show any loss of guest upon heating 
and exhibited a melting endotherm corresponding to the monoclinic form of Paracetamol. 
No additional data were included to confirm the conversion, but this type of study can 
provide very important information on high temperature transitions and processes such as 
drying and accelerated stability.
111
 
SOLUTION STABILITY  
Solution stability is defined as the ability of the co-crystal components to stay in solution 
and not readily crystallize, it can be an important parameter to investigate during 
development, not only limited to solutions or suspensions, but also applied to solid dosage 
forms that will dissolve in the gastro-intestinal (GI) tract. A variety of vehicles can be 
employed including water, simulated gastric fluid (SGF), simulated intestinal fluid (SIF), 
formulation vehicles, and buffered solutions. In many cases, solubility or dissolution 
experiments can be incorporated in order to get a more complete picture of the behaviour 
and the solid form remaining at the end of the experiment. Because dissociation of a co-
crystal can occur, then solution stability can be a key consideration for development. The 
results however should always be weighed with other properties and needs. 
Studies of co-crystals in water can give an indication of possible dissociation and 
precipitation of another form such as a hydrate. During the study of caffeine co-crystals,
123
 
the 2:1 caffeine/oxalic acid co-crystal was found to be stable at all relative humidities up to 
98% RH for a seven week period. For further tests of the stability, the material was 
slurried in water at ambient temperature for two days. No change in physical form was 
observed, demonstrating the stability of the material. In order to determine the form 
present in aqueous solutions of a 1:1 carbamazepine/saccharin co-crystal, the material was 
slurried with equal parts carbamazepine dihydrate and saccharin in solution.
121
 After one 
day, only the co-crystal was evident based on PXRD data and the carbamazepine dihydrate 
was not detected. 
SOLUBILITY 
Improvement of a poorly soluble compound is one of the main reasons to investigate co-
crystals. For neutral molecules, co-crystals can certainly expand the solid forms possible 
for development. For a free acid or free base, both salts and co-crystals can be used to 
improve the solubility. 
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However, it is not always straightforward to determine whether a salt or a co-crystal has 
been formed
86
 and a variety of techniques may be needed from the simplest to the more 
sophisticated in order to understand the system. 
When studying solubility data, various considerations must be taken into account. The first 
one is the equilibrium versus kinetic solubility measurements. Kinetic solubility values are 
approximate values usually based on one measurement at one time point. For equilibrium 
solubility, a number of time points and measurements are taken to ensure that the solution 
has reached the equilibrium, as evidenced by a plateau in the concentration data. In other 
words, this is called powder dissolution.
53
 
The time required to reach the equilibrium solubility can also be a factor for development 
based on the residence time in the stomach and intestines. It is desirable to have the soluble 
drug while it is in the (GI) tract since very long dissolution times may result in less 
absorption of the drug. 
Powder dissolution rates can also be particle size dependent. Another consideration is form 
changes during the experiment. When form changes occur, the solubility data obtained 
may not be relevant to the starting compound in the experiment. Form changes can be 
suggested by solubility data collected at different time points by a precipitous drop in 
concentration indicating crystallisation of a less soluble form.
89,90 
Suggested form changes 
can be confirmed by analysis of the solid form remaining at the end of the experiment 
(figure 1.15). 
 
Figure 1.15: Schematic representation of a solubility curve caused by a form change 
and precipitation of a less stable form (curve A); at equilibrium, the curve will level 
out to the solubility of the less soluble form. Curve B represents the less soluble form. 
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INTRINSIC DISSOLUTION 
Dissolution rate is influenced measuring intrinsic dissolution and is a technique in 
functionality and characterisation of bulk substances as well as excipients. 
Intrinsic dissolution measures the rate of dissolution (the dissolution of a pure substance 
under the conditions of constant surface area)
122 
without the effect of particle size, the 
process that is accomplished by pressing a disk or pellet, normally using a Woods 
apparatus in a dissolution vessel.
118 
Over time the concentration of solution is measured to 
determine the dissolution rate (in mg/cm
2
.min). The disk must be left intact during the 
experiment, so compression pressures may be critical for poorly compressible powders. It 
is also important that there is no form change upon pressing the pellet or during the 
dissolution study. XRPD data can be obtained on the initial disk and the remaining disk 
after completion of the experiment to determine any major form changes that may affect 
the dissolution data.
91
 
A good example is that of glutaric acid where data for the glutaric acid co-crystal of 2-[4-
(4-chloro-2-fluorphenoxy) phenyl]pyrimidine-4-carboxamide
124 
were collected in water 
over 90 min and showed that the co-crystal dissolution was more or less 18 times faster 
than that of the parent compound. XRPD of the remaining solid showed mainly the 
glutaric acid co-crystal, with only minor peaks for the parent material, indicating that the 
results were not skewed by remarkable form changes over the course of the experiment.
126
 
BIOAVAILABILITY 
Bioavailability refers to the degree at which an active drug reaches the circulatory system 
when a given dose is administrated into the body.
92
 Animal bioavailability is an important 
factor to consider when preparing new forms of a compound, and studies are conducted in 
different ways in order to obtain specific information for development. Animals such as 
rodents, rabbits, dogs, pigs, and primates are commonly used in  bioavailability studies. 
Small studies (4-6 animals) are usually performed during early development to determine 
pharmacokinetic data quickly on a new form. Normally the same animals are usually used 
for all forms/formulations with a week washout period between the doses. This gives a 
direct comparison within the same animals for all the materials in the study.
92
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A study with both the parent material and the co-crystal will provide a direct appraisal of 
bioavailability enhancements due to the co-crystal. During bioavailability appraisal, the 
amount of drug in the blood is measured after oral administration of the original form and 
after administration of the co-crystal. Blood samples are taken periodically after dosing to 
investigate blood levels over time. It is important to note that the materials used in the 
study need to be formulated in the same way if a direct comparison is desired. Most dosing 
is done orally and formulation possibilities include powder in a capsule, powder and 
excipient in a capsule, or liquid formulations (solutions or suspensions). It is important to 
differentiate between solutions and suspensions since dissolution of the solid in a solution 
could significantly improve bioavailability.
124
  
For suspensions it is helpful to know how much of the compound may actually be 
dissolved in order to determine how that may affect the results. Absolute bioavailability 
includes not only the co-crystal formulation, but an IV formulation as well to determine 
maximum exposure based on the IV data and a comparison with the oral formulation.
124
 
As an example of how the co-crystal can improve bioavailablity, 1:1 AMG 517/sorbic acid 
co-crystal
124 
was compared to the parent free base in a rat bioavailability study. 
A significant increase in bioavailability was observed for the co-crystal. It was found that a 
30 mg/kg dose of the co-crystal resulted in comparable exposure to a 500 mg/kg dose of 
the free base.
124
 
CO-CRYSTAL POLYMORPHISM 
Investigation on different polymorphic forms of a particular compound is common in 
solid-state pharmaceutics. 
Because these polymorphic forms can have different physical and chemical properties, 
steps should be taken to identify and characterize all forms during development. 
Polymorphic co-crystals also exist and possess different physicochemical properties 
between them. 
As previously stated (polymorphism section), it was observed that the APIs form new 
species that present distinct physicochemical properties (polymorphs) due to crystallisation 
process. 
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Therefore, like other solid state compounds, the existence of polymorphic co-crystals is 
also possible
125 
and present different physicochemical properties between forms. 
A typical example of co-crystal polymorphism was observed when a chloroform solution 
of caffeine and glutaric acid were allowed to evaporate slowly and two polymorphs having 
different morphologies rods (form I) and blocks (Form II) were produced.
126
 
SCALE-UP 
Scalable processes offering high co-crystal purity and yields must be designed and 
established for a pharmaceutical co-crystalline material to move from small scale 
screening exercises to large scale for development of drug products. Co-crystal quantities 
of milligrams to a few grams are typically produced depending on the types of 
characterization and/or initial physicochemical studies such as the rate of dissolution, 
solubility study, bioavailability, etc. the materials are subjected to.
127  
Slow evaporation 
and grinding are two  reported  common techniques used for co-crystal growth; 
unfortunately the two approaches possess some limitations upon scale-up. Therefore, 
additional routes must be utilized.
127
 
In one account, the preparation of a carbamazepine/saccharin co-crystal was produced on a 
scale of 30 g using solution crystallization.
121
 where the components were dissolved in a 
ethanol-methanol mixture (3:1 ratio) and refluxed at 70°C for 60 minutes. The solution 
was cooled down and then filtered, the precipitate was dried and characterized as the 1:1 
co-crystal of carbamazepine and saccharin. Interestingly, no seeding applied under the 
reaction conditions selected for the production of the desired co-crystalline form in high 
purity.
127
 
Three criteria were outlined during the scale-up study of carbamazepine/nicotinamide co-
crystal using solution-crystallization methodology: (a) determine an appropriate solvent 
system; (b) identify the pathway, through multicomponent solid−liquid phase equilibrium 
diagrams, to produce the desired form; (c) determine a mechanism to induce nucleation 
and control the desaturation kinetics of the process. Through a seeding strategy in ethanol, 
the co-crystal was successfully produced on a 1 L scale with yields in excess of 90%. 
The use of ternary phase diagrams must be taken into consideration when scaling up co-
crystals from solution. This is because information regarding the relationship between 
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equilibria of the solid phases and solvent choices is obtainable. Critically, the individual 
components’ solubility must to be determined and mapped since the phase region where 
the most thermodynamically stable co-crystal is located will be altered due to whether or 
not they possess similar solubilities in a given solvent.
104,108,119,125,128,129
 
Scaleable co-crystal processes must be evaluated and optimized for the pharmaceutically 
based co-crystalline materials to move further into development and become viable options 
as marketed products. 
INTELLECTUAL PROPERTY AND MANAGEMENT OF LIFECYLE 
Patents are the basic element of drug development, especially in solid forms. 
Pharmaceutical patents can cover different areas such as composition of matter (molecular 
structure, solid form or formulation) method of use (medical indication) and 
manufacturing processes.
107
 Novelty, utility and non-obviousness are three criteria to be 
satisfied for an invention to qualify for patent coverage.
 
Co-crystals represent a broad patent space since there is a large number of co-formers 
available based on the possible compounds in the EAFUS (Everything Added to Food in 
the US) and GRAS (Generally Regarded as Safe) lists.
130,131
 Because of the lack of 
predictability in the field, it is expected that in many circumstances patent coverage will be 
narrow. 
Co-crystals can also play a role in lifecycle management
90,132
 that can involve drug product 
improvements along with new solid forms. Early in the development process, chemical 
structures are patented and additional IP protection can be obtained by patenting different 
solid forms throughout development.  
If an approved drug product contains a new patented solid form, especially where the solid 
form offers a commercial advantage over the original form, the solid form patent might 
provide meaningful IP protection after the expiration of the original patent. However, a 
solid form that was not found by the innovator, but was found and patented by a 
competitor, could significantly alter this strategy.  
Co-crystal screens for potential blockbuster drugs could end up being very large in order to 
protect, not only the co-crystals found, but also any polymorphs, hydrates, solvates, or 
other solid forms of the individual co-crystals.
27
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1-ADAMANTANAMINE 
1-Adamantanamine (ADT) free base, also called 1-aminoadamantane is an intermediate 
compound and it is an effective base for salt formation. The rate of activity of the free base 
compared to the salt forms might differ. Its trade names as the HCl salt form are 
Amantadine
®
, Midantan
®
 and Symmetrel
®
. It is used for its antiviral activity in the 
prevention and the early-stage treatment of influenza A. The drug also increases dopamine 
level in the CNS; it is for this reason why it is often applied in medical practice for the 
treatment of dementia, Parkinson’s disease, Alzheimer’s diseases, stroke, hypoxic brain 
afflictions and neuroinfections.
133-138
 
ADT possesses an interesting structure consisting of the presence of an adamantane moiety 
linked to an amino group which confers to the molecule the special chemical property of a 
diamond-like structure (figure 1.16).
148 
The system is rigid but strain-free demonstrating 
that there is no angle or torsional strain present. Consequently, it is a highly stable 
structure.
149
 
 
Figure 1.16: 1-adamantanamine (ADT) structure. 
ADT hydrochloride chemically referred to as tricycle (3.3.1.1
3,7
)decan-1-amine 
hydrochloride, is a stable, white or nearly white crystalline powder, freely soluble in water 
and soluble in alcohol and chloroform.
139
 
1-adamantanamine hydrochloride (ADTHCl) is a M2 inhibitor since it specifically inhibits 
replication of the influenza group A virus,
140,141
 containing the M2 protein (absent in B 
group viruses figure 1.17). The M2 protein functions as an ion channel and prevent 
exposure of the viral hemagglutinin to low intracellular pH to which it is sensitive.
144,145
 
The apparent antiviral activity of ADTHCl results from the ability of the drug to prevent 
viral penetration into the host cell by blocking ion channel proteins existing in the virion 
lipid envelope of the group A viruses or suppressing the uncoating process.
142,143
 
NH2
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Figure 1.17: The schematic presentation of 1-adamantanamine activity.
146 
The antiparkinson activity is less known, although it is also related to the ability of 1-
adamantanamine to block neuromuscular transmission, which may, however depend on its 
capacity to increase the synthesis and release of dopamine.
147
 ADTHCl is also believed to 
be effective against the dengue virus.
150
 The dengue virus belongs to the family of 
Togoviruses and the subgroup Flaviviridae. The Flaviviruses are a family of at least 66 
viruses, 29 of which cause human diseases including dengue, yellow fever, Murray Valley 
encephalitis and Japanese encephalitis. Dengue occurs mainly in tropical areas of Asia, 
Oceania, Africa, Australia and the Americas. Some outbreaks of dengue have involved one 
million or more cases with attack rates of 50-90%.
150
 The World Health Organization 
estimates 50 million cases of dengue infection occur each year, resulting in approximately 
24,000 deaths (WHO 1998).
150
 
MOTIVATION OF THE STUDY 
Several studies have reported that the change in physicochemical properties that may occur 
during the manufacturing process and storage of pharmaceutical formulations should have 
a direct impact on the bioavailability of a drug and hence, consequently on the patient. 
Modifying the physicochemical properties of a pharmaceutical compound through salt 
formation, polymorphism and complexation/co-crystallisation may improve the 
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performance of ADT. Therefore, due to its anti-parkinsonian and varied antiviral activities, 
a study of supramoleculary derivatised forms of ADT is well placed in a preformulation 
exercise to investigate these forms for future formulation research. 
OBJECTIVES OF THE STUDY 
The objectives of this study were: 
1. To give an account of the systematic conversion of ADTHCl to bis(adamantan-1-
aminium) carbonate, with the initial intention having been to convert ADTHCl to its 
free base. 
2. To give an account of the systematic conversion of bis(adamantan-1-aminium) 
carbonate into various polymorphs and to isolate and characterise these modified 
forms. 
3. To give an account of the systematic conversion of bis(adamantan-1-aminium) 
carbonate into various salt complexes and/or co-crystals. 
4. To conclude theoretically whether the polymorphic salts and salt complexes/co-crystals 
might present any pharmaceutical or technological advantages (viz. solubility, melting 
point, moisture uptake, chemical stability etc.) over ADT and ADTHCl. 
 
Chapter two will discuss the various techniques used for the preparation of salts, 
polymorphs and non-covalent complexes/co-crystals. Furthermore, chapter two will 
discuss all the relevant analytical techniques applied in this study. 
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CHAPTER 2: MATERIALS AND EXPERIMENTATION 
This chapter contains a full description of the experimentation to prepare salts, 
polymorphs and complexes/co-crystals of 1-adamantanamine. It also presents the 
materials used in this study and describes all the analytical techniques (laboratory and 
computational) applied to critically analyse the various forms produced. 
THE USED COMPOUNDS 
 1-adamantanamine (ADT), was purchased in its HCl salt form from  Sigma-Aldrich 
Chimie GmbH (Steinheim, Germany). Benzoic acid, 4-hydroxybenzoic acid, trans-
cinnamic acid, 4-hydroxycinnamic acid, succinic acid, l-tartaric acid, l-glutamic acid, l-
glutaric acid, salicylic acid and citric acid monohydrate were all purshased from Sigma-
Aldrich Chimie GmbH (Steinheim, Germany) as well. 
PREPARATION OF POLYMORPHS 
Different techniques such as crystallization from solution and recrystallization from neat 
API (via; the sublimation technique, thermal treatment, crystallization from the melt and 
grinding)
1,2
 were used for polymorph screening into several polymorphic forms. 
CRYSTALLISATION FROM SOLVENT EVAPORATION 
SINGLE SOLVENT EVAPORATION 
A measured mass of the compound was dissolved in a known volume of solvent. The 
mixture was stirred and heat was applied to temperatures set at 10°C below the boiling 
point of the solvent and below the melting point of the parent compound. Using a syringe, 
solvents were added drop-wise into a vial dovetailed with a magnetic stirrer while on a hot 
plate until the powders were completely dissolved. 
Solutions of solvent and the compound being crystallised were filtered using a micro-filter 
(0.45 μm syringe filter to remove most nuclei and other impurities) and transferred to a 
clean and labelled vial and closed with Parafilm
®
. A few holes were made in a closing 
piece of parafilm
®
 using needles to facilitate the evaporation of the solvent. The solution 
was left undisturbed for a reasonable period of time, allowing for the evaporation process 
to occur
,4,5,6 
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EVAPORATION FROM A BINARY MIXTURE OF SOLVENTS 
 Multi-solvent evaporation methods which eventually depend on the difference in 
solubility of the solute in different solvents were also used. The second solvent, in which 
the solute is slightly soluble or insoluble was added to a saturated solution of the 
compound in a good solvent. The preparation was stored in a stable place to allow for 
evaporation. 
As the solution evaporated, the volume of the solution was reduced. As the solvents 
evaporated at different rates, the composition of the solvent mixture and concentration 
changed over time, which facilitated the crystallisation process.
4,5,6
 
VAPOUR DIFFUSION 
A solution of the solute was dissolved in a good solvent such as methanol which was 
placed in a small vial that was kept in another big container in which a small quantity of a 
miscible and volatile non-solvent was added. 
The big container was then sealed. The sample preparation was left for a reasonable period 
of time to allow diffusion of the non-solvent through the vapour phase into the solution of 
the small vial as the equilibrium was reached or until saturation or super-saturation was 
achieved. The solubility of the compound in a precipitant used in such a technique should 
be very low (much less than 1 mg/ml) and the precipitant (the solvent in which the 
compound is poorly soluble) should be miscible with the solvent and the saturated solution 
of the small vial. Due to the behaviour of a used solvent in the presence of the preparation, 
there will be crystallisation.
4,5,6
 
THERMAL TREATMENT 
THERMAL TREATMENT BY DSC 
With the application of differential scanning calorimetry (DSC), there are possibilities to 
observe a variety of endotherms. The first one corresponds to a phase transition, followed 
by a second endothermic peak corresponding to the melt. Sometimes the observation of a 
third peak is possible. This is an exothermic peak that comes between the two endothermic 
ones and represents a crystallisation step.  
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These peaks (endothermic and/or exothermic) are associated with a series of thermal 
events, including guest release, phase transformation, recrystallization, melting, as well as 
decomposition. Hence, the onset temperatures and enthalpy changes (ΔH) of these thermal 
events can be established and finally new forms may be insulated accordingly.
1,2 
CRYSTALLISATION FROM THE MELT 
When the cooling process is applied to the melts of polymorphic substances, it often gives 
the unstable form which subsequently rearranges into the stable form. Super-cooling is 
necessary to crystallise the metastable form from the melt. This is because the metastable 
form always has the lower melting point when compared to other forms. In this case, after 
melting has completed, the system is super-cooled below the melting point of the 
metastable form, while at the same time, the crystallisation of the more stable form or 
forms is achieved.
3
 
Further quenching or cooling a melt leads to the formation of an amorphous solid which on 
heating, subsequently undergoes the glass transition followed by crystallisation.
4, 5,6
 
GRINDING METHOD  
NEAT GRINDING 
Neat grinding is one of the traditional methods of polymorph screening and complex 
formation. The sample powder was manually ground for a reasonable period of about 30 
minutes using a mortar and a pestle. The powder was then transferred from the motar to an 
airtight container.
9
 
SOLVENT DROP-GRINDING 
The same process as applied in the previous paragraph was assisted by adding a few drops 
of solvent
9 
while grinding. 
SUBLIMATION METHOD 
A small amount of the compound, (20 mg) was placed in a petri dish covered with a watch 
glass. The petri dish was then gently heated on a hot plate and the watch glass was 
observed to determine if crystals were growing on it.
10
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PREPARATION OF CO-CRYSTALS/ COMPLEXES 
Different techniques were applied during the process of complexation. These include 
vapour diffusion, solvent evaporation, dry grinding and solvent-assisted grinding.  
SOLVENT EVAPORATION 
SINGLE SOLVENT EVAPORATION  
A stochiometric amount of two parent compounds were dissolved in a necessary volume 
(e.g. 2 mL) of solvent. With temperatures kept below the melting point of the lowest 
melting constituent and about 10
o
C below the appraised boiling point of the solvent 
system, the two samples were separately dissolved in the solvent while being stirred with a 
magnetic stirrer on a hot plate until the powders were completely dissolved. The two 
solutions were then mixed together in the vial containing the smaller quantity and was 
extracted using a syringe. The solution was then filtered through a 0.45 μm micro-filter 
and transferred to a clean and labelled vial and closed with Parafilm
®
. A few holes were 
made in the parafilm
®
 using needles, to facilitate solvent evaporation. 
CO-CRYSTALLISATION OR COMPLEX FORMATION VIA BINARY 
MIXTURE OF SOLVENTS 
In this method, co-crystal/complex preparation was done using slow evaporation of a 
mixture of solvents in several stoichiometric ratios. The stoichiometric amounts of the 
compound and co-crystal formers were dissolved in a known volume of a mixture of 
solvents. 
All temperatures were kept below the melting point of the lowest melting component and 
approximately 10
o
C below the estimated boiling point of the solvent system.  
Samples were dissolved separately in the respective solvent systems, stirred with a 
magnetic stirrer while on a hot plate until the powders were completely dissolved.  
The two solutions were then mixed together in the vial with the lesser amount of solvent, 
stirred, extracted via a syringe and filtered from the syringe through a 0.45 μm micro-filter. 
and transferred to a clean and labelled vial and closed with Parafilm
®
. The parafilm
®
 was 
perforated using needles to facilitate solvent evaporation.  
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The solution was left undisturbed for a reasonable period of time allowing the evaporation 
process to take place in a desirable manner unless unforeseen circumstances arose. 
VAPOUR DIFFUSION  
A solution of the solute and co-former in a stoichiometric amount was prepared using a so-
called good solvent (solute and co-former soluble solvent) and was placed in a small vial 
that was stored in another big container, containing a small amount of a miscible, volatile 
non-solvent. 
The bigger container was tightly closed. The sample preparation was left for a reasonable 
period of time to allow diffusion of the non-solvent vapour phase into the solution of the 
small vial creating an equilibrium in vial contents. As the equilibrium was reached, 
saturation or super-saturation was achieved. The solubility of the compound in a 
precipitant used in such a technique should be as low as possible (much less than 1 
mg/ml), and the precipitant (the solvent in which the compound is poorly soluble) should 
be miscible with the solvent and the saturated solution in the small vial. 
GRINDING METHOD 
NEAT GRINDING 
Neat grinding, also called dry grinding, consists of mixing stoichiometric amounts of 
crystal components together and grinding them either manually using a mortar and pestle 
or mechanically.
7
 Several pharmaceutical complexes/co-crystals have been successfully 
synthesised by neat grinding.
8
 
SOLVENT-DROP GRINDING 
By the addition of a small amount of suitable solvent to the ground mixture (API and co-
former) complexation is accelerated.  
This is a particularly promising preparation method of which the efficacy of the method 
has been reported.
9
 The solvent-drop grinding method avoids excessive use of 
crystallisation solvent compared to the solvent evaporation method, hence it can be 
regarded as a green process. The solvent-drop grinding method could also prove useful for 
polymorph control
5
 and selective polymorph transformation.
9
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ANALYTICAL METHODS USED 
HOT STAGE MICROSCOPY (HSM) 
The use of this technique allows the observation of different thermal events while heating 
or cooling the sample crystal or powder on a hot stage. 
A Linkam TP92 temperature control unit connected to a Linkam TH MS600 hot stage was 
used to heat samples at a controlled rate. Observations and visual characterisation were 
taken by a real-time Sony Digital Hyper HAD colour video camera fitted to a Nikon SMZ-
10 stereoscopic microscope. Images were recorded and were analysed by the Soft Imaging 
system (Essential Stream)® Analysis. This interconnected system proves to be very useful 
and allows distinguishing new solid phases such as polymorphs, co-crystals and/or 
complexes to be identified. 
HSM results and the DSC analysis were correlated to TGA analyses that was also 
performed to assess % solvent content in samples. During the heating process on the HSM, 
the appearance of bubbles coming from the sample in an inert medium (e.g. silicone oil), 
usually indicated solvent loss. Other thermal changes such as polymorphic transition and 
decomposition were indicated by colour changes in the sample being analysed. 
DIFFERENTICIAL SCANNING CALORIMETRY (DSC) 
A Perkin-Elmer PC-7 series thermal analysis system at a scanning rate of 10
o
C per min 
was used under N2 gas purged with a flow rate of 20 mL/min. DSC traces were recorded 
over a temperature range between 30 and 460
o
C. Sample sizes were in the range of 1-4 mg 
for all compounds. Crystalline samples were taken from the vial, dried on filter paper and 
crushed to an appropriate particle size and sealed in a aluminium pan.  
A sealed and empty pan was used as a reference. The DSC analyser was calibrated by 
measuring the onset temperatures of the melting of indium (m.p. 156.6
o
C) and zinc (m.p. 
419.5
o
C) while the heat flow was calibrated from the enthalpy of melting of indium (28.62 
J/g). Endothermic and exothermic peaks appearing in the DSC graphs were analysed in 
terms of their onset temperatures, temperature range of the peak (determined from the first 
derivative of the trace) and the enthalpy of the peak (measured in J/g).  
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Various endothermic and exothermic peaks observed in the DSC trace are associated to 
various thermal behaviours and were interpreted in correspondance with HSM to be 
associated with solvent loss, phase changes in the sample and decomposition. 
THERMOGRAVIMETRIC ANALYSIS (TGA) 
The TGA analysis on a Perkin-Elmer PC thermal system was used at a scanning rate of 
10°C, under N2 purged at a flow rate of 20 mL per minute. The calibration of the 
instrument was performed using indium (m.p. = 156.6°C) and aluminium (m.p.= 660.3°C).  
This technique was used to measure the mass loss of samples as a function of temperature 
or time and the decomposition of desolvated materials. Crystalline samples were first dried 
on filter paper to remove the suerficial solvent. An empty porcelain pan was weighed, and 
then the instrument balance was tarred. Sample (crystalline or powder) were then placed in 
a porcelain pan and the weight was recorded. The programmed TG technique was carried 
out over a temperature range between 30°C and 400°C at a predetermined heating rate of 
10°C per minute. Samples were continuously purged by a stream of dry nitrogen gas, the 
solvent stoichiometry of the compounds was determined from the percentage mass loss. 
FTIR SPECTROPHOTOMETRIC ANALYSIS  
Infra-Red spectra of the drug substance as well as products were obtained using a Perkin-
Elmer 100 FTIR instrument fitted with UATR and controlled with Spectrum
®
 software 
version 6.3.5.0176 for the analysis of samples. 
Samples were analysed mostly in a powder form or crystalline form over the range 600-
4000 cm
-1
. The percentage transmittance was recorded against frequency. This analytical 
technique was used to investigate different functional groups in samples and prove the 
existence of intermolecular interactions during the co-crystal/complexation processes. 
1
HNMR ANALYSIS 
NMR is one of the most powerful spectrometric techniques used for structure analysis of 
compounds due to its ability to access information of the chemical structure at molecular 
level. 
1
HNMR was performed in this study to identify the product of the conversion 
(parent compound). The tubes were imported from Sigma-Aldrich WILMAD
®
, USA.  
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The spectrum was recorded on a Varian XR200 MHZ spectrometer, using CD3OD as 
NMR solvent and internal standard.   
X-RAY POWDER DIFFRACTION (PXRD)  
Powder X-ray diffraction was used to determine the characteristic fingerprint traces of 
crystalline materials. This technique can uniquely identify materials therefore allowing for 
the identification of new species of polymorphs, complexes and co-crystals. This technique 
is particularly used in the absence of good quality crystals for single crystal structure 
determination.  
Polymorphism can be detected due to different packing arrangements that polymorphs 
exhibit. Powder patterns of ground samples were recorded on a Philips PW1050/25 
vertical goniometer with Ni-filtered CuKα radiation (λ = 1.5418 Å) produced at 40 kV and 
25 mA. Samples were packed in aluminium or glass sample holders and step scans of 0.1
o
 
2θ, with 2 seconds counting times, in the range 4-45o 2θ being employed.  
In cases where sample material was limited, PXRD patterns were recorded using a Huber 
Imaging Plate Guinier Camera 670. Some of the samples were in powder form, manually 
ground and were analysed using a flat method. Other preparations were packed into 
Lindermann capillaries with an internal diameter of 1 mm and a glass thickness of 0.01 
mm. Nickel-filtered CuKα radiation (λ = 1.5418 Å), produced at 48 kV and 30 mA by a 
Philips PW1120/00 generator fitted with a Huber long fine-focus tube PW2273/20 and a 
Huber Guinier Monochromator Series 611/15, was employed. A 2θ range of 4 to 100.0o 
was used with a step (Generation of polymorphs, hydrates, solvates and amorphous solids, 
1999) size of 0.005
o
 2θ.  Temperature Controller HTC 9643 unit was not used during this 
process. 
SINGLE X-RAYS DIFFRACTION (SXRD) 
Bruker KAPPA APEX II DUO diffractometer was employed for crystal structure 
determination of the Single Crystal. Good crystals (essentially found between 0.2 and 0.5 
mm in all dimensions, were selected for their ability to consistently extinguish plane-
polarised light. The Bruker KAPPA APEX II DUO diffractometer used graphite-
monochromated Mo-Kα radiation (λ= 0.71069 Å).  
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After their removal from polytope vial, the unit cells of the crystals were determined at 
low temperature (100 ±2 K). Further, the data reduction was performed using the program 
SAINT.
11 
 
The space group determination was carried out by analysing the systematic absence and 
matching conditions observed to a well-known space group. 
OTHER USED RESOURCES 
The Cambridge Strctural Database (CSD) Conquest 1. 16. Ink as well as  Mercury 3.3. Ink 
was used in this research to search for relevant structures reported in this work. 
ACD/ChemSketch
®
 freeware was also employed to draw different structures relevant to 
the dissertation. 
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CHAPTER 3: 1-ADAMANTANAMINE SALT FORMATION 
This chapter presents the conversion of ADTHCl into its free base form (ADT), which 
however, lead to formation of the ADT salt known as bis(adamantan-1-aminium) 
carbonate (ADTCO3). Identification of the newly formed salt is discussed in this chapter 
where different methods were used and contributed to the conclusive ADTCO3 result. 
INTRODUCTION TO 1-ADAMANTANAMINE HCl (ADTHCl) 
The 1-adamantanamine hydrochloride (ADTHCl) is commercially available as 
Amantadine
®
 or Symmetrel
®
 and its derivative rimantadine is known as α-methyl-1-
adamantanemethylamine and flumadine
®
. Both are symmetric tricyclic amine compounds 
that inhibit strains of influenza A by blocking the M2 protein that functions as an ion 
channel.
1-3
 The transmembrane domain of the M2 protein is a transmembrane domain 
which is highly conserved in all avian viruses.
5,6
 
ADTHCl and rimantadine are both effective at low doses against H1N1, H2N2 and H3N2 
strains. Both were reported to be effective against viruses which use an M2 ion channel in 
the initial uncoating steps of replication.
1-3
  
 It was also found that ADTHCl due to its ability of blocking neuromuscular transmission, 
depending on its capacity to increase the synthesis and release of dopamine, has 
antiparkinson activity.
4
 A summary of the pharmacological activities of ADTHCl is 
presented in table 3.1. 
Table 3.1: Summary of Pharmacological activities of ADTHCl. 
Activity Reference 
Antiviral 7, 8, 9, 10, 11, 12 
Anti-parkinsonian 13 
Anti-dengue 14 
 
For the purposes of this study, ADTHCl was purchased from Sigma-Aldrich. ADTHCl 
was converted to its free base form, ADT (figure 3.1). The free base was considered as an 
appropriate starting material for subsequent experimentation for reasons such as; lower 
physical properties (melting temperature) in comparison to ADTHCl, the pharmacological 
activity of the adamantane ring, and the availability of amine functional group for 
intermolecular interactions. 
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1-ADAMANTANAMINE HCl (ADTHCl) CONVERSION TO THE FREE BASE 
The conversion of ADTHCl to its free base (ADT) was synthesised by the following 
chemical precipitation reaction. The reaction had to proceed as follows: 
C10H18N. Cl + NaHCO3 (Aq) → C10H17N ↑ +[Na
+Cl− + CO3
2− + H2O](Aq) Equation.3.1 
Distilled water was used to prepare a saturated or supersaturated solution with sodium 
hydrogen carbonate (NaHCO3) powder. An amount of ADTHCl was added to the solution. 
The mixture was stirred for 15 to 30 minutes, using a magnetic stirrer at room temperature. 
A precipitate formed was collected from the solution using a 0.45 μm sized filter paper. 
Since the free base does not dissolve in water, the collected precipitate was the “assumed” 
free base desired. 
The precipitate was dried in an oven that was maintained at 40°C for 1-2 days until 
consistant white mass was produced. This fine, dry powder  was collected and removed 
from the oven and kept in an airtight container at room temperature. Identification tests 
were completed on the precipitate collected to verify the physicochemical identity of the 
compound. Several analytical techniques were applied to the powder. 
CHARACTERISATION OF THE CONVERTED SAMPLE  
To characterise the converted sample, different analytical techniques such as DSC, HSM, 
TGA, FTIR, 
1
H-NMR, PXRD, single X-ray diffraction. A literature search was conducted 
and after careful examination of all data, the following reaction was in fact the resultant 
reaction: 
C10H17N. HCl + NaHCO3 (Aq) → [2(C10H18N
+), CO3
2− + Na+Cl−](aq)          Equation 3.2 
The following analytical techniques provided evidence for the resultant reaction which 
suggests a carbonate salt instead of the free base precipitating. 
PROTON-NMR ANALYSIS (
1
HNMR) 
NMR is one of the most powerful spectrometric techniques used for structure analysis of 
compounds due to its ability to access information of the chemical structure at molecular 
level. 
1
HNMR was initially performed in this study to identify the product of the 
conversion (starting material).  
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The tubes were bought from Sigma-Aldrich WILMAD
®
, USA. The 
1
HNMR spectrum was 
recorded on a Varian XR200 MHZ spectrometer using CD3OD as the solvent: ρ: 1.4-1.6, 
(12H, triplet) 
   ρ: 1.8-2, (3H, multiplet) 
Physical data: molecular formula 2C10H18N
+. CO3
2−; m.p: 160-180
o
C; 
1
HNMR (200MHz, 
CD3OD). ρH: 2.0-1.8 (multiplet, 3H), 1.6-1.4 (triplet, 12H). The additional patterns 
observed were due to the interaction of solvent with other hydrogen atoms of that molecule 
as well as the existence of intramolecular interactions in it. The molecule has 3 types of 
non-equivalent hydrogen atoms (figure 3.1). This findings did not show whether the result 
of the conversion is indeed 2(C10 H18 N
+)
,CO3
2-
 or C10H17N ↑since these two have the 
same number of non-equivalent hydrogen atoms. 
 
Figure 3.1: 
1
HNMR pattern of the converted sample. 
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THERMAL ANALYSIS 
HOT STAGE MICROSCOPY ANALYSIS 
An assessment on the physical and chemical properties was conducted. In this process, 
thermal analysis by HSM was performed under silicon oil at a heating rate of 10°C per 
minute. Changes associated with heating of the sample were observed under a microscope 
over the temperature range from 20°C until 230°C. The melting temperature of the 
converted sample by HSM was found to be in the range between 157°C and 170°C. 
However, bubbling occurred, which in fact was created by fumes released between the two 
glass slides of the sample holder and cover slide, commencing early around 136°C until 
the completion of melting at 170°C (figure 3.2). The gaseous fumes given off were 
accounted for as a sublimation process occurring in the temperature range of 136°C to 
170°C. Decomposition of the sample followed immediately at about 185°C. 
 
Figure 3.2: HSM of the converted sample. 
DSC AND TGA ANALYSES 
The DSC analysis was performed at a constant rate of 10°C per minute under nitrogen gas 
purged at 20 mL per minute. A trace produced showed a single broad endotherm in the 
temperature range between 140°C and 180°C, peaking at 170.67°C with an onset at 
146.86°C. In addition, DSC analysis confirmed the sublimation results that were observed 
when using HSM analysis of this compound since the DSC pan and cover were covered 
with powder sublimates after each experiment run. Figure 3.3 also confirms the 
decomposition immediately after the melt at 183°C. 
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Figure 3.3: The DSC of the converted sample. 
TGA analysis was also performed at a constant rate of 10°C per minute, under nitrogen 
purged at 20 mL per minute and proved that there was no solvent (water) included in the 
structure since there was negligible mass loss in the 30-170°C temperature range. The 
TGA calculated a mass loss of 0% (n = 0) (figure 3.4).  
This correlates well with the DSC result since the more pronounced mass loss was 
observed in the melting range followed immediately by the decomposition of the sample. 
           
Figure 3.4: The TGA of the converted sample. 
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FTIR SCPECTROPHOTOMETRY ANALYSIS  
FTIR analysis of the converted sample and that of the purchased free base were conducted 
to elucidate the chemical functional groups of the converted sample as well as the 
purchased free base.  
The following spectra (transmittance versus wavelength) were produced and 
comparatively presented, where the amine and other functional groups were identified in 
specific regions of the spectra (figure 3.5). 
The analysis of the converted sample spectrum was identified as bis(adamantan-1-
aminium) carbonate (ADTCO3) using FTIR based on the key intensity shifts in 
comparison to the expected (ADT) free base and ADTHCl FTIR spectra. New peaks and 
peak shifts were identified in the fingerprint and functional groups regions of the converted 
sample spectrum (table 3.2). 
The absence of the expected two peaks in the 3300 cm
-1
 region of the ADTCO3 spectrum, 
attributed to N-H stretching vibration of the primary amine group that originates from the 
participation of hydrogens of the amine functional group into intramolecular hydrogen 
bonding found in this compound. Furthermore, the amine group presents an extra 
hydrogen atom and formed an aminium group. The medium intensity band at 2910 cm
-1
 
and the weak one at 2852 cm
-1
 are assigned to the stretching vibration of the C-H group. 
The strong bands at 1639.64 and 853.41 cm
-1
 were assigned to the N-H deformation bands 
and 1550.51 cm
-1
 band was attributed to the -C=O of the carbonate attached to the 
adamantane ring. The -C-O vibrations were observed in the finger print of this spectrum at 
around 1000 cm
-1
. The absorption bands 2267.81 and 1456 cm
-1 
were attributed to the –C-
N or –C=O attached to the ring by the hydrogen interactions. The intramolecular hydrogen 
bonding in this compound was mainly observed at 2564.96 cm
-1
 created shifts and 
overlapping in functional groups. 
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Figure 3.5: Spectra of ADTHCl, ADT and ADTCO3 compared. 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
ADT (purchased)
Converted sample
ADTHCl
2915.30
2854.69
2707.89
2620.89
2587.08
2527.48 2063.34
1604.38
1512.10
1500.03
1477.24
1453.55
1376.87
1365.46
1349.76
1324.76
1312.91
1201.57
1125.96
1112.51
1085.91
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913.96
811.05
3339.27
2898.93
2846.65
2657.45
1587.08
1450.62
1358.83
1314.77
1264.37
1186.19
1144.14
1096.08
1042.23
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984.77
948.65
930.99
897.35
811.01
776.83
719.68
2910.14
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2723.02
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1550.94
1456.96
1381.45
1353.92
1317.09
1291.08
1142.40
1126.84
1113.92
1088.18
1039.84
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932.53
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780.95
722.54
668.71
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Table 3.2: Specific bands assigned to given functional groups and key intensity shifts. 
Functional groups ADT ADTCO3 ADTHCl Comments/shifts 
N-H 3339 cm
-1
 - - Primary amine 
C-H 2898 cm
-1
 
1450 cm
-1
 
2910 cm
-1
 
1456 cm
-1
 
2915 cm
-1
 
1453 cm
-1
 
Adamantane ring 
C=O - 1639 cm
-1
 - Carbonate ion 
NHCl - - 2063 
2097 cm
-1
 
1604 cm
-1
 
Influence of HCl  
NH
3+
 - 2564 cm
-1
 - H-bonding area 
C-O/ C-N - 2267 cm
-1
 - H-bonding effect 
 
SINGLE X-RAY DIFFRATION  
A full data set was collected for the sample by single X-ray diffraction. The unit cell data 
for ADTCO3 which ultimately confirmed the formation of ADTCO3 are recorded in table 
3.3. However, all data are not presented since literature review shows that ADTCO3 had 
already been isolated and elucidated by single X-ray diffraction.
15
 
Table 3.3: The space groups and unit cell data for ADTCO3. Experimental compared 
to theoretical at room temperature. 
 Experimental  REFCODE (YAXNOC)
15
 
Space group P -3 c1 P -3 c1 
Number of molecule per Unit cell Z = 2 Z = 2 
Unit cell axis lengths a = 6.578 Å 
b= 6.492 Å 
c= 25.789 Å 
a = 6.434 (<1) Å 
b= 6.434 (<1) Å 
c= 25.474 (2) Å 
Unit cell angles γ = 89.952o 
β = 90o 
γ = 119.8o 
γ = 90o 
β = 90o 
γ = 120o 
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EXPERIMENTAL POWDER X-RAY DIFFRATION  
PXRD was performed to assess not only the crystallinity but also to confirm the identity of 
ADTCO3 (figure 3.6). The obtained pattern shows a very sharp signal at 2θ value 17.245° 
with smaller peaks at 2θ values 6.685°, 15.72°, 20.78°, 28.425° and 35°. The 
distinctiveness of the compound in question was also investigated by comparing the 
experimental pattern to literature
6 
which confirmed the identity of the structure. 
  
Figure 3.6: Experimental and calculated PXRD (YAXNOC) patterns of ADTCO3. 
The experimental PXRD showed a very good correlation to the calculated PXRD pattern
15 
(figure 3.6), confirming the integrity of the ADTCO3 sample. 
In conclusion, we see that the expected conversion of ADTHCl to ADT free base led to a 
conversion to ADTCO3. ADTCO3 was conclusively confirmed using HSM, DSC, TGA, 
1
HNMR, FTIR, single XRD and PXRD. Even though a conversion of ADTHCl to free 
base is a well-known technique, ADTCO3 formed because of the ability of the primary 
amine to absorb CO2 in the atmosphere which was also confirmed by Nowakoska et al
15
, 
2012. Thus, it is recommended to prepared a free base under nitrogen and perform all 
experimentation in neutral atmosphere to prevent a further conversion of the free base into 
ADTCO3. The alternative conversion using NaOH is also advised. 
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CHAPTER 4: POLYMORPHISM OF BIS(ADAMANTAN-1-
AMINIUM) CARBONATE 
This chapter describes the occurrence of the polymorphism phenomenon
1-6
 of 
bis(adamantan-1-aminium) carbonate (ADTCO3). The experimentation revealed the 
appearance of 4 different polymorphic forms of ADTCO3, where Form I was identified as 
the converted ADTCO3 presented in chapter 3. Form I was recrystallized from a single 
solvent (methanol) while Form IV was also recrystallized from a single solvent (ethanol).  
Form II and Form III were obtained from binary mixtures of solvents, methanol-
chloroform and methanol-ethyl acetate, respectively. Conclusions drawn were based on 
the application of several different analytical techniques which provided the results and 
confirmed the different polymorphic forms.  
INTRODUCTION 
ADTCO3, the converted salt form (discussed in chapter 3) showed the ability to crystallise 
into new polymorphic forms. Table 4.1 is representative of experiments done for this study 
with regards to polymorphism of ADTCO3. 
Table 4.1: Selected ADTCO3 polymorphism experiments conducted. 
METHOD 1: SLOW EVAPORATION USING DIFFERENT SINGLE SOLVENTS 
SOLVENT ADTCO3 form Crystallinity 
Ethanol Form IV Present 
Methanol Form I Present 
METHOD 2: SLOW EVAPORATION USING A BINARY MIXTURE OF 
SOLVENTS IN 1:1 RATIO 
Solvent 1 Solvent 2 ADTCO3 
Methanol Ethanol Form I  
Methanol  Chloroform  Form II 
Methanol  Ethyl acetate Form III 
METHOD 3: GRINDING TECHNIQUE 
Solvent  Concentration  ADTCO3 
Neat grinding - Form I 
Methanol   20 mg/2 mL Form I 
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A full representation of all experiments conducted is presented in Appendix A. 
Using various techniques such as DSC, HSM, FTIR and X-ray diffraction, four 
polymorphic forms of ADTCO3 were identified and are discussed below. 
POLYMORPHISM OF ADTCO3 
The starting material, ADTCO3 will be referred to as Form I. Several techniques were 
employed to investigate the polymorphism effects of ADTCO3. The preparation and 
isolation of the new forms will follow with a full characterisation of each form being fully 
illustrated and discussed. 
PREPARATION OF ADTCO3 POLYMORPHS 
The following methods were used to prepare the four polymorphs of ADTCO3: single 
solvent evaporation and crystallisation using binary mixtures of solvents. 
Form I-Single solvent evaporation 
Single crystals of Form I were prepared by solubilizing the ADTCO3 powder mass in the 
solvent, methanol. The mixture was placed on a hot plate to approximately 10°C below the 
boiling point of methanol and stirred continuously with a magnetic stirrer until the 
ADTCO3 powder solubilised. The saturated solution was filtered through a 0.45 μm filter 
and kept in a vial under a secured and undisturbed area. Vials were covered by perforated 
parafilm
®
 to allow for evaporation of the solvent to occur so that the crystallisation process 
at ambient environmental conditions would be ensured. Clear, hexagonal crystals were 
formed and fully characterised (figure 4.1). 
 
Figure 4.1: Photographs of Forms I-IV crystals recorded at room temperature. 
Form II- Recrystallization using binary mixtures of solvents 
Form II was prepared by recrystallizing 20 mg of the starting material (ADTCO3) in a 
binary mixture of methanol and chloroform in a 1:1 ratio.  
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The mixture was placed on a hot plate to approximately a 10°C below the boiling point of 
chloroform and stirred continuously with a magnetic stirrer until the ADTCO3 powder 
solubilised. The saturated solution was filtered through a 0.45 μm filter and kept in a vial 
under a secured area. Vials were covered by perforated parafilm
®
 to allow for evaporation 
of the solvent to occur at 20°C. Quartz-like crystals of irregular shapes were harvested and 
further analysed (figure 4.2).  
Form III  
Form III was prepared by recrystallizing ADTCO3 in a binary mixture of methanol: 
acetone in a 1:1 ratio. 20 mg of ADTCO3 powder was carefully weighed and transferred 
into a clean polytop vial. Firstly, 1 mL of methanol (solvent) was added to solubilise the 
powder. Then, 1 mL of acetone (precipitant) was added drop-wise while the solution was 
heated on a hot plate and continuously stirred using a magnetic stirrer to 10°C below the 
boiling point of acetone (the least stable solvent). The solution was filtered using a 0.45 
μm filter with a syringe, then the solution was kept in a vial covered by perforated 
parafilm
®
 to facilitate evaporation of the solvent at ambient temperature. Flat glass plate-
like crystals were produced (figure 4.1). 
From IV-Single solvent evaporation 
Form IV was synthesised by solubilizing 20 mg ADTCO3 in ethanol. The mixture was 
placed on the hot plate at approximately 10°C below the boiling point of ethanol and 
stirred continuously until all powder was dissolved. The solution was then 0.45 μm filtered 
in the vial covered by perforated parafilm
®
 to allow for evaporation at 20°C. Small, 
hexagonal crystals formed and were kept in a vial to be further analysed (figure 4.1). 
The synthesis of Form I could also be achieved by recrystallization of ADTCO3 in binary 
mixtures of solvents. Equal amounts of methanol:acetone, methanol:1,4-dioxane, 
methanol: ethanol, ethanol:acetone and ethanol:propane-2-ol (1:1 ratio), were individually 
added to 20 mg of ADTCO3 and gently heated to 10°C below the boiling point of the 
lower b.p. solvent. The saturated solution was filtered and solvent evaporation proceeded 
as in the production of form I with methanol solvent. Hexagonal crystals were obtained 
though much smaller in size. The smaller crystal size was possibly due to factors such as 
concentration of the recrystallization solution and the rate of solvent evaporation.  
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Furthermore, Form I could also be prepared by both neat and methanol assisted grinding 
of 20 mg of ADTCO3 in a mortar with a pestle for 30 minutes. 
By recrystallizing ADTCO3 in a binary mixture of methanol and diethyl ether, Form II 
was reproduced. 
Form III was also prepared by solubilising ADTCO3 powder in binary mixtures of 
methanol:ethyl acetate and ethanol:ethyl acetate in a 1:1 ratio. 
Finally, Form IV synthesis was achieved by recrystallizing ADTCO3 in a binary mixture 
of methanol and ethanol (1:1 ratio). 
ANALYSES OF ADTCO3 POLYMORPHIC FORMS 
Physicochemical characterisation of the obtained crystal forms was determined by HSM, 
DSC, TGA, FTIR spectroscopy and PXRD. 
THERMAL ANALYSES 
HOT STAGE MICROSCOPIC ANALYSIS (HSM) 
To analyse the thermal behaviour of different crystal forms, HSM was performed and each 
product was exposed to the heating process at a constant rate of 10°C/min under silicone 
oil in order to assess the presence of “so-called” impurity (water/solvent) that could be 
entrapped in the molecular structure of the formed crystals. Changes were observed under 
the microscope and analysed using the Essential Stream software
®
 (Figure 4.2). 
For Form I hexagonal crystals showed with bubbling at 130°C. At this stage bubbling was 
accounted for due to the fragmentation of large hexagonal crystals. Furthermore, phase 
change occurred as the temperature increased with melt taking place between 168°C and 
173°C, until 182°C where no more crystal was left on the slide fixed to the hot stage. No 
discoloration or any other sign of decomposition was observed. 
All photographs were taken at (a) ambient temperature (b), the first sign of change (c) 
clear melting (d) and the completion of melting or decomposition (figure 4.2). 
For Form II, bubbling commenced from 140°C, crystal size reduction continued and 
melting occurred between 183-185°C. 
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Form III showed bubbling from 157°C with a melt between 185-190°C. 
Finally, Form IV showed an onset of melting at 180°C. The melting process was 
identified as crystal fragmentation and bubble production occurred until complete phase 
change between 205°C and 209°C. 
 
Figure 4.2: The HSM photographs of Form I to IV of ADTCO3. 
 
DSC and TGA analyses of ADTCO3 Forms I to IV 
Thermal analysis was performed on a Perkin Elmer Differential Scanning Calorimeter 
DSC7 using TA Pyris software version 9.0.00148. The instrument was calibrated using 
Indium. Aluminium pans were used as sample holders. An empty pan was sealed and used 
as the reference. The flow of inert nitrogen at a rate of 20 mL/min was used while heating 
samples in the DSC from 30°C to the required temperatures depending on the stability of 
the analytical sample. For all the ADTCO3 forms, DSC was performed at a constant rate of 
10°C/min in the temperature range 30-260°C. 
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To support HSM and DSC findings and ensuring the purity of samples, TGA was 
performed. Crystals were weighed (1–3 mg) into a ceramic crucible using a micro balance. 
The TGA scans were obtained and recorded on a Perkin Elmer TGA 4000, using Pyris 
software version 11.0.3.0470. TGA traces were recorded at a heating rate of 10°C per 
minute. 
Form I crystals showed a broad endotherm in the temperature range of 147-180°C 
peaking at 170°C. This compared well with the starting material and is therefore called 
Form I (figure 4.3a). 
The TGA analysis for this form indicated a negligible mass loss in the range 30-178°C, 
thus confirming that there is no solvent or water present in the molecular structure of 
Form I crystals. The TGA trace (figure 4.3b) presented a 0.0% mass loss (n = 0.0) before 
melting. This correlates with the HSM & DSC results. Decomposition of the sample 
commenced immediately after the melt from 180°C with a sharp decline in mass loss seen 
in by TGA analysis. 
  
Figure 4.3: The DSC (a) and TGA (b) trace of Form I. 
For Form II, the DSC analysis showed a broad endotherm in the temperature range 170-
200°C peaking at 185°C (figure 4.4). No solvent release was detected by DSC analysis. 
Therefore, bubble production experienced during the HSM analyses was created by crystal 
fragmentation prior to melt.  
TGA analysis indicated negligible mass loss in the range of 30-170°C, thus confirming 
that these crystals are not solvates. The TGA trace showed that there was only 1.1% mass 
loss (n = 0.23). 
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Figure 4.4: The DSC trace of form II. 
DSC analysis for Form III showed a double headed endotherm in the temperature range 
of 140-200°C, peaking at 170°C suggestive of Form I and 192°C suggestive of Form III. 
The two peaks do not suggest a conversion from Form I to Form III since this would 
have been seen in all other DSC analysis. It does however indicate that not all samples (i.e. 
form I) had changed to Form III during preparation (figure 4.5). 
The TGA analysis for this form also showed a negligible mass loss. Thus, confirming the 
absence of solvent in the molecular structure of these crystals form. The TGA trace was 
recorded and presented a 0% (n = 0) mass loss in the range 30-140°C. There was a good 
correlation between the thermal analytical results. 
  
Figure 4.5: The DSC trace of Form III. 
The DSC analyses for Form IV showed a trace with a very broad endotherm between 
187.54 and 220°C peaking at 203°C (figure 4.6a). The broad endotherm correlates with the 
HSM result characterised by complete phase change between 205-209°C (i.e. melt). 
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TGA for this form also confirmed the absence of solvent in the molecular structure of the 
crystal since the analysis of the trace recorded in the temperature range 30-205°C showed 
negligible loss of mass 2% (n = 0.7) (figure 4.6b). 
  
Figure 4.6: The DSC (a) and TGA (b) traces of Form IV. 
 
FTIR SPECTROSCOPY 
FTIR analysis was performed to identify the amine and other important functional groups 
in the different forms of ADTCO3. Patterns obtained were compared to the originally 
converted spectrum. Spectra of these forms appeared to be quite similar since they possess 
identical functional groups, with only some slight differences observed (figure 4.7). 
The lack of ADTCO3 FTIR spectrum in the literature led to the initial identification of the 
spectrum for Form I. Subsequently, when spectra of Forms II, III and IV were compared 
to Form I only small differences were observed and that was sufficient to identify the 
polymorphs of ADTCO3. 
The characteristic absorption bands at 2910 cm
-1
 and 2852 cm
-1
 are assigned to the C-H 
(sp
3
 and sp
2
) vibration of adamantane ring. The weak bands at 2722 cm
-1
, 2563 cm
-1
 may 
be attributed to the NH3
+
.  
A very weak absorption band at 1730 cm
-1 
is ascribed to C=O vibrations for the carbonate. 
The absorption band at 2250 cm
-1
 is assigned to the C–N vibration, the absorption bands at 
1639 cm
-1
, 1548 cm
-1
, 1456 cm
-1
 may be assigned to the C=O of the carbonyl while the 
rest of bands found in the fingerprint of the spectrum (1381-1290 cm
-1
, 1142-1087 cm
-1
, 
1039 cm
-1
, 979 cm
-1
, 932 cm
-1
, 852 cm
-1
, 815 cm
-1
, 780 cm
-1
, 752 cm
-1
, 722 cm
-1
 and 667 
cm
-1
) may be attributed to the C-O of the carbonyl and C-H deformation (table 4.2). 
(a) (b) 
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Figure 4.7: FTIR-spectra of Forms I, II, III and IV of ADTCO3. 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
FORM I
FORM II
FORM III
FORM IV
2910.00
2852.25
2721.99
2563.79 2249.77
1638.76
1548.91
1456.83
1381.38
1354.04
1337.90
1316.94
1290.91
1142.03
1126.45
1113.29
1087.68
1039.22
979.76
932.22
852.76
815.05
780.80
752.61
722.38
666.58
2910.41
2852.56
2722.21
2563.65
2250.33 1638.65
1548.59
1456.96
1381.54
1354.04
1337.72
1316.91
1291.03
1142.04
1126.89
1113.58
1087.96
1039.72
979.97
932.64
852.73
815.57
780.98
752.80
722.79
666.78
2909.43
2851.85
2722.54
2564.20
2332.73
2250.09
1730.63
1638.53
1550.50
1456.76
1381.17
1353.90
1337.53
1316.74
1290.66
1142.07
1126.19
1113.12
1087.89
1039.41
979.61
931.87
852.93
814.59
780.29
2910.20
2852.27
2721.52
2564.57
2250.34
1639.16
1548.29
1456.91
1381.60
1353.76
1317.18
1290.98 1141.97
1126.90
1113.75
1087.70
1039.64
979.96
932.42
852.65
815.27
780.92
722.55
667.86
 
 
 
 
Chapter 4 
 
 
84 
 
Table 4.2: Shifts observed for forms I, II, III and IV of ADTCO3. 
Functional  Group Form I (cm-1) Form II (cm-1) Form III (cm-1) Form IV (cm-1) 
C-N 2249 2250 2250 2250 
NH3
+ 2721 
2563 
2722 
2563 
2722 
2564 
2721 
2564 
C-H 2852 2852 2851 2852 
C=O 1638 
1548 
1456 
1638 
1548 
1456 
1638 
1550 
1456 
1730 
1639 
1548 
1456 
 
C-H 2910 2910 2909 2910 
From the FTIR results, it is evident that IR analysis is not a good technique to distinguish 
polymorphs from one another; however slight shifts in the bands and/or intensity 
differences are due to the intermolecular forces between the differences in packing 
arrangements of the molecules in the unit cell.  
Furthermore, it is possible to ascertain whether the different forms had indeed crystallised 
as salts by identifying the NH3
+
 group within each spectrum. 
PXRD ANALYSIS 
Experimental PXRD patterns of the four forms presented a very close match since only a 
few variations in patterns were detected (figure 4.8). Along the Form I trace the intense 
peaks in the regions 17.56°, 20.8° and 34.51°
 
and
 
the short peaks at 13.79°, 15.77° and 
42.96
o 
are presented. Along the Form II pattern different peaks at 2θ values 5,815°, 16.7°, 
21.03°, 31.015° and 34.99° are identified. Along the Form III new peaks at 17.19
o
, 
20.98°, 35.05°, 43.0°, 44.19° and 49.5° are presented. Form IV trace presented distinct 
peaks at 2θ values of 13.7°, 15.75°, 17.23 °, 32° and 35, 21°. 
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Figure 4.8: The PXRD patterns of forms I-IV of ADTCO3. 
 
Figure 4.9: The DSC of forms I-IV. 
Even though small changes such as new peaks, additional shoulders or shifts in the 
position often imply the presence of different polymorphs, the PXRD patterns stacked 
(figure 4.8) together with the DSC curves stacked (figure 4.9) is a clear and undeniable 
indication of the four polymorphic forms of ADTCO3. 
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CHAPTER 5: SALT CO-CRYSTALLISATION OF 
BIS(ADAMANTAN-1-AMINIUM) CARBONATE 
 
This chapter describes the preparation and results of the co-crystallisation experiments of 
bis(adamantan-1-aminium) carbonate (ADTCO3) with 10 selected co-formers presenting 
complementary accepter or donor functional groups. A full physicochemical 
characterisation of the obtained ADTCO3 products is discussed with reasonable 
conclusions drawn.  
INTRODUCTION 
Co-crystallisation is an effective crystal engineering approach used to modify structures 
and properties of crystalline drugs. The approach is normally applied to neutral drugs such 
as free acids and bases. However, with the discovery of polymorphs of piroxicam-4-
hydroxybenzoic acid co-crystal (1:1, v/v) in both neutral and zwitterion forms, an overlap 
rose between definitions of a co-crystal and a salt. Thus, the salt co-crystallisation 
approach
1
 was incorporated. 
ADTCO3, a zwitterion
2
 was unexpectedly derived from ADTHCl by conversion using the 
precipitation reaction of ADTHCl with sodium bicarbonate solution during an attempt to 
synthesise the ADT free base (Chapter 3). Subsequently, salt co-crystallisation 
experimentation was a newly defined approach added to the study. 
ADTCO3 is insoluble in water. Co-crystallising ADTCO3 with different co-crystal formers 
may significantly impart not only solubility enhancement but also other physicochemical 
properties such as pharmaceutical manufacturing and biological activity enhancement. 
Co-crystallisation of ADTCO3 was performed using: benzoic acid (BA), 4-hydroxybenzoic 
acid (HBA), trans-cinnamic acid (CIN) and 4-hydroxycinnamic acid (HCIN) selected for 
their antiviral and antioxidant activities. Succinic acid (SUC), L-glutamic acid (GLA), L-
glutaric acid (GA), L-tartaric acid (LTTA), salicylic acid (SA) and citric acid monohydrate 
(CA) were selected from the Generally Regarded as Safe (GRAS) list
3
, for their good co-
forming properties as carboxylic acids. 
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Table 5.1: The empiric formula, melting ranges/points and uses of ADTCO3 and 
selected co-formers. 
Compound Abbrev. structure Melting range Uses 
Bis(adamantan-1-
aminium) carbonate 
ADTCO3 
 
170-180°C Antiviral, 
antiparkinson 
Benzoic acid BA 
O
OH
 
122.4°C Antioxidant 
4-Hydroxybenzoic acid HBA 
O
OH
OH  
210°C Antioxidant 
Trans-cinnamic acid CIN 
O
OH
 
133°C Antimicrobial 
4-hydroxycinnamic acid HCIN 
O
OH
OH  
214°C Antioxidant 
Succinic acid SUC 
O
OHO
OH  
185-187°C Flavourant 
L-Glutamic acid GLA 
O
OH
O
OH
NH2  
205°C Flavourant 
L-Glutaric acid GA 
O
OH
O
OH
OH
OH
 
98°C Virucidal 
activity 
L-Tartaric acid LTTA 
 
171-174°C Antioxidant 
Salicylic acid SA 
OH
O OH
 
159°C Keratolytic 
Citric acid monohydrate CA OH
OH
O
OH
O
OH
O
OH2
 
135-152°C Preservative 
ADTCO3 is poorly soluble (or insoluble) in most organic solvents; for this reason, slow 
solvent evaporation was not frequently used for salt co-crystallisation. However, a few 
experiments were conducted using this technique. The ADTCO3 structure (figure 5.1) 
lends itself to co-crystallisation due to the possible intermolecular interactions of one 
proton of the aminium group together with hydrogen atoms of the amantadine ring and one 
atom of the carbonate that is free to participate in further interactions. 
N
+
H
H
H
2
CO
3
-2
OH
OH
OH
O
O
OH
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Figure 5.1: ADTCO3 structure along the b axis highlighting the proton donor and 
acceptor groups in (blue) with hydrogen bonds coloured in red. 
Table 5.2 is a representation of the experiments conducted to prepare ADTCO3 salt co-
crystals. A complete set of the experimental data is presented in Appendix B. All 
experiments commenced with Form I of ADTCO3, the starting material identified in 
‘chapter 3’. For co-crystal experimentation, it was of utmost importance to ensure that all 
analytical results exclude the different polymorphic forms (I-IV) of ADTCO3 identified.  
Table 5.2: Representation of the experiments conducted to prepare ADTCO3 co-
crystals using the salt co-precipitation method. 
Host Co-former Solvent 1 Solvent 2 Ratio Salt co-crystal Results 
ADTCO3 BA Methanol - 1:1 ADTCO3BA Positive  
ADTCO3 BA  Ethanol - 1:1 ADTCO3BA Positive 
ADTCO3 BA Ethanol Ethyl ether 1:1 ADTCO3BA Positive 
ADTCO3 BA Methanol  Ethyl ether 1:1 ADTCO3BA Positive 
ADTCO3 BA Amyl alcohol - 1:1 ADTCO3BA Positive 
 
PREPARATION AND ANALYSIS OF ADTCO3 CO-CRYSTALS 
ADTCO3BA (FORMS 1 to 5) – Polymorphism of ADTCO3BA salt co-crystals 
The co-precipitation and grinding techniques are traditional methods that are reported to be 
effective in crystal screening since they very often lead to valuable results.
4
 
 
  
N
+
H
H
H
2
CO
3
-2
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In this study, ADTCO3 salt co-crystals were generally prepared by these two techniques 
inclusive of co-precipitation by single and binary mixtures and grinding by the neat and 
solvent-drop method. 
PREPARATION 
ADTCO3BA1 
A stoichiometric amount of ADTCO3 (20 mg) and BA (18 mg) in a 1:1 ratio was dissolved 
in 2 mL of methanol in two separate polytop vials.  A hot plate was used to heat the two 
solutions to approximately 10°C below the boiling point of methanol while continuously 
stirring using magnetic stirrers. The two samples were then transferred into one vial and 
stirred again for a period of 10 to 15 minutes. The final solution was filtered using a 0.45 
μm micro-filter and kept in a clean polytop vial sealed with perforated parafilm® to 
facilitate the evaporation of the solvent. 
Long, thin fibre-like crystals were produced. 
ADTCO3BA2 
To prepare ADTCO3BA2 co-crystal, a stoichiometric amount of the two samples 
(ADTCO3 and BA powders in 1:1 ratio) was solubilised in ethanol in two different polytop 
vials. Using a hot plate, the same procedure as applied to ADTCO3BA1 was pursued. Thin 
needle-like, clear crystals were produced after a few days and were fully analysed.  
ADTCO3BA3 
The ADTCO3BA3 was synthesised by the co-precipitation method using ethanol and ethyl 
acetate. During this process, a stoichiometric amount of ADTCO3 (20 mg) and 16.5 mg of 
BA in 1:1 ratio were weighed, transferred each in separate polytop vials and dissolved 
each in a binary mixture of ethanol and ethyl acetate (50:50). With constant stirring on the 
hot plate using a magnetic bar, the two solutions were heated to 10°C below the boiling 
point of the least stable solvent; ethanol for this instance. The two solutions were 
transferred to the same polytop vial, stirred for a further 20 minutes and filtered using a 
syringe and a 0.45 μm microfilter. The final solution was kept in a secure and stable area to 
allow for evaporation at 20°C. Thin fibre-like crystals of ADTCO3BA3 were harvested 
after 4 days for further analyses. 
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ADTCO3BA4 
The ADTCO3BA4 co-crystal was synthesized through recrystallization of both ADTCO3 
and BA from a mixture of methanol and ethyl acetate in a 1:1 ratio. ADTCO3 (20 mg) was 
transferred to a polytop vial and 16.5 mg of BA was added to another. With consistent 
stirring using magnetic stirrers, the two solutions were heated to 10
o
C below the boiling 
point of the lowest boiling solvent (methanol in this case). Then, the two solutions were 
mixed into one polytop vial using a syringe and continuously stirred for approximately 15 
minutes. Filtration was performed using a syringe and a 0.45 µm micro-filter. The 
resulting solution was kept in a secured space for evaporation to occur at ambient 
temperature and pressure. Holes were made in parafilm
®
 covering the solution to allow for 
evaporation. As evaporation occurred, saturation increased and these resulted to the 
formation of crystals. Long, thin and hair-like crystals were produced and fully 
characterized. 
ADTCO3BA5 
ADTCO3BA5 was synthesised by neat grinding. During this process, a stoichiometric 
amount of ADTCO3 (20 mg) and BA (16.5 mg) in a 1:1 ratio; was weighed, transferred in 
a mortar and manually grounded together for 30 minutes using a pestle. This salt co-crystal 
form was reproduced by solvent drop grinding as well. Solvents used were propan-2-ol, 
methanol, ethanol, acetone, ether acetate, diethyl ether and chloroform. 
THERMAL ANALYSIS 
HSM and DSC ANALYSIS 
An investigation on the thermal behaviour of the produced crystals as one of the most 
important steps in drug pre-formulation was performed. The stability (both, physical and 
chemical) of a pharmaceutical substance directly affects its solubility and plays an 
important role during the drug development process which could lead to serious 
consequences during the clinical bioavailability and storage periods if not monitored. 
From literature, the melting point range of BA is 121-123°C whereas melting for ADTCO3 
and its decomposition occur between 150°C and 180°C peaking at 170°C with an emission 
of gas.
2
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The experimental results showed a melting range of 150-180°C also peaking at 170°C with 
bubbling and sublimation occurring between 120°C and 130°C. Hence, the theoretical melt 
for ADTCO3 corresponded well with the experimental melt obtained. 
HSM analysis was performed on ADTCO3BA1 with the sample immersed in silicone oil 
to assess the presence of solvent in the crystal. This would be indicated by bubble 
formation prior to melting. Melting occurred in the temperature range 180-250°C. The 
crystal decomposed with an emission of gas bubbles immediately thereafter (figure 5.2). 
To prepare ADTCO3BA2, the sample was submerged into silicone oil and was gently 
heated at a constant rate of 10°C/min. Melting occurred slowly in the temperature range 
from 209°C to 240°C. Emission of bubble gas from the sample and particle size reduction 
implied that decomposition occurred soon after melting (figure 5.2). 
Thermal behaviour by HSM analysis at a constant rate of 10°C per minute with 
ADTCO3BA3 crystals submerged in silicon oil was performed. The product melts in the 
temperature range of 181-240°C. Decomposition characterised by sample discoloration 
was observed around 240°C. 
ADTCO3BA4 
HSM analysis of the results showed a melt in the temperature range between 200-238°C 
(figure 5.2). Bubbles observed at 137°C, is a sign of solvent evaporation. However, this 
was a surficial solvent since TGA analysed showed a negligible mass loss at that 
temperature. This HSM also confirmed that no solvent is present in the molecular structure 
of the crystal since bubbling only occurred during the melting and decomposition of 
crystals on the hot stage. 
HSM analysis was also conducted to analyse the thermal behaviour of the produced 
ADTCO3BA5. The sample was submerged in silicone oil on the stage of the microscope. 
Heating was applied at a constant rate of 10°C per minute and melting characterised by 
sample size reduction was observed in the temperature range 190-250°C. The powder 
degraded in the temperature range of 260-264°C as indicated by spontaneous bubbling. 
HSM photographs of ADTCO3BA1 to ADTCO3BA5 are recorded at different 
temperatures in figure 5.2. 
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Figure 5.2: HSM photographs of ADTCO3BA salt co-crystal forms at (a) room 
temperature, (b) first change in crystal, (c) onset of melting and (d) onset of 
decomposition. 
ADTCO3BA1 DSC analysis showed a melt of 239°C in the temperature range of 180-
245°C with a very broad endothermic peak as shown in figure 5.3. Decomposition 
followed the melt immediately. 
ADTCO3BA2 DSC analysis showed superficial solvent (ethanol) coming off at 77°C with 
an onset at 72.37°C. The melting point of ADTCO3BA2 occurred in the temperature range 
of 200-225°C illustrated by a sharp endothermic peak at 212°C with an onset at 205°C. 
Degradation was clearly seen commencing within the melt peak from 225°C identified as 
an irregular baseline.  
ADTCO3BA3 DSC analysis presents a melt in the temperature range between 197.73°C 
and 237°C as indicated by a broad endothermic peaking at 229°C. 
ADTCO3BA4 DSC trace showed a melt in the temperature range of 214-245°C with a 
broad endotherm peaking at 241°C followed immediately by degradation of the sample. 
ADTCO3BA5 DSC analysis produced a trace with a broad endotherm presenting a melt in 
the temperature range of 225-260°C, peaking at 250°C. 
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Figure 5.3: DSC traces of ADTCO3BA forms 1 to 5. 
TGA ANALYSIS 
Thermogravimetric analysis was performed to assess possible included solvent in the 
molecular structure of the five forms of ADTCO3BA (figure 5.4). 
ADTCO3BA1 showed a negligible mass loss of 0.3% (n~0.04). Thus, bubbling observed 
over heating on the hot stage was due to superficial solvent loss on the crystal not 
adequately removed prior to analysis. 
ADTCO3BA2 showed a 0% mass loss in the temperature range 30-205°C prior to the melt 
of the sample. This finding proved the material to be a non-solvate/hydrate. The first 
endotherm at 77°C on the DSC graph was indeed just superficial solvent given off due to 
sample that was not fully dried prior to its analysis. 
ADTCO3BA3 TGA trace was analysed and presented a mass loss of 4.6% (n = 0.161) in 
the temperature range between 30°C and the onset of the melt of ADTCO3BA3. The initial 
mass loss was accounted for as unidentifiable impurities present in the sample which 
contaminated the product during preparation. 
ADTCO3BA4 TGA analysis was 1.87% (n = 0.077). The mass loss was negligible and 
does not make any contribution to the structure of this compound. 
ADTCO3BA5 also showed a negligible mass loss in the range 30-179°C, confirming the 
absence of solvent in the molecular structure of this product.  
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Figure 5.4: TGA traces of ADTCO3BA forms 1 to 5. 
FTIR ANALYSIS 
FTIR spectroscopy analysis
6
 was performed on ADTCO3BA (forms 1-5) to investigate 
firstly, the interaction between the functional groups of the two parent compounds and 
secondly, the identification of salt forming co-crystals (or salt forming solvated co-
crystals). Finally, the polymorphism phenomenon of forms 1 to 5 was characterised.  
 Based on different band shifts presented in the table 5.3, it has been confirmed that there 
are interactions occurring between the pure drug and the excipient. Salt formation was 
justified by the presence of NH3
+
 bands which shifted differently from one form to another 
due to its participation in interactions with OH or C=O of carbonyl group (-COOH). 
According to figure 5.6, the probable interaction occurring are: NH3
+
···OH, NH3
+
···C=O 
and possibly C=O···H–O. 
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Figure 5.5: FTIR spectra of 1-5 form of ADTCO3BA forms 1 to 5. 
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Table 5.3: Different band shifting (in wavenumber cm
-1
) observed in the ADTCO3BA spectra Forms 1 to 5. 
Group ADTCO3 BA ADTCO3BA1 ADTCO3BA2 ADTCO3BA3 ADTCO3BA4 ADTCO3BA5 
NH3
+
 2564 cm
-1
 - 2568 cm
-1
 - 2562 cm
-1
 2567 cm
-1
 2570 cm
-1
 
 - 1601 cm
-1
 2623 cm
-1
 2612 cm
-1
 2623 cm
-1
 2623 cm
-1
 2624 cm
-1
 
 - 1582 cm
-1
 1593 cm
-1
 - 1586 cm
-1
 1592 cm
-1
 1561 cm
-1
 
C=O  1679 cm
-1
 - - 1667 cm
-1
 1668 cm
-1
 1701 cm
-1
 
C=O 1639 cm
-1
 - 1627 cm
-1
 1611 cm
-1
 1629 cm
-1
 1629 cm
-1
 1627 cm
-1
 
 1550 cm
-1
 - 1544 cm
-1
 1533 cm
-1
 1513 cm
-1
 1523 cm
-1
 1521 cm
-1
 
C-H 2910 cm
-1
 - 2907 cm
-1
 2913 cm
-1
 2907 cm
-1
 2907 cm
-1
 2908 cm
-1
 
O-H - 3071 cm
-1
 3387 cm
-1
 - - - - 
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Figure 5.6: Structure presenting the possible sites for interactions between ADTCO3 
and BA. 
The absorption band at 1639 cm
-1
 ascribed to the C=O vibration of ADTCO3 carbonate 
shifted to 1627 cm
-1
, 1611 cm
-1
, 1629 cm
-1
, 1629 cm
-1
 and 1627 cm
-1
 the spectra of 
ADTCO3BA forms 1-5 respectively, suggesting the interaction with OH of –COOH 
functional group. The 1550 cm
-1
 band that was assigned to the C=O vibration of the 
carbonate has shifted to 1544 cm
-1
, 1533 cm
-1
, 1513 cm
-1
, 1523 cm
-1
 and 1521 cm
-1
 in the 
spectra of ADTCO3BA forms 1-5 respectively, suggesting the effect of the same 
intermolecular interactions. NH3
+
 band found at 2564 cm
-1
 in the ADTCO3 spectrum has 
shifted differently in the spectrum of each ADTCO3BA form due to its interaction 
involvement with BA functional groups as shown (figure 5.6). Furthermore, the 3071 cm
-1
 
band assigned to the OH of the carboxylic acid (COOH) was not present in the entire range 
of ADTCO3BA forms spectra except for the ADTCO3BA1 spectrum where this peak 
shifted to 3387 cm
-1
, suggesting the interactions with NH3
+
. All these changes confirmed 
the co-crystallisation process between ADTCO3 and BA and formation of ADTCO3BA as 
a salt co-crystal in different forms. 
PXRD ANALYSIS 
To further compare and sustain thermal and spectroscopic findings 5 patterns of 5 
ADTCO3BA forms were compared. Firstly, they all showed good crystallinity. Secondly, 
patterns differ from those of both ADTCO3 and BA.  
Furthermore, each of ADTCO3BA forms produced a unique PXRD pattern compared to 
others with peaks appearing at different 2 θ values (figure 5.7). This provided evidence of 
the co-crystallisation of ADTCO3 and BA into different forms. 
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While the BA trace presented peaks appearing at 2 θ 8.5°, 16.14°, 16.99°, 19°, 21.06°, 
23.52°, 25.61°, 27.53° and 29.98°, along the ADTCO3 curve, peaks are found at 6.84°, 
15.79°, 17.25°, 20.73°, 28.48° and 35°. 
ADTCO3BA1 co-crystal presents a trace with peaks at 8.4°, 15.88°, 18.35°, 19.28° and 
21.43° (figure 5.7). 
New intense peaks along ADTCO3BA2 pattern are formed at 2 θ 14°, 17° and 29°. 
For ADTCO3BA3, the pattern showed different peaks in the region of 2θ 15.74°, 16.2°, 
16.65°, 18.4°, 19.25°, 21.76°, 27.8° and 34.4°. 
 Along ADTCO3BA4 curve, different intense peaks appeared in the region of 2θ values 
16.5°, 19° and 22.5°. 
For ADTCO3BA5, intense peaks appear at 2θ values 15.79° and 21.4°. Additional peaks 
are formed at 2θ 5.6°, 8.3°, 18.3°, 19.2° and 29.6°. 
Compared to ADTCO3 and BA PXRD patterns (figure 5.7), it is clearly evident that all 
five forms of ADTCO3BA differ in their packing arrangements from one another in the 
unit cell. Hence, the five polymorphic forms of ADTCO3BA are undeniably proven.  
 
Figure 5.7: PXRD of 1-5 forms of ADTCO3BA salt co-crystal. 
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ADTCO3HBA 
PREPARATION 
A stoichiometric amount of ADTCO3 (20 mg) and HBA (29 mg) in a 1:1 ratio was 
transferred to a mortar and ground using a pestle for 30 minutes. The process was assisted 
by a few drops of methanol. The product was reproduced by grinding with a few drops of 
1, 4-dioxan, ethanol, diethyl ether, acetone, chloroform, ethyl acetate and amyl alcohol. A 
fine white powder resulted as ADTCO3HBA. 
THERMAL ANALYSIS 
HSM AND DSC ANALYSIS 
A small amount of ADTCO3HBA was submerged in silicone oil on a glass slide and 
analysed by HSM. Heating was applied at a constant rate of 10°C per minute and thermal 
changes of ADTCO3HBA were observed under the microscope. HSM photographs (figure 
5.8) were recorded and analysed using Essentials stream software
®
. 
HSM clearly showed the recrystallization process of the sample (a phase change of powder 
to crystal) around 206 °C. This continued until the sample melted in the temperature range 
235-239 °C. Decomposition was characterised by discoloration and was observed from 
250 °C.  
 
Figure 5.8: HSM photographs of ADTCO3HBA recorded at (a) room temperature, 
(b)  the crystallisation of sample (c) the melting point (d) the completion of melt with 
immediate decomposition occurring. 
Analysis on DSC was performed and showed a melt in the temperature range between 
236°C-245°C with a very sharp endotherm peaking at 238°C (figure 5.9).  
 (a) 25°C     (b) 208°C     (c) 239°C     (d) 250 °C 
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A slight exothermic curve preceding the melt peak suggested that the powder firstly re-
crystallised around 200°C, then proceeded to melt at 238°C. These results are consistent 
with the HSM findings. 
ADTCO3HBA was confirmed as a new form since a single peak was seen on the DSC 
trace which differed from both the parent compounds melting points (ADTCO3 m.p.: 
170°C and HBA m.p.: 214.5°C). 
 
Figure 5.9: DSC trace of ADTCO3, HBA and ADTCO3HBA. 
TGA ANALYSIS 
The TGA trace for ADTCO3HBA (figure 5.10) presented a 0% mass loss in the range 30-
200°C. This proved that there was no solvent present in the molecular structure of the 
product. A significant mass loss did however occur immediately after the melt of the 
sample suggesting decomposition of the sample. 
 
Figure 5.10: TGA trace for ADTCO3HBA. 
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FTIR ANALYSIS 
Infrared spectrum for ADTCO3HBA presented various shifts of bands, intensity changes 
and the appearance of new bands (figure 5.11) providing evidence of intermolecular 
interactions between ADTCO3 and HBA. 
Formation of ADTCO3HBA was evidenced by various band shifts in figure 5.11. The most 
probable intermolecular interactions between ADTCO3 and HBA are as follows: 
NH3
+
···O-H, HN3
+
···C=O (COOH), CO3
2-
···OH, CO3
2-
···O-H (COOH), C-H···O-H, C-
H···C=O (COOH). 
Based on table 5.9, ADTCO3HBA firstly presents the key intermolecular interactions 
between ADTCO3 and HBA. Secondly, it is observed that ADTCO3HBA retains its salt 
behaviour (NH3
+
 ion) due to the presence of 2608 cm
-1
 having shifted from 2564 cm
-1
. The 
appearance of 2162 cm
-1
 is an indication that neutral N−H···O−H hydrogen bonding has 
occurred. Thus, ADTCO3HBA will henceforth be referred to as a salt co-crystal. 
Figure 5.11 and Table 5.9 suggests that NH3
+
 ion  interacts with the –OH group since the 
NH3
+
 ion band shifts significantly and the –OH band for HBA is lost completely in the 
spectrum. The interactions also had an effect on 2910 cm
-1 
absorption band ascribed to the 
stretching vibrations of C-H shifted to 2921 cm
-1
. Displacements of C=O of ADTCO3 from 
2267 cm
-1 
to 2162 cm
-1
, C=O of HBA from 1669 cm
-1 
to 1682 cm
-1 
and 1607 cm
-1
 to 1605 
cm
-1
 in ADTCO3HBA originated from.  
Further, one could see from figure 5.11 that ADTCO3HBA salt co-crystal formation is also 
identified by 1519 cm
-1
, 1496 cm
-1
 and 1425 cm
-1 
absorption bands attributed to the C-H 
deformation or C-C stretching vibration. The characteristic absorption bands at 1374 cm
-1
 
and 1309 cm
-1
 assigned to the C-O stretching vibration of the carbonyl group, 1278 cm
-1
, 
1222 cm
-1
 and 1206 cm
-1
 of the aromatic C-O, 1164 cm
-1
, 1137 cm
-1
 and 1095 cm
-1
 
attributed to C-H bending vibration. Furthermore, 975 cm
-1
, 855 cm
-1
, 806 cm
-1
 and 790-
716 cm
-1
 absorption bands are ascribed to aromatic C-H deformation of methyl groups that 
were all affected by the above interactions. 
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Figure 5.11: FTIR spectra of ADTCO3, ADTCO3HBA and HBA. 
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Shifts in the FTIR spectrum of ADTCO3HBA compared to both ADTCO3 and HBA are 
tabulated in the following table (table 5.4). The table was further used to predict the 
possible interaction sites for ADTCO3 and HBA (figure 5.12). 
Table 5.4: Important shifts in the ADTCO3HBA spectrum. 
Groups ADTCO3 HBA ADTCO3HBA Shifts 
NH3
+
 2564 cm
-1
 - 2608 cm
-1
 43 cm
-1
 
C=O 1639 cm
-1
 1669 cm
-1
 
1607 cm
-1
 
1682 cm
-1
 
1605 cm
-1
 
27 cm
-1
 
2 cm
-1
 
C–H 2910 cm
-1
 - 2921 cm
-1
 11 cm
-1
 
 2267 cm
-1
 - 2162 cm
-1
 105 cm
-1
 
O−H - 3374 cm
-1
 Lost  - 
 
 
Figure 5.12: The possible site of action for the interactions between ADTCO3 and 
HBA. 
PXRD ANALYSIS 
To further investigate the formation of ADTCO3HBA salt-co-crystal and support the 
previous analytical conclusions, powder X-ray diffraction analysis was performed.  
A distinctive pattern was compared to both starting materials ADTCO3 and HBA (figure 
5.13). ADTCO3HBA differed to its parent compounds at 2θ 16
o
, 17.9
o
, 19.1
o
, 20.3
o
 and 2θ 
27.1
o 
(figure 5.14). Figure 5.14 also showed that ADTCO3HBA could be reproduced using 
the solvent-drop grinding techniques with several solvent systems. 
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Figure 5.13: PXRD of ADTCO3, HBA and ADTCO3HBA. 
 
Figure 5.14: PXRD of ADTCO3HBA prepared by various solvent assisted grinding. 
 
ADTCO3CIN 
PREPARATION 
To synthesise ADTCO3CIN, ADTCO3 and trans-cinnamic acid (CIN) powders were 
ground together in a mortar using a pestle. The stoichiometric amount of ADTCO3 (20 mg) 
together with CIN (19.5 mg) in a 1:1 ratio were manually ground for 30 minutes, with 
continuous introduction of methanol drops while grinding. ADTCO3CIN was produced 
and fully characterised using different techniques. 
The same product was reproduced by grinding with a few drops of a variety of organic 
solvents including acetone, ethanol, water, propane-2-ol, ethyl acetate, diethyl ether and 
amyl alcohol. 
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THERMAL ANALYSIS 
HSM and DSC 
HSM analysis was performed to assess the thermal behaviour of ADTCO3CIN. 
Photographs were recorded using Essential stream software
®
. Melting accompanied by 
bubbling commenced at 255°C and was characterised by a phase change from solid to 
liquid on the hot stage (figure 5.15). Decomposition was characterised by spontaneous 
bubbling and discoloration of the sample observed at 263°C. 
 
Figure 5.15: HSM photographs of ADTCO3CIN at (a) room temperature (b) melting 
temperature, (c) the onset of decomposition and (d) completion decomposition. 
DSC analysis was performed at a constant rate of 10°C per minute. The DSC trace showed 
a melt in the temperature range 245-256°C illustrated by an endothermic peak at 254°C 
with an onset at 230°C (figure 5.16). Both parent compounds have significantly lower 
melting points compared to the new product (ADTCO3 m.p. is 150-180°C and CIN m.p is 
133°C). 
 
Figure 5.16: DSC of ADTCO3, CIN and ADTCO3CIN. 
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TGA ANALYSIS 
To further support the previous analysis and assess the purity of ADTCO3CIN, TGA was 
conducted. The TGA trace (figure 5.17) presented a mass loss 0 % in the range 30-183°C, 
prior to the melt. A significant mass loss commenced with the onset of melting and 
continued with the sample degradation process. 
 
Figure 5.17: TGA trace of ADTCO3CIN. 
FTIR ANALYSIS 
The FTIR analysis performed on the ground sample produced a spectrum with shifts in 
bands, changes in intensity and formation of new bands all observed in comparison to 
parent compounds (figure 5.18). This justified the effect of intermolecular interactions 
between ADTCO3 and CIN. 
Generally, the absorption bands decreased or shifted to the left in the ADTCO3CIN 
spectrum. The important shifts observed in the ADTCO3CIN spectrum were attributed to 
the effect of intermolecular interactions predicted in figure 5.18 and conclusively 
confirmed the new entity. 
From the FTIR results based on table 5.5 and figure 5.19, the most plausible interactions 
between the parent compounds could be O-H⋯NH (NH3+), C=O⋯NH3+ and C-
H⋯O=C had occurred. 
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Figure 5.18: FTIR of ADTCO3, CIN and ADTCO3CIN. 
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Table 5.5: Important shifts detected in the ADTCO3CIN spectrum. 
Groups ADTCO3 CIN ADTCO3CIN Shifts 
NH3
+
 2564 cm
-1
 - 2628 cm
-1
 63 cm
-1
 
C=O 1639 cm
-1
 - 1638 cm
-1
 1 cm
-1
 
C-H 2910 cm
-1
 - 2912 cm
-1
 2 cm
-1
 
 2267 cm
-1
 - 2162 cm
-1
 105 cm
-1
 
C-C - 1601 cm
-1
 1593 cm
-1
 7 cm
-1
 
Aromatic  - 1495 cm
-1
 1503 cm
-1
 8 cm
-1
 
 
 
Figure 5.19: The possible interactions sites for ADTCO3 and CIN 
Firstly the presence of 2162 cm
-1
 band in ADTCO3CIN spectrum is an indication that O-
H⋯NH has occurred. The loss of bands at 3067 cm-1, 3027 cm-1 and 2543 cm-1 ascribed to 
the O-H of the carbonyl (-COOH) in the ADTCO3CIN spectrum is a result of the possible 
hydrogen bonding (O-H⋯NH3+) interactions and evidence of co-crystal formation. The 
presence of 2564 cm-1 band (NH3+ of ADTCO3) which shifted to 2528 cm
-1
 in the 
ADTCO3CIN spectrum was due to the hydrogen bonding with OH of the carbonyl (O-
H⋯NH3+) and confirmed that the produced ADTCO3CIN is a salt co-crystal.  
Further, 1639 cm
-1
 and 1551 cm
-1
 bands assigned to the C=O stretching vibration slightly 
shifted as a result of its participation into H-bonding with the NH (NH3+) group. 
Furthermore, the appearance of characteristic absorption bands at 1391 cm
-1
, 1363 cm
-1
, 
1241 cm
-1
, 1196 cm
-1
, 1170 cm
-1
, 1127 cm
-1
, 1117 cm
-1
 and 1093 cm
-1
 band attributed to 
the C-O stretching vibrations confirmed the deprotonating of the carbonyl group (-COOH). 
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POWDER X-RAY DIFFRACTION ANALYSIS 
Experimental PXRD analysis was performed to confirm the formation of the ADTCO3CIN 
salt co-crystal. The ADTCO3CIN pattern presents new peaks at 2θ 17.35
o
 and 19.6
o
 while 
new short peaks were formed at 2θ of 7.1o, 10.5o, 14.4o, 15.5o, 15.7o, 22.1o and 24.9o 
(figure 5.20). The pattern differs significantly from the parent compounds patterns, 
confirming the newly derivatised salt co-crystal. 
 
Figure 5.20: PXRD of ADTCO3, CIN and ADTCO3CIN. 
 
ADTCO3HCIN 
PREPARATION 
For the synthesis of ADTCO3HCIN, a stoichiometric amount of ADTCO3 (20 mg) and 
HCIN (21.65 mg) in a 1:1 ratio was weighed and added together in a mortar and ground 
for a 30 minute period using a pestle. This is referred to as neat grinding.  
Neat grinding was a preferred technique from a pharmaceutical perspective because it 
ensured the use of few additives. The same product was reproduced by grinding with a few 
drops of chloroform, methanol, ethanol, chloroform, acetone and amyl alcohol. The 
produced white powder was kept in an airtight polytope vial for analysis. 
THERMAL ANALYSIS 
HSM and DSC 
HSM analysis was performed with the sample submerged in silicon oil to assess the 
thermal behaviour and composition of ADTCO3HCIN. The thermal behaviour was 
observed upon heating at a constant rate of 10°C per minute.  
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Slight bubbling occurred prior to the melt between 150°C and 180°C. Melt was 
characterised by bubbling and a phase change to liquid in the temperature range of 227-
250°C (figure 5.21). Discoloration and spontaneous bubbling occurred at 255°C indicating 
the commencement of decomposition. 
 
Figure 5.21: HSM photographs of ADTCO3HCIN at (a) room temperature, (b) the 
melting temperature, (c) onset of decomposition and (d) completion of decomposition. 
DSC analysis of ADTCO3HCIN was performed and produced a trace with a unique broad 
melting endotherm between 240
 
°C and 270°C peaking at 250.80°C, with an onset at 
240°C (figure 5.22). Melting was preceded by a solvent loss indicated by a small bump at 
185°C which was evident during the HSM analysis by the occurrence of bubbling. 
 
Figure 5.22: DSC trace of ADTCO3HCIN. 
THERMOGRAVIMETRIC ANALYSIS 
The HSM and DSC analyses were supported by thermogravimetric analysis performed to 
further investigate the purity and composition of ADTCO3HCIN. The TGA trace (figure 
5.23) showed a mass loss of 3.45% in the temperature range 30-200
o
C and thus, confirmed 
the presence of possible water molecules in the molecular structure since no solvent was 
used to prepare the sample. 
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Figure 5.23: TGA trace of ADTCO3HCIN. 
FTIR ANALYSIS 
Infrared spectroscopic analysis for ADTCO3HCIN produced a distinct spectrum compared 
to that of ADTCO3 and HCIN (figure 5.24). Different functional groups from both parent 
compounds are observed with various shifts, changes in intensity of bands and the 
appearance of new bands in the ADTCO3HCIN spectrum. This therefore confirmed the 
existence of interactions (e.g. hydrogen bonds) between the two parent compounds (salt 
co-crystallisation). 
The ADTCO3HCIN salt co-crystal was identified by FTIR analysis since the majority of 
bands in the spectrum decreased in wave length. From figure 5.25 and table 5.6, it can be 
confirmed that the possible intermolecular interactions occurring are C=O⋯NH3+, H-
O⋯NH3+ or C=O⋯H-O. Firstly, 2162 cm
-1 band in the ADTCO3HCIN spectrum is an 
indication that H-O⋯NH (NH3+) has occurred. Secondly, the loss of 3353 cm
-1 
and 2576 
cm
-1
 of HCIN assigned to the O-H stretching vibration some important bands in the 
ADTCO3HCIN spectrum is due to the interaction with NH (O-H⋯NH3+). And the 
presence of weak absorption bands at 2628 cm
-1
 assigned to the NH3
+
 in the 
ADTCO3HCIN spectrum which shifted from 2564 cm
-1
 confirmed the interaction with OH 
(H-O⋯NH3+) and retention of salt characteristic by this new entity. 
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Figure 5.24: FTIR of ADTCO3, ADTCO3HCIN and HCIN. 
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Table 5.6: Important shifts in the ADTCO3CIN spectrum. 
Groups ADTCO3 HCIN ADTCO3HCIN Shifts 
NH3
+
 2564 cm
-1
 - 2628 cm
-1
 63 cm
-1
 
C=O 1639 cm
-1
 
1550 cm
-1
 
- 
- 
1638 cm
-1
 
1547 cm
-1
 
1 cm
-1
 
3 cm
-1
 
C‒H 2910 cm
-1
 - 2911 cm
-1
 1 cm
-1
 
 2267 cm
-1
 - 2162 cm
-1
 105 cm
-1
 
C‒C - 1601 cm
-1
 1593 cm
-1
 7 cm
-1
 
Aromatic  - 1495 cm
-1
 1503 cm
-1
 8 cm
-1
 
 
 
Figure 5.25: The possible sites for interactions between ADTCO3 and HCIN. 
The effects of the above interactions is seen on C-H stretching vibration of the methyl (sp
3
 
or sp
2
) at 2910 cm
-1
 and 2852 cm
-1
 which shifted slightly to 2912 cm
-1 
and 2853 cm
-1
 
respectively. The 1639 cm
-1 
bands of C=O in ADTCO3 has shifted to 1638 cm
-1
 in the 
ADTCO3HCIN spectrum due to C=O⋯NH3
+
 interactions. The 1601 cm
-1 
and 1495 cm
-1 
bands of the aryl in HCIN spectrum also shifted to 1593 cm
-1 
and 1503 cm
-1 
respectively. 
Furthermore, the changes in location of various bands observed in the fingerprint region of 
the ADTCO3HCIN spectrum also confirmed salt co-crystal formation. 
EXPERIMENTAL PXRD 
The salt co-crystal ADTCO3HCIN formation is confirmed in figure 5.26 at 2θ 6.7
o
, 8.1
o
, 
10.2
o
, 15.3
o
, 16.5
o 
and 19.43
o
. This was compared to both ADTCO3 and HCIN PXRD 
patterns. Figure 5.27 illustrates the reproducibility of ADTCO3HCIN salt co-crystal using 
other several solvents. 
 
 
 
 
Chapter 5 
 
 
115 
 
 
Figure 5.26: PXRD of ADTCO3, HCIN and ADTCO3HCIN. 
 
Figure 5.27: PXRD pattern of ADTCO3HCIN prepared by different solvent-assisted 
grinding systems. 
ADTCO3SUC 
PREPARATION 
ADTCO3SUC was prepared by neat grinding of ADTCO3 (20 mg) with SUC (18 mg) in a 
1:1 ratio for 30 minutes in a mortar using a pestle. Solvent drop-grinding with methanol, 
ethanol, chloroform, acetone, amyl alcohol, butan-2-ol, diethyl ether, 1,4-dioxan, ethyl 
acetate and propane-2-ol also reproduced the same product. A full characterisation was 
conducted using a combination of different analytical techniques.  
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Furthermore, the product was prepared by the co-precipitation technique as well. The 
equimolar amount of ADTCO3 and SUC was separately dissolved in minimum volumes of 
methanol at approximately 10°C below the boiling point of the solvent. The two solutions 
were then mixed and the resultant solution was stirred for up to 15 minute using a 
magnetic bar, filtered (0.45 µm microfilter) and allowed to crystallise at room temperature. 
Large cubic crystals were harvested and fully analysed. 
THERMAL ANALYSIS 
HSM analysis was conducted at a constant rate of 10°C per minute, with the sample 
submerged in silicon oil to analyse the thermal behaviour of ADTCO3SUC. HSM 
photographs are presented in figure 5.28. Phase transition was observed at around 140°C 
and the melting process occurred at 197°C which was immediately followed by 
spontaneous bubbling (decomposition). This analysis identified the existence of two 
different forms of this product.  
 
Figure 5.28: HSM photographs of ADTCO3SUC recorded at (a) room temperature, 
(b) transition temperature to a 2nd form (metastable) (c) the melting temperature of 
the most stable form. 
The DSC analysis of ADTCO3SUC showed a curve with two endotherms. The DSC curve 
is presented in figure 5.29. The first endotherm appears in the temperature range 135-
144°C peaking at 140.67°C with an onset at 139.64°C (figure 5.29) establishing the phase 
transition [metastable (form II) to stable (form I)] and the second endotherm corresponding 
to the melting process appears between 180°C and 200°C, peaking at 195°C. A very good 
correlation between HSM and the DSC analysis resulted. 
Succinic acid was reported to exhibit two different polymorphs, α-succinic acid which is 
triclinic and only stable above 137°C and β-succinic acid which is monoclinic 188°C.6,7 
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Figure 5.29: DSC trace of ADTCO3SUC. 
TGA ANALYSIS 
The HSM and DSC findings are additionally supported by thermogravimetric analysis 
performed to further investigate the purity and composition of ADTCO3SUC co-crystal. 
The TGA trace showed a 0% mass loss in the temperature range 30-176°C (figure 5.30) 
and thus, confirmed the absence of water/solvent in the molecular structure of this 
compound. The mass loss step is observed in the melting and decomposition range. 
 
Figure 5.30: TGA trace of ADTCO3SUC. 
FTIR ANALYSIS 
Thermal analysis findings are additionally supported by FTIR analysis. The comparison of 
ADTCO3SUC spectrum to that of ADTCO3 and SUC is presented (figure 5.31).  
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Figure 5.31: FTIR of ADTCO3, ADTCO3SUC and SUC. 
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The following table 5.7 presents the important shifts observed in the spectrum of 
ADTCO3SUC. 
Table 5.7: Functional groups compared in ADTCO3, SUC and ADTCO3SUC spectra. 
Groups ADTCO3 SUC ADTCO3SUC Shifts 
NH3
+
 2564 cm
-1
 - 2629 cm
-1
 64 cm
-1
 
C=O  1682 cm
-1
 1690 cm
-1
 7 cm
-1
 
 1550 cm
-1
 - 1556 cm
-1
 6 cm
-1
 
 1639 cm
-1
 - 1611 cm
-1
 28 cm
-1
 
C-H 2910 cm
-1
 - 2905 cm
-1
 5 cm
-1
 
  2629 cm
-1
 2633 cm
-1
 4 cm
-1
 
 1456 cm
-1
 - 1450 cm
-1
 6 cm
-1
 
 2723 cm
-1
 - 2734 cm
-1
 11 cm
-1
 
C-O-H - 1409 cm
-1
 1401 cm
-1
 7 cm
-1
 
O-H - 2930 cm
-1
 3078 cm
-1
 148 cm
-1
 
 
 
Figure 5.32: The possible sites of interactions for ADTCO3 and SUC. 
Based on figure 5.32, the interactions O-H⋯NH3
+
, O-H⋯C=O and C=O⋯NH3
+
 were 
expected. Shifts of bands presented in table 5.7 clearly confirmed the existence of the 
interactions between ADTCO3 and SUC functional groups. Figure 5.31 showed a loss of 
2564 cm
-1 
band assigned to the NH3
+
 in ADTCO3SUC spectrum, thus confirming the 
product ADTCO3SUC as a co-crystal not as a salt. The ADTCO3SUC spectrum displays a 
weak band at 3078 cm
-1
 band assigned to the O-H of the carbonyl group (COOH), which 
as a result of O-H⋯NH3
+
 interaction, has shifted from 2930 cm
-1
. 
The C-H vibrations at 2910 cm
-1
 and 1456 cm
-1
 in ADTCO3 spectrum have shifted to 2905 
cm
-1
 and 1450 cm
-1
 respectively.  
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The 1682 cm
-1
 band attributed to the C=O of SUC has shifted to 1690 cm
-1 
in the 
ADTCO3SUC spectrum as a result of the possible C=O⋯NH3
+
 interactions. All these 
changes confirmed the formation of the ADTCO3SUC co-crystal.   
PXRD ANALYSIS 
The PXRD pattern in figure 5.33 is quite different from the PXRD patterns of the starting 
materials ADTCO3 and SUC. In addition to thermal as well as spectroscopic analysis, this 
confirmed the co-crystallisation between the two parent compounds. The pattern also 
matches other patterns of the same product obtained from grinding with various solvent 
systems (figure 5.34) and the crystal resulting from co-precipitation. The most stable phase 
presented new intense peaks at 2θ 15.33o, 18.1o and 19o. Weaker peaks identified at 2θ 
21.7
o
, 24
o
, 28.5
o
, 32.6
o
 and 34.2
o
 confirming the crystallinity of the produced entity. 
 
Figure 5.33: PXRD of ADTCO3, SUC and ADTCO3SUC. 
The same pattern was produced by PXRD analysis of ADTCO3SUC samples prepared 
through grinding, assisted by a few drops of methanol, ethanol, chloroform, acetone, amyl 
alcohol, diethyl ether, ether acetate, butan-2-ene and propane-2-ol, butan-2-ol and 1,4-
dioxan. 
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Figure 5.34: PXRD patterns of ADTCO3SUC synthesised in various solvents. 
In conclusion, due to the HSM and DSC findings reported, a second form for 
ADTCO3SUC was definitely identified. However, variable temperature PXRD together 
with the HSM and DSC analysis would have resulted in a more conclusive result. 
ADTCO3LTTA 
PREPARATION 
A stoichiometric amount of ADTCO3 (20 mg) and LTTA (19.8 mg) in a 1:1 ratio was 
transferred to a motor and ground manually for 30 minutes using a pestle. A white powder 
was produced and kept in the airtight polytope vial for analysis. The same product was 
obtained from solvent evaporation with a 1:1 of both compounds solubilised (in separate 
vials) in methanol at 10°C below the b.p. of the solvent. The two solutions were then 
added together and magnetically stirred on a hot plate, filtered (0.45µm) and the resulting 
solution was allowed to crystallise at room temperature.  
THERMAL ANALYSIS 
HSM and DSC ANALYSIS 
HSM analysis was performed with the sample submerged in silicon oil. The analysis 
showed bubbling at ~135°C and continued as the temperature increased until the melt 
occurred in the range of 197°C-210°C.  
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Decomposition occurred immediately after melting which was observed by spontaneous 
bubbling and discoloration of the sample. HSM photographs recorded at different 
temperatures due to thermal events observed are presented in the figure 5.35. 
 
Figure 5.35: HSM photographs of ADTCO3LTTA at (a) ambient temperature (b) 
first change (bubbling), (c) melting and (d) decomposition. 
DSC analysis of the parent compounds (figure 5.36) showed a melt in the temperature 
range of 171-174°C for L-tartaric acid and the melt of ADTCO3 was observed in the range 
of 155-180°C. ADTCO3LTTA showed two endothermic peaks with firstly a small 
endotherm appearing at 140.9°C, suggesting that some water was coming off since no 
solvent was used to prepare this product. Secondly, a broad endothermic peak at 206.1°C 
corresponding to the melt of the product was observed. Both parent compounds melting 
points were nowhere close to the melt of the product produced. 
 
Figure 5.36: DSC traces of ADTCO3, ADTCO3LTTA and LTTA. 
DSC and HSM results consistently presented a different melt compared to both parent 
compounds, thus confirming the new entity. 
 
 
 
 
Chapter 5 
 
 
123 
 
TGA ANALYSIS 
The TGA trace (figure 5.37) presented a mass loss of 5.25 % (n = 0.86) in the range of 30-
203°C which confirmed the presence of solvent in the molecular structure of 
ADTCO3LTTA. The second mass loss step is a result of the melt and immediate 
decomposition of the sample. 
 
Figure 5.37: TGA trace of ADTCO3LTTA. 
FTIR ANALYSIS 
In order to qualitatively analyse various functional groups in ADTCO3LTTA, FTIR 
spectrum was recorded and compared to the parent compounds, ADTCO3 and LTTA as 
shown in figure 5.38. The absorption bands in the spectrum of ADTCO3LTTA differ 
significantly to the other two spectra. Shifts and changes of band intensities were carefully 
studied since these would appear as a result of intermolecular interactions. Particular 
differences in the spectra are presented in table 5.8.  
From the FTIR results; table 5.8 and figure 5.38, the possible N-H⋯O-H, N-H⋯C=O, O-
H⋯C=O interactions occurred. The ADTCO3LTTA spectrum (figure 5.38) showed a loss 
of 3328 cm
-1 
and 3096 cm
-1 
bands of LTTA ascribed to O-H of hydroxyl and COOH 
groups and 2564 assigned to NH3
+
 vibration from ADTCO3, suggesting that this was due 
to the interaction with H−O⋯NH3
+
. Furthermore, the loss of NH3
+
 also confirmed that 
ADTCO3LTTA was synthesised as a co-crystal. 
0
0.5
1
1.5
2
2.5
3
30 130 230 330 430 530
W
e
ig
h
t/
 m
g 
Temperature/ °C 
 
 
 
 
Chapter 5 
 
 
124 
 
 
Figure 5.38: FTIR of ADTCO3, ADTCO3LTTA and LTTA. 
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Table 5.8: Some shifts of bands in ADTCO3LTTA spectrum. 
Groups ADTCO3 LTTA ADTCO3LTTA Shifts 
NH3
+
 2852 cm
-1
 - weak - 
 1639 cm
-1
 - 1661 cm
-1
 21 cm
-1
 
C-H 2910 cm
-1
 - 2903 cm
-1
 6 cm
-1
 
 1456 cm
-1
 - 1450 cm
-1
 6 cm
-1
 
O-H - 3399 cm
-1
 3387 cm
-1
 11 cm
-1
 
 - 3328 cm
-1
 - - 
 - 3096 cm
-1
 - - 
 
 
Figure 5.39: The possible sites of intermolecular interactions of ADTCO3 and LTTA. 
The overlapping bands around 3387 cm
-1
 was due to the moisture (water molecules) also 
detected by thermal analysis. The 2903 cm
-1
 and 2853 cm
-1
 bands attributed to the C-H sp
3
 
and sp
2
 stretching vibration of cycloalkanes slightly shifted from 2910 cm
-1
and 2852 cm
-1
. 
The characteristic bands at 1661 cm
-1
 assigned to the C=N vibration and come from the 
proton transfer from nitrogen of NH3
+
 to the oxygen atom of the carbonyl group through 
hydrogen bonding. The C=O bond also shifted to the carbon-nitrogen. 
Differences of ADTCO3LTTA to pure compounds were also observed at 1629 cm
-1
, 1585 
cm
-1
, 1547 cm
-1
 and 1512 cm
-1
. These were attributed to the C=O vibration of the 
carboxylate salt. Furthermore, shifting of weak bands in the region between 1450 cm
-1
, 
1426 cm
-1 
and 1366 cm
-1
 which were attributed to the C-H bending of methyl groups also 
confirmed the effect of interactions, hence the formation of a new product ADTCO3LTTA. 
PXRD ANALYSIS 
Remarkable differences of PXRD patterns of ADTCO3, LTTA and ADTCO3LTTA (figure 
5.40) confirmed a definite solvated salt co-crystal as identified by both thermal and 
spectroscopic analyses. However, ADTCO3LTTA pattern does not show a strong 
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crystallinity characteristic. This could have been compromised during the grinding process 
while preparing the sample. New intense peaks appear at 2θ 14.69o and 18.1o. Other weak 
peaks were identified at 2θ 7.38o, 13.1o, 16.6o and 15.7o. 
 
Figure 5.40: PXRD patterns of ADTCO3, LTTA and ADTCO3LTTA. 
 
ADTCO3SA 
PREPARATION 
Salicylic acid with its keratolytic character was used to co-crystallise ADTCO3. Neat 
grinding was used to synthesise ADTCO3SA. A stoichiometric amount of ADTCO3 (20 
mg) and SA (18 mg) in a 1:1 ratio was manually ground into a mortar using a pestle for 30 
minutes. A white powder, ADTCO3SA complex was reproduced by the same procedure 
assisted by a few drops of methanol, ethanol and 1,4-dioxan.  
THERMAL ANALYSIS 
HSM and DSC analysis 
Ab initio HSM analysis was performed upon heating the sample at a constant rate of 
10°C/min with the sample submerged in silicon oil to assess the possible inclusion water 
and/or solvent in the molecular structure of ADTCO3SA. The first change was observed at 
160°C, where crystallisation of the powdered sample commenced and the melt followed in 
the temperature range of 207-215°C (figure 5.41). 
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Figure 5.41: HSM photographs of ADTCO3SA recorded at: (a) room temperature, 
(b) crystallisation, (c) the melting temperature. 
DSC analysis produced a trace with the unique sharp endotherm peaking at 211°C 
corresponding to the melt of ADTCO3SA and an onset at 208.56°C. Decomposition 
occurred immediately after melting (figure 5.42). 
 
Figure 5.42: DSC trace of ADTCO3SA. 
A different melt was consistently reported by both HSM and DSC compared to both parent 
compounds, thus confirming the formation of ADTCO3SA. 
TGA ANALYSIS 
The TGA trace showed a 0% mass loss in the temperature range 30–205°C, thus 
confirming the absence of solvent in the molecular structure of this compound. TGA 
further confirmed that the melt proceeded around 208-212°C followed immediately by 
decomposition. 
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FTIR ANALYSIS 
FTIR analysis was performed for the parent compounds and ADTCO3SA, the prepared salt 
co-crystal. FTIR spectra are presented in figure 5.43. ADTCO3SA was identified by FTIR 
spectrum showing differences at various regions of which some are shown in table 5.9. 
These changes are an indication of new bonds and formation of the new chemical entity, 
the ADTCO3SA salt co-crystal.  
Noticeable shifts in the ADTCO3SA spectrum confirmed the existence of intermolecular 
interactions between ADTCO3 and SA, thus confirming the new entity. The possible 
interactions according to figure 5.44 would be NH3
+⋯C=O, NH3
+⋯O-H and O-H⋯O-H.  
Initially, the presence of NH3
+
 bands in the ADTCO3SA spectrum confirmed that the 
product ADTCO3SA retained the salt characteristic. The loss of characteristic absorption 
bands at 3231 cm
-1
 and 1654 cm
-1
 assigned to O-H and C=O of the carbonyl group 
(COOH) in the ADTCO3SA spectrum is an indication that a new salt co-crystal has 
formed. This loss was probably due to either NH3
+⋯O-H of the hydroxyl group and/or 
NH3
+⋯C=O of the carbonyl (–COOH) group.   
These interactions also affected the C-H vibrations of the adamantane ring methyl slightly 
shifted from 2910 and 2854 in the ADTCO3 spectrum to 2909 cm
-1
 and 2854 cm
-1
 in the 
ADTCO3SA spectrum. The 1659 cm
-1 
band assigned to C=O vibration of SA carbonyl 
group (-COOH) disappeared as a result of its possible interaction with NH3
+
. The C=O of 
the  ADTCO3 carbonate group CO3
2-
 shifted slightly to 1638 cm
-1
. Furthermore, various 
displacements observed in the fingerprint region of ADTCO3SA spectrum justified the 
formation of the salt co-crystal. 
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Figure 5.43: FTIR of ADTCO3, ADTCO3SA and SA. 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
1 
2
3
2910.14
2852.28
2723.02
2564.96 2267.81
1639.48
1550.94
1456.96
1381.45
1353.92
1338.72
1317.09
1291.08
1142.40
1126.84
1113.92
1088.18
1039.84
980.10
932.53
853.41
815.26
780.95
722.54
668.71
2909.77
2854.08
2722.65
2616.97
2268.71
1638.39
1582.86
1548.52
1482.95
1456.18
1381.16
1373.18
1354.05
1339.74
1317.48
1291.72
1249.82
1153.92
1141.19
1126.79
1114.04
1089.15
1029.13
980.25
932.55
862.68
854.03
843.39
811.35
750.31
743.17
699.73
667.09
3231.62
2851.58 2591.24
1654.88
1609.43
1579.23
1481.75
1464.77
1441.21
1382.82
1324.05
1291.01
1243.04
1207.72
1153.56
1089.18
1030.21
964.32
887.27
867.19
852.08
783.87
690.51
657.81
ADTCO3 
ADTCO3SA 
SA 
 
 
 
 
Chapter 5 
 
 
130 
 
Table 5.9: Some important changes and shifts observed in ADTCO3SA spectrum. 
Groups ADTCO3 SA ADTCO3SA Shifts 
NH3
+
 2564 cm
-1
 - Disappeared - 
C=O (-COOH) - 1654 cm
-1
 Disappeared - 
C=O 1639 cm
-1
 - 1638 cm
-1
 1 cm
-1
 
C-H 2910 cm
-1
 - 2909 cm
-1
 1 cm
-1
 
 2852 cm
-1
 - 2854 cm
-1
 2 cm
-1
 
aryl - 1579 cm
-1
 1582 cm
-1
 3 cm
-1
 
O-H - 3231 cm
-1
 Disappeared - 
The possible sites for intermolecular interactions are presented in the following figure (see 
next page): 
 
Figure 5.44: The possible sites for ADTCO3-SA interactions. 
POWDER X-RAY DIFFRACTION (PXRD) 
The PXRD pattern of ADTCO3SA is presented in figure 5.45 and show differences at 7.5
o
, 
14.4
o
, 15.4
o
, 15.58
o
, 16
o
 and 21.1
o
 2θ values. These results support thermal and FTIR 
spectroscopic findings, confirming the formation of ADTCO3SA as a new chemical entity, 
viz. a salt co-crystal. 
The same pattern was observed by grinding the two parent compounds ADTCO3 and SA 
with several solvents (figure 5.46).  
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Figure 5.45: PXRD of SA, ADTCO3SA and ADTCO3. 
 
Figure 5.46: PXRD of ADTCO3SA synthesised by neat grinding and solvent-drop 
grinding. 
 
ADTCO3CA 
PREPARATION 
To synthesise ADTCO3CA, a stoichiometric amount of ADTCO3 (20 mg) and CA (27.7 
mg) in a 1:1 ratio was neatly ground in a mortar using a pestle for 30 minutes. 
ADTCO3CA was reproduced by grinding assisted by a few drops of methanol or ethyl 
acetate. A white crystalline powder was produced and kept in a polytop vial and further 
analysed using a combination of various analytical techniques. 
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Furthermore, the same material in single crystal form was produced by dissolving the same 
amount of ADTCO3 and CA powder in minimum volumes of methanol separately at 
approximately 10°C below the b.p. of the solvent.  
The two solutions were added together and the resultant mixture was stirred magnetically 
for 15 min, filtered (using a 0.45 µm filter) and allowed to crystallise at 20°C. 
THERMAL ANALYSIS 
HSM & DSC analysis 
Thermal analysis by HSM was performed upon heating the sample at a constant rate of 
10°C/min and the sample was submerged in silicon oil to investigate the purity of 
ADTCO3CA. The melt occurred at 138°C and decomposition was characterised by 
discoloration and spontaneous bubbling immediately after the melt. Photographs of 
ADTCO3CA are presented in figure 5.47. The melting temperature of ADTCO3CA 
differed from that of ADTCO3 and CA, thus confirming the formation of a new form, viz. 
ADTCO3CA. 
 
Figure 5.47: HSM photographs of ADTCO3CA at (a) room temperature (b) melting 
starting point (c) melting and (d) decomposition. 
The HSM findings were additionally supported by DSC analysis where a generated curve 
shows the unique melt at 142.50°C and an onset at 137.24°C while ADTCO3 melts at 
170°C and CA at 155°C. The first endotherm in CA curve is due to water coming off since 
the former is a monohydrate drug. Decomposition comes immediately after melting 
(Figure 5.48). DSC results are consistent to HSM findings and, thus confirmed the 
formation of the complex. 
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Figure 5.48: DSC trace of ADTCO3CA. 
TGA ANALYSIS 
The TGA showed a negligible mass loss of 0% in the temperature range 30-135°C. 
FTIR ANALYSIS 
FTIR is a very good technique to give an insight into the kind of interactions occurring 
between an API and a co-former. FTIR spectra of ADTCO3, CA and ADTCO3CA are 
presented in figure 5.49. Noticeable shifts, changes in intensity of bands and new bands are 
observed in ADTCO3CA spectrum in comparison to ADTCO3 and CA. This confirmed the 
existence of intermolecular interactions between the complementary functional groups of 
ADTCO3 and CA as highlighted in figure 5.50, hence the formation of ADTCO3CA salt 
co-crystal. 
Based on table 5.10 and figure 5.50, the plausible intermolecular interactions are: 
C=O···NH3
+
, NH3
+
···O-H, NH3
+
···OH (-COOH), C=O···HO (H2O) or NH3
+
···OH (H2O). 
Shifts in FTIR spectrum of ADTCO3CA were observed as a result of the above 
interactions. Firstly, one can see that the salt characteristic of ADTCO3 was lost since 
NH3
+
 bands completely disappeared in ADTCO3CA spectrum and the appearance of 1981 
cm
-1 
band is an indication of NH···O-H neutral hydrogen bonding, thus formation of 
ADTCO3CA co-crystal. Secondly, a small bump around 3500 cm
-1
 attributed to OH was 
observed as a result of the possible interactions that have been mentioned. 
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Figure 5.49: FTIR of ADTCO3CA, ADTCO3 and CA respectively.
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Table 5.10: Shifts in the ADTCO3CA spectrum. 
Groups ADTCO3 CA ADTCO3CA Shifts cm
-1
 
C-H 2852 cm
-1
 - 2887 cm
-1
 35 cm
-1
 
 2910 cm
-1
 - 2913 cm
-1
 3 cm
-1
 
NH3
+
 2564 cm
-1
 - lost cm
-1
 - 
 - 2544 cm
-1
 2518 cm
-1
 26 cm
-1
 
 1550 cm
-1
 - 1559 cm
-1
 8 cm
-1
 
C=O - 1721 cm
-1
 1706 cm
-1
 15 cm
-1
 
 - 1752 cm
-1
 lost - 
O-H - 3295 cm
-1
 3150 cm
-1
 144 cm
-1
 
 
Given a structure of CA with different O-H, C=O and COOH functional groups as well as 
a H2O molecule, there is a very high probability of intermolecular interactions around the 
molecule. 
 
Figure 5.50: Possible sites for intermolecular between ADTCO3 and CA. 
The characteristic absorption band at 3150 cm
-1
 assigned to the O-H stretching vibration of 
the carbonyl group (-COOH) shifted from 3295 cm
-1
 due to the interactions with NH3
+
 of 
ADTCO3.  
The 2913 cm
-1 
and 2887 cm
-1 
bands assigned to the C-H stretching vibration of the 
cycloalkanes shifted from 2910 cm
-1
 and 2952 cm
-1
 respectively. Furthermore, 2518 cm
-1
 
band in ADTCO3CA spectrum assigned to OH of (-COOH) has shifted from 2544 cm
-1
 
band (present in CA spectrum) as a result of interaction suggested in figure 5.50. 
Furthermore, 1706 cm
-1
 and 1559 cm
-1
 absorption bands that can be assigned to the C=O 
of the carbonyl functional group have shifted from 1721 cm
-1
 (CA) and 1550 cm
-1
 
(ADTCO3), suggesting the interaction with NH3
+
 of ADTCO3 (C=O⋯H-N). All these 
changes and other different displacements in the fingerprint region of the spectrum 
confirmed the formation of ADTCO3CA salt co-crystal.  
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EXPERIMENTAL PXRD 
To further support the previous analyses, experimental X-ray powder diffraction analysis 
provide us with a definite conclusion with regards to the formation of ADTCO3CA. 
Compared to both ADTCO3 and CA, new intense peaks in ADTCO3CA spectrum appear 
at   6.9
 o
, 17.35 
o
, 23.3
 o
, 24.8
 o
, 26
 o
 and 31
o
 2θ values (figure 5.51). 
 
Figure 5.51: PXRD of CA, ADTCO3CA and ADTCO3. 
 
ADTCO3GLA 
PREPARATION 
To synthesize ADTCO3GLA, a grinding technique was performed. A stoichiometric 
amount of ADTCO3 (20 mg) and GLA (19.4 mg) in a 1:1 ratio were manually ground in a 
mortar with pestle for a period of 30 minutes. The process was assisted by a few drops of 
chloroform. A white powder was obtained and fully characterised.  
ADTCO3GLA in a crystal form was also produced by solvent evaporation method using 
propan-2-ol or methanol. 
THERMAL ANALYSIS 
HSM & DSC analysis 
HSM analysis for ADTCO3GLA was conducted with the sample submerged in silicon oil 
and heat applied at a constant rate of 10°C per minute. Bubbling was observed as the 
solvent evaporated at 135°C and melting occurred at around 160°C. Decomposition was 
indicated by explosive bubbling immediately after the melt (figure 5.52). HSM 
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photographs recorded at different temperatures according to changes observed are 
presented below. 
 
Figure 5.52: The HSM photographs of ADTCO3GLA taken at (a) room temperature, 
(b) bubbling of the sample, (c) melting and (d) decomposition. 
Analysis by DSC of the sample produced a graph with two broad endotherms (figure 
5.53). The first endotherm peaking at 139.17°C with an onset at 131.56°C was due to 
solvent loss.  The second endotherm formed at 168°C with an onset at 161.92°C was 
accounted for as the melting point of the sample which was immediately followed by 
decomposition. 
   
Figure 5.53: DSC trace of ADTCO3GLA. 
HSM and DSC findings were further supported by TGA analysis performed to investigate 
the amount of solvent present in ADTCO3GLA. The TGA trace (figure 5.54) showed a 
10.3% (n = 2.4) mass loss in the temperature range of 30-144°C, thus confirming that the 
product is a solvate. 
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Figure 5.54: TGA trace of ADTCO3GLA. 
FTIR ANALYSIS 
Infrared spectroscopic analysis also produced a different spectrum compared to both host 
and guest compounds. Shifts and changes in band intensities of the parent compounds are a 
result of intermolecular interactions between ADTCO3 and GLA as well as the solvent that 
is incorporated in the molecular structure of ADTCO3GLA (figure 5.55). 
Based on FTIR shifts presented in table 5.11 and figure 5.56, the most probable 
interactions would be; NH3
+
···NH2, NH2···O=C, NH3
+
···OH (-COOH), NH3
+
···C=O (-
COOH) and C=O···HO. The decrease in intensity of NH3
+
 in ADTCO3GLA spectrum 
suggests its implication into the above interactions. The loss of 3012 cm
-1
 and 2739 cm
-1
 
assigned to the O-H functional group in ADTCO3GLA spectrum is a result of their 
possible interactions with NH3
+
. Furthermore, shifting of -NH3
+ 
function group suggests 
that there is an interaction with the carbonyl (-COO) of GA and retention of salt 
characteristic. In the ADTCO3 spectrum, bands at 1639, 1550 cm
-1
 that can be assigned to 
C=O of the carbonate shifted to 1608 cm
-1
 and 1529 cm
-1
 in the ADTCO3GLA spectrum, 
suggesting the interaction with OH of (-COOH). All these interactions confirmed the 
formation of ADTCO3GLA as a solvated salt co-crystal. 
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Figure 5.55: FTIR spectra of ADTCO3, ADTCO3GLA and GLA. 
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Table 5.11: Shifts in the ADTCO3GLA spectrum. 
Groups ADTCO3 GLA ADTCO3GLA Shifts 
NH3
+
 2564 cm
-1
 - weak - 
C=O 1639 cm
-1
 - 1608 cm
-1
 29 cm
-1
 
 - 1637 cm
-1
 - - 
 1550 cm
-1
 - 1529 cm
-1
 21 cm
-1
 
NH2 - 3012 cm
-1
 lost - 
OH - 2739 cm
-1
 lost - 
 
The possible sites for intermolecular interaction between ADTCO3 and GLA are shown in 
the figure 5.56. 
 
Figure 5.56: The possible sites for ADTCO3 –GLA interactions. 
EXPERIMENTAL PXRD 
In figure 5.57 the ADTCO3GLA pattern is different form the PXRD patterns of the starting 
compounds labelled ADTCO3 and GLA. This is consistent with the results from thermal 
and spectroscopic analyses, which confirm that this is a new salt complex (solvated form).  
New intense peaks along the ADTCO3GLA curve appear at 2θ 15.4
o
, 15.86
o
, 16.2
o
, 16.56
o
, 
18.5
o
 values.  
 
Figure 5.57: PXRD of ADTCO3, ADTCO3GLA and GLA. 
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ADTCO3GA 
PREPARATION 
A minimum volume of solvent (methanol) at approximately 10°C below the b.p. of the 
solvent was used for the synthesis of ADTCO3GA. Stoichiometric amount of ADTCO3 
and GA in a 2:1 ratio was separately dissolved, mixed, filtered ( using a 0.45 μm 
microfilter) and allowed to crystallise at 20°C. Irregularly shaped crystals were produced 
and characterized. 
THERMAL ANALYSIS 
HSM and DSC ANALYSIS 
The thermal analysis of ADTCO3GA by HSM was conducted by heating the sample at a 
constant rate of 10°C/min, with the sample submerged in a drop of silicon oil.  Changes of 
the sample on hot stage were carefully observed and photographs were recorded at 
different temperatures due to physical changes as shown in figure 5.58. 
 
Figure 5.58: HSM photographs of ADTCO3GA recorded at (a) room temperature (b) 
first change (c) melting and (d) decomposition. 
The DSC trace for ADTCO3GA (figure 5.59) indicates a melting point at 185°C with a 
single endotherm (180-187°C). This finding correlates well to the HSM observations.  
Furthermore, the melt differs from that of both starting materials ADTCO3 (170°C) and 
GA (98°C). The analysis suggests that this is due to the higher stability of the newly 
formed salt co-crystal or strong intermolecular interactions created by the preparation 
process.  
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Figure 5.59: The DSC of ADTCO3, GA and ADTCO3GA. 
The TGA trace (figure 5.60) shows a negligible mass loss of 0.68% (n~1) in the 
temperature range of 30-165°C and thus confirms the absence of a solvent in the molecular 
structure of this complex. The significant mass loss step is observed from the onset of 
melting to the decomposition. 
 
Figure 5.60: TGA trace of ADTCO3GA co-crystal. 
FTIR SPECTROSCOPIC ANALYSIS 
FTIR analysis produced a unique spectrum in comparison to that of the parent compounds 
ADTCO3 and GA. Shifts and changes in intensity (figure 5.61) are seen in the spectrum of 
ADTCO3GA, providing evidence of the intermolecular as well as the formation of the new 
chemical ADTCO3GA. Table 5.17 presents the important shifts observed in ADTCO3GA 
spectrum. 
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Figure 5.61: FTIR spectra from ADTCO3, ADTCO3GA and GA. 
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Table 5.12: Shifts observed in the ADTCO3GA spectrum. 
Groups ADTCO3 GA ADTCO3GA Shifts 
NH3
+
 2564 cm
-1
 - 2566 cm
-1
 2 cm
-1
 
C=O
-
 1639 cm
-1
 - 1614 cm
-1
 24 cm
-1
 
 1550 cm
-1
 - 1546 cm
-1
 4.7 cm
-1
 
C=O - 1690 cm
-1
 1714 cm
-1
 24 cm
-1
 
O-H···N -  1930 cm-1 New  
O-H - 2953 cm
-1
 - - 
 - 3010 cm
-1
 - - 
 
 
Figure 5.62: The possible binding sites for intermolecular interactions between 
ADTCO3GA. 
Based on FTIR shifts presented in table 5.12 and figure 5.62, the most probable 
interactions would be; NH3
+
···OH (-COOH), NH3
+
···C=O (-COOH) and C=O···HO. 
The presence on NH3
+
 at 2566 cm
-1
 showed that the salt characteristic of ADTCO3 is 
retained in the product and shifting of this function group suggested that there is an 
interaction with the carbonyl (-COOH) of GA. Furthermore, the loss of 3010 cm
-1
 and 
2953 cm
-1
 bands assigned to OH of the carbonyl group (COOH) of GA is a result of 
possible interactions with NH3
+
. 
The appearance of 1930 cm
-1
 band in ADTCO3GA spectrum is an indication of the 
existence of NH···OH neutral hydrogen bonding. 
Bands at 1639 cm
-1
 and 1550 cm
-1
 assigned to C=O of the carbonate in the ADTCO3 
spectrum shifted to 1614 cm
-1
 and 1546 cm
-1
 in the ADTCO3GA spectrum; suggesting the 
interaction with OH of (-COOH). The C=O (-COOH) band at 1690 cm
-1
 also shifted to 
1714 cm
-1
. All these changes and shifts confirmed the formation of ADTCO3GA as a salt 
co-crystal. 
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EXPERIMENTAL PXRD 
PXRD analysis of ADTCO3GA pattern supports the results from the previous analyses 
with regards to the co-crystal formation. The pattern shows co-crystallisation occurring 
between the two parent compounds, with most of peaks disappearing from the parent 
compounds (figure 5.63). The new intense peaks appear at 13.1
o
, 14.6
o
, 16.64
o
 and 18
o
 2θ 
values.  
 
Figure 5.63: PXRD of ADTCO3GA, GA and ADTCO3. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
The present study was undertaken to investigate the possible impact of polymorphism and 
co-crystallisation on the physicochemical properties of bis(adamantan-1-aminium) 
carbonate (ADTCO3). 
Initially, ADTCO3 was unexpectedly produced in an attempt to convert 1-adamantanamine 
hydrochloride (ADTHCl) into the free base (ADT) and was fully characterised. Then, 
nineteen supramoleculary derivatised forms were synthesised of which four were 
identified as polymorphic forms of ADTCO3 and fifteen salt co-crystals forms were 
synthesised and characterised.  
CONVERSION OF ADTHCl TO ADTCO3 
1-adamantanamine (ADT free base), the antiviral and anti-parkinsonian agent was the 
desired product of the conversion process. However, even though the conversion 
procedure was correct, ADTCO3 was produced instead due to the ability of the primary 
amine to absorb carbon dioxide (CO2) from the atmosphere.
19
 This changed the focus of 
the research to investigate different aspects of supramolecular chemistry with regard to 
polymorphism and salt co-crystallisation of the converted ADTCO3.  
The converted ADTCO3 was analysed by DSC and PXRD and the results were similar to 
what has been reported in the literature.
19
 Structure elucidation was not included in this 
study since all the information about the ADTCO3 structure had already been reported by 
Nowakowska et al.
19
  
Thermal analysis presented a ADTCO3 melt in the temperature range (150-175°C) which 
correspond to the melting range reported.
19
 All other analytical data such as PXRD and 
basic single unity cell dimension analysis by X-ray diffraction were similar to  the reported 
data. ADTCO3 was then selected for further studies.  
POLYMORPHISM 
Polymorphism is a common phenomenon studied during pharmaceutical preformulation 
studies.  
It should be noted that from previous literature searches, no study on solid state 
characterisation of neither ADT nor ADTCO3 had been reported at the time of writing this 
 
 
 
 
Chapter 6 
 
 
148 
 
thesis. Four different polymorphic forms of ADTCO3 were identified during the 
polymorphism study. 
By recrystallization from methanol, ADTCO3 presented a single crystal (Form I) having 
the same melt as the starting material, Form II was obtained from a binary mixture of  
methanol-chloroform (1:1), Form III from a binary mixture of methanol and ethyl acetate 
(1:1) and Form IV was obtained from ethanol solubilisation.  
Forms I, II, III and IV were isolated as crystals and characterised by combination of 
several analytical techniques including DSC, HSM, TGA, FTIR and PXRD. Thermal, 
spectroscopic and PXRD analysis showed that form I matches the originally converted 
material. In addition, Form II, III and IV showed different melting points. Form I melts at 
170°C and was considered as least stable while form IV with a melt of 203°C was 
considered the most stable thermodynamically. Form II and III showed a melt at 185°C 
and 193°C, respectively. 
These melting temperatures differ significantly and together with PXRD patterns were 
sufficient to confirm polymorphism of ADTCO3. 
SALT CO-CRYSTALLISATION 
Making co-crystals of ADT with selected co-crystal formers from the GRAS list was one 
of the objectives of this study. Introduction of the unexpected ADTCO3 led to salt co-
crystallisation studies. Ten co-formers and salt co-crystals were synthesised by co-
precipitation, neat grinding and solvent assisted grinding. Fifteen salt co-crystals were 
synthesised and analysed by HSM, DSC, TGA, FTIR and PXRD analysis.  
FTIR results presented the intermolecular interactions highlighting the significance of the 
hydrogen bond interactions during non-covalent bonding. Not only were the products seen 
to interact intermolecularly but together with the PXRD results, it was clearly evident that 
molecules were packing in different ordered systems and co-crystals were indeed different 
to their parent compounds. 
The stability of each polymorph and co-crystal was investigated by DSC and TGA 
analysis. Degradation of a compound generally occurs after its melt barring no form 
change occurs during the melting process. Degradation would then commence 
immediately after the melt of the most stable form. 
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RECOMMENDATIONS 
First of all, it would be of interest to fill in the gaps in the current study. Physicochemical 
characterisation of all supramolecular forms synthesised during the present study is an 
important step to be further supported. Therefore, we recommend that future work should 
include solubility studies, dissolution testing and the study of the antiviral activity on all 
synthesised products. Findings can then be compared to the untreated compounds: 
amantadine hydrochloride and 1-adamantanamine.  
Hydrogen bonding is an important factor for molecular co-crystallization, and played a 
significant role in the co-crystallisation of the different synthesised products. Structure 
elucidation by single X-ray diffraction and refinements would be of interest to further 
study the molecular interactions and packing arrangement within the co-crystals. 
Primary amines are sustainable to capture CO2 in the atmosphere. Therefore, performing 
any conversion to the free base and recrystallization procedure must be done under 
nitrogen flow to obtain the free base of amantadine. However, alternative methods may 
also include protecting the amine functional group from air. A typical example of this is 
sublimation. Sublimating ADTCO3 may generate the glassy form of amantadine free base. 
In terms of preparative techniques, solvent screening is a useful tool when studying the 
impact of supramolecular chemistry on physicochemical properties of a drug substance 
since the formation of single crystals by recrystallization offers an opportunity to further 
study the structure of the new products. However, the grinding method would be an easy 
and a preferable technique to synthesise salt co-crystals especially for those with a limited 
solubility. Therefore, a combination of these techniques will lead to more results and will 
provide vital information on these structures. 
Investigation of polymorphism phenomenon in a compound is of utmost importance since 
different polymorphs of the same drug impart different physicochemical, kinetic and 
pharmaceutical properties. Therefore, apart from solubility study, dissolution test and 
antiviral activity, selection on the best polymorph and co-former is recommended. 
An outstanding knowledge of the active pharmaceutical ingredient and excipients is very 
important for the prediction of the expected results. A typical example is that of functional 
groups and their complementarity in the prediction of intermolecular interactions in the 
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product. The understanding of a compounds’ molecular reactivity is a key factor to protect 
it from any degradation caused by temperature, light, air etc and identifying the best 
processing method. Therefore, stability studies under different conditions also need to be 
carried out. 
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Appendix A 
Appendix A presents a list of all experiments for the production of ADTCO3 polymorphic 
forms.  
Recrystallization outcomes 
Method 1: Single solvent evaporation 
No SOLVENT API Crystal 
1 No Form I No crystal 
2 Ethanol Form IV Crystal  
3 Methanol Form I  Crystal  
9 Amyl alcohol  Form I Crystal  
 Water Form I No crystal 
12 Polyethylene  - No crystal 
Method 2: Slow evaporation using binary mixtures of solvents 
no Solvent 1 Solvent 2 Ratio API 
1 Methanol Diethyl ether 1:1 Form I 
2 Methanol Ethanol 1:1 Form I 
3 Methanol Acetone 1:1 Form I 
4 Methanol 1-4, dioxane 1:1 Form II 
5 Methanol Chloroform 1:1 Form II 
6 Methanol  Etyl Actt 1:1 Form III 
6 Ethanol Methanol 1:1 Form I 
 Ethanol Etyl Actt 1:1 Form III 
7 Ethanol Prop-2-ol 1:1 Form I 
8 Ethanol Acetone 1:1 Form I 
9 Methanol  Water 1:1 Form I 
Method 3: Grinding (neat & solvent assisted) 
no Solvent 1 Solvent 2 API Time (min) Crystal  
1 - - Form I 30 Negative  
2 Acetone  - Form I 30 Negative 
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3 Methanol  - Form I 30 Negative 
4 Ethanol  - Form I 30 Negative  
5 water - Form I 30 Negative  
6 Methanol Diethyl ether Form I 30 Negative  
7 Methanol Ethanol Form I 30 Negative 
8 Methanol Acetone Form I 30 Negative 
9 Methanol 1-4, dioxane Form I 30 Negative 
10 Methanol Chloroform Form I 30 Negative 
11 Methanol  Etyl Actt Form I 30 Negative 
12 Ethanol Methanol Form I 30 Negative 
13 Ethanol Etyl Actt Form I 30 Negative 
14 Ethanol Prop-2-ol Form I 30 Negative  
15 Ethanol Acetone Form I 45 Negative 
16 Methanol  Water Form I 50 Negative 
Method 4: Vapour diffusion 
No  Solvent 1 Precipitant  Outcomes 
1 Methanol  Acetone  Negative  
2 Methanol  Chloroform  Negative  
3 Methanol  Ether acetate Negative 
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Appendix B 
Appendix B presents a range of experiments conducted for the preparation of salt 
complexes including (co-crystals and solvates). 
Method 1: Co-precipitation 
No API Co-former Molar ratio Solvent Results 
1 ADTCO3 BA 1:1 Methanol Crystals  
 2     1:1 Ethanol Crystals 
 3     1:1 Amyl alcohol Crystals 
 4     1:1 But-1-ol  Crystals 
5   1:1 Acetone  No-crystals 
6   1:1 Chloroform No-crystals 
7   1:1 Ethyl acetate No-crystals 
8   1:1 Diethyl ether No-crystals 
 9  ADTCO3 HBA 1:1 Methanol Crystals 
 10     1:1 Ethanol Crystals 
11   1:1 But-1-ol  Crystal 
12   1:1 Acetone  No-crystal 
13   1:1 Chloroform No-crystal 
14   1:1 Ethyl acetate No-crystal 
15   1:1 Diethyl ether No-crystal 
16   1:1 But-1-ol  No-crystal 
17 ADTCO3 CIN 1:1 Methanol Crystal  
18   1:1 Ethanol Crystals 
19   1:1 But-1-ol  No-crystal 
20   1:1 Acetone  No-crystal 
21   1:1 Chloroform No-crystal 
22   1:1 Ethyl acetate No-crystal 
23   1:1 Diethyl ether No-crystal 
24   1:1 But-1-ol  No-crystal 
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25 ADTCO3 HCIN 1:1 Methanol Crystal  
26   1:1 Ethanol Crystal  
27   1:1 But-1-ol  Crystal  
28   1:1 Acetone  No-crystal 
29   1:1 Chloroform No-crystal 
30   1:1 Ethyl acetate No-crystal 
31   1:1 Diethyl ether No-crystal 
32   1:1 But-1-ol  No-crystal 
33 ADTCO3 SUC 1:1 Methanol Crystal 
34   1:1 Ethanol Crystal 
35   1:1 But-1-ol  No-crystal 
36   1:1 Acetone  No-crystal 
37   1:1 Chloroform No-crystal 
38   1:1 Ethyl acetate No-crystal 
39   1:1 Diethyl ether No-crystal 
40   1:1 But-1-ol  No-crystal 
41 ADTCO3 TTA 1:1 Methanol Crystal  
42   1:1 Ethanol Crystal 
43   1:1 But-1-ol  No-crystal 
44   1:1 Acetone  No-crystal 
45   1:1 Chloroform No-crystal 
46   1:1 Ethyl acetate No-crystal 
47   1:1 Diethyl ether No-crystal 
48   1:1 But-1-ol  No-crystal 
49 ADTCO3 GLA 1:1 Methanol Crystal 
50   1:1 Ethanol Crystal 
51   1:1 But-1-ol  No-crystal 
52   1:1 Acetone  No-crystal 
53   1:1 Chloroform No-crystal 
54   1:1 Ethyl acetate No-crystal 
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55   1:1 Diethyl ether No-crystal 
56   1:1 But-1-ol  No-crystal 
57 ADTCO3 GA 1:1 Methanol Crystal 
58   1:1 Ethanol Crystal 
59   1:1 But-1-ol  No-crystal 
60   1:1 Acetone  No-crystal 
61   1:1 Chloroform No-crystal 
62   1:1 Ethyl acetate No-crystal 
63   1:1 Diethyl ether No-crystal 
64   1:1 But-1-ol  No-crystal 
65 ADTCO3 SA 1:1 Methanol Crystal 
66   1:1 Ethanol Crystal 
67   1:1 But-1-ol  No-crystal 
68   1:1 Acetone  No-crystal 
69   1:1 Chloroform No-crystal 
70   1:1 Ethyl acetate No-crystal 
71   1:1 Diethyl ether No-crystal 
72   1:1 But-1-ol  No-crystal 
73 ADTCO3 CA 1:1 Methanol Crystal 
74   1:1 Ethanol crystal 
75   1:1 But-1-ol  No-crystal 
76   1:1 Acetone  No-crystal 
77   1:1 Chloroform No-crystal 
78   1:1 Ethyl acetate No-crystal 
79   1:1 Diethyl ether No-crystal 
80   1:1 But-1-ol  No-crystal 
Method 2:  Crystallisation from the binary solvent mixture 
API Co-former  Solvent 1 Solvent 2 Molar ratio results 
ADTCO3 BA Ethanol Chloroform 1:1 + 
    Ethanol Ethyl acetate 1:1 + 
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Method 3: (a): Neat grinding 
API Co-former Molar ratio Time (min) Result 
ADTCO3 BA 1:1 30 + 
 1 HBA 1:1 30 + 
 3 CIN  1:1 30 + 
 4 HCIN 1:1 30 + 
 5 SUC 1:1 30 + 
 6 TTA 1:1 30 + 
 7 GLA 1:1 30 + 
 8 GA 1:1 30 + 
 9 SA 1:1 30 + 
 10 CA 1:1 30 + 
 11 MLA 1:1 30 + 
Method 4: Solvent assisted grinding 
No API Co-former Solvent Ratio Time Results 
1 ADTCO3 BA Methanol 1:1 30 + 
2    Ethanol 1:1 30 + 
3     Acetone  1:1 30 + 
4     Chloroform 1:1 30 + 
5     Water 1:1 30 - 
6     Propan-2-ol 1:1 30 + 
7     Butan-1-ol 1:1 30 + 
8     Ethyl acetate 1:1 30 + 
9     Diethyl ether 1:1 30 + 
10     1,4-Dioxane 1:1 30 + 
11  ADTCO3 4HBEA Methanol 1:1 30 + 
12     Ethanol 1:1 30 + 
13     Acetone  1:1 30 + 
14     Chloroform 1:1 30 + 
15     Water 1:1 30 - 
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16     Propan-2-ol 1:1 30 + 
17     Butan-1-ol 1:1 30 + 
18     Ethyl acetate 1:1 30 + 
19     Diethyl ether 1:1 30 + 
20     1,4-Dioxane 1:1 30 + 
21     Toluene 1:1 30 + 
22  ADTCO3 CIN A Methanol 1:1 30 + 
23     Ethanol 1:1 30 + 
24     Acetone  1:1 30 + 
25     Chloroform 1:1 30 + 
26     Water 1:1 50 - 
27     Propan-2-ol 1:1 45 + 
28     Butan-1-ol 1:1 45 + 
29     Ethyl acetate 1:1 30 + 
30     Diethyl ether 1:1 30 + 
31     1,4-Dioxane 1:1 30 + 
32  ADTCO3 4HCIN A Methanol 1:1 30 + 
33     Ethanol 1:1 30 + 
34     Acetone  1:1 30 + 
35     Chloroform 1:1 30 + 
36     Water 1:1 50 - 
37     Propan-2-ol 1:1 45 + 
38     Butan-1-ol 1:1 45 + 
39     Ethyl acetate 1:1 30 + 
40     Diethyl ether 1:1 30 + 
41    1,4-Dioxane 1:1 30 + 
42  ADTCO3 SUC Methanol 1:1 30 + 
43     Ethanol 1:1 30 + 
44     Acetone  1:1 30 + 
45     Chloroform 1:1 30 + 
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46     Water 1:1 50 - 
47     Propan-2-ol 1:1 45 + 
48     Butan-1-ol 1:1 45 + 
49     Ethyl acetate 1:1 30 + 
50     Diethyl ether 1:1 30 + 
51     1,4-Dioxane 1:1 30 + 
52  ADTCO3 TTA Methanol 1:1 30 + 
53     Ethanol 1:1 30 + 
54     Acetone  1:1 30 + 
55     Chloroform 1:1 30 + 
56     Water 1:1 50 - 
57     Propan-2-ol 1:1 45 + 
58     Butan-1-ol 1:1 45 + 
59     Ethyl acetate 1:1 30 + 
60     Diethyl ether 1:1 30 + 
61     1,4-Dioxane 1:1 30 + 
62     Toluene 1:1 60 + 
63  ADTCO3 GLA Methanol 1:1 30 + 
64    Ethanol 1:1 30 + 
65     Acetone  1:1 30 + 
66     Chloroform 1:1 30 + 
67     Water 1:1 50 - 
68     Propan-2-ol 1:1 45 + 
69     Butan-1-ol 1:1 45 + 
70     Ethyl acetate 1:1 30 + 
71     Diethyl ether 1:1 30 + 
72     1,4-Dioxane 1:1 30 + 
73     Toluene 1:1 60 + 
74  ADTCO3 GLA Methanol 1:1 30 + 
75     Ethanol 1:1 30 + 
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76     Acetone  1:1 30 + 
77     Chloroform 1:1 30 + 
78     Water 1:1 50 - 
79     Propan-2-ol 1:1 45 + 
80     Butan-1-ol 1:1 45 + 
81     Ethyl acetate 1:1 30 + 
82     Diethyl ether 1:1 30 + 
83     1,4-Dioxane 1:1 30 + 
84     Toluene 1:1 60 + 
85  ADTCO3 GA Methanol 1:1 30 + 
86     Ethanol 1:1 30 + 
87     Acetone  1:1 30 + 
88     Chloroform 1:1 30 + 
89     Water 1:1 50 - 
90     Propan-2-ol 1:1 45 + 
91     Butan-1-ol 1:1 45 + 
92     Ethyl acetate 1:1 30 + 
93     Diethyl ether 1:1 30 + 
94     1, 4-Dioxane 1:1 30 + 
95  ADTCO3 MLA Methanol 1:1 30 + 
96     Ethanol 1:1 30 + 
97     Acetone  1:1 30 + 
98   Chloroform 1:1 30 + 
99   Water 1:1 50 - 
100   Propan-2-ol 1:1 45 + 
101   Butan-1-ol 1:1 45 + 
102   Ethyl acetate 1:1 30 + 
103   Diethyl ether 1:1 30 + 
104   1,4-Dioxane 1:1 30 + 
105   Toluene 1:1 60 + 
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106 ADTCO3 CA Methanol 1:1 30 + 
107   Ethanol 1:1 30 + 
108   Acetone  1:1 30 + 
109   Chloroform 1:1 30 + 
110   Water 1:1 60 + 
111   Propan-2-ol 1:1 45 + 
 
NB: Signs +/- indicate if whether the crystal has formed or not. They also indicate if results were 
successful or not. 
 
 
 
 
 
 
 
